<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/218140-a-pharmaceutical-composition-of-a-cetp-inhibitor by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:31:08 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 218140:&quot;A PHARMACEUTICAL COMPOSITION OF A CETP INHIBITOR&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;A PHARMACEUTICAL COMPOSITION OF A CETP INHIBITOR&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A pharmaceutical composition comprising a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof, an antihypertensive agent or a pharmaceutically acceptable salt thereof, an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier or diluent.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The present invention relates to a pharmaceutical composition for treating a disorder or condition of the kind such as herein described comprising: (a) 26.26% to 35.37% w/w of a cholesteryl ester transfer protein (CETP) inhibitor which is a compound of formula I:  (Formula Removed)<br>
or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug; wherein R1 is Y, W-X or W-Y; wherein W is carbonyl; X is -O-Y; wherein Y for each occurrence is independently Z or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo and said nitrogen is optionally mono-, or di-substituted with oxo; R2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon,   may   optionally   be   replaced   with   one   heteroatom   selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo; or said R2 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;    R3 is a fully saturated, one<br>
or two membered carbon chain wherein said carbon is optionally mono-substituted with oxo, and said carbon chain is mono-substituted with V; wherein V is a partially saturated, fully saturated or fully unsaturated five to six membered   ring   optionally   having   one   to   three   heteroatoms   selected independently from oxygen, sulfur and nitrogen;    wherein said V substituent is optionally mono-, di-, or tri-substituted independently with halo, (C1-C2)alkyl, wherein said (C1-C2)alkyl substituents are also optionally   substituted with from one to five fluorines; R4 is acetyl, formyl or (C1-C6)alkoxycarbonyl; R5 and R8 are hydrogen; R6 and R7 are independently hydrogen, halo, (C1-C2)alkoxy or a saturated (C1-C2)alkyl chain wherein said (C1-C2)alkyl chain is optionally mono-, di- or tri-substituted independently with fluorines, or a pharmaceutically acceptable salt thereof; (b)  1.6% to 4.75% w/w of an antihypertensive agent or a pharmaceutically acceptable salt; (c)   0.76% to 1.06% w/w of  an HMG CoA reductase inhibitor wherein the HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, glenvastatin, dalvastatin, carvastatin, crilvastatin,  bervastatin, cerivastatin,   rosuvastatin,   pravastatin,   mevastatin,   or   rivastatin   or   a pharmaceutically acceptable salt of said HMG CoA reductase inhibitor , and the balance being optional conventional pharmaceutically acceptable carrier or diluent of the kind such as herein described.<br>
Background of the Invention Artherosclerosis and its associated coronary artery disease (CAD) is the leading cause of mortality in the industrialized world. Despite attempts to modify secondary risk factors (smoking, obesity, lack of exercise) and treatment of dysiipidemia with dietary modification and drug therapy, coronary hard disease (CHD) remains the most common cause of death in the U.S., where cardiovascular disease accounts for 44% of all deaths, with 53% of these associated with atherosclerotic coronary heart disease.<br>
Risk for development of this condition has been shown to be strongly correlated with certain plasma lipid levels. While elevated LDL C may be the most recognized form of dysiipidemia, it is by no means the only significant lipid associated contributor to CHD. Low HDL-C is also a known risk factor for CHD (Gordon, DJ., et al,: "High-density Lipoprotein Cholesterol and Cardiovascular Disease", Circulation, (1989), 79: 8-15).<br>
High LDL-cholesterol and triglyceride levels are positively correlated, while high levels of HDL-cholesterol are negatively correlated with the risk for developing cardiovascular diseases. Thus, dysiipidemia is not a unitary risk profile for CHD but may be comprised of one or more lipid aberrations.<br>
Among the many factors controlling plasma levels of these disease dependent principles, cholesteryl ester transfer protein (CETP) activity effects all three. The role of this 70,000 dalton plasma glycoprotein found in a number of animal species, including humans, is to transfer cholesteryl ester and triglyceride between lipoprotein particles, including high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL), and chylomicrons. The net result of CETP activity is a lowering of HDL cholesterol and an increase in LDL cholesterol. This effect on lipoprotein profile is believed to be proatherogenic, especially in subjects whose lipid profile constitutes an increased risk for CHD.<br>
Commonly assigned U.S. Patent No. 6,197,786 (the disclosure of which is hereby incorporated by reference) discloses certain CETP inhibitors including<br>
[2R4S]]-4-[(3,5-bis-trifluoromethyl-ben2yl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-qufnoIine-1-carboxylic acid ethyl ester also known as torcetrapjb^Jn-addition, these CETP inhibitors are disclosed as being useful for such indications as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injdury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia.<br>
In addition, the CETP inhibitors are stated to be useful in combination with a second compound, said compound being an HMG-CoA reductase inhibitor, an microsomal triglyceride transfer protein (MTP)/Apo B secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant. Barter, Philip J.; Brewer, H. Bryan; Chapman, M. John; Hennekens, Charles H.; Rader, Daniel J.; Tall, Alan R., Hanson Institute and the Department of Cardiology (P.J.B.), Royal Adelaide Hospital, Adelaide, Australia, NY, USA.    Arteriosclerosis, Thrombosis, and Vascular Biology (2003), 23(2), 160-167 is a discussion regarding CETP inhibitor studies.<br>
Summary of the Invention The present invention relates to a method (designated the A method) of treating a disorder or condition selected from cerebrovascular disease, coronary artery disease, hypertension, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular disease, peripheral vascular disease, reno-vascular disease, renal disease, splanchnic vascular disease, vascu)ar hemostatic disease, diabetes, inflammatory disease, autoimmune disorders and other systemic disease indications, immune function modulation, pulmonary disease, antioxidant disease, sexual dysfunction, cognitive dysfunction, schistosomiasis and cancer in a mammal, comprising administering to said mammal a therapeutically effective amount of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically<br>
acceptable salt thereof; optionally in combination with an HMG CoA reductase inhibitor or a pharmaceuticaily acceptable salt thereof, in amounts that render the active agents effective in the treatment of said disorder or condition.<br>
Another aspect of this invention is a method (designated the B method) of treating a disorder or condition selected from cerebrovascular disease, coronary artery disease, hypertension, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular disease, peripheral vascular disease, reno-vascular disease, renal disease, splanchnic vascular disease, vascular hemostatic disease, diabetes, inflammatory disease, autoimmune disorders and other systemic disease indications, immune function modulation, pulmonary disease, anti-oxidant disease, sexual dysfunction, cognitive dysfunction, schistosomiasis and cancer in a mammal comprising administering to said mammal a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceuticaily acceptable salt thereof; and an antihypertensive agent or a pharmaceuticaily acceptable salt thereof, optionally in combination with an HMG CoA reductase inhibitor or a pharmaceuticaily acceptable salt thereof, in amounts that render the active agents effective in the treatment of said disorder or condition.<br>
1<br>
A preferred method according to methods A or B is wherein cerebrovascular disease is selected from the group consisting of ischemic attacks, ischemic stroke, acute stroke, hemorrhagic stroke, neurologic deficits post-stroke, wherein the treatment would shorten recovery time after stroke and provide thrombolytic therapy for stroke.<br>
A preferred method according to methods A or B is wherein coronary artery disease is selected from the group consisting of atherosclerotic plaque, vulnerable plaque, vulnerable plaque area, arterial calcification, increased coronary artery calcium score, dysfunctional vascular reactivity, vasodilation disorders, coronary artery spasm, first myocardial infarction, myocardia re-infarction, ischemic cardiomyopathy, stent restenosis, PTCA restenosis, arterial restenosis, coronary bypass graft restenosis, vascular bypass restenosis, decreased exercise treadmill time, angina pectoris/chest pain, exertional dyspnea, decreased exercise capacity, ischemia, silent ischemia, increased severity and frequency of ischemic symptoms, reperfusion after thrombolytic therapy for acute myocardial infarction.<br>
A preferred method according to method B is wherein hypertension is selected from the group consisting of lipid disorders with hypertension, systoiic hypertension and diastolic hypertension.<br>
A preferred method according to methods A or B is wherein plasma small dense LDL, oxidized LDL, VLDL, apo(a) or Lp(a)) are reduced or pre-beta HDL, HDL-1 ,-2 and 3 particles are increased.<br>
A preferred method according to methods A or B is wherein diabetes is selected from the group consisting of type II diabetes, Syndrome X, Metabolic syndrome, lipid disorders associated with insulin resistance, non-insulin dependent diabetes, microvascular diabetic complications, reduced nerve conduction velocity, reduced or loss of vision, diabetic retinopathy, increased risk of amputation, decreased kidney function, kidney failure, metabolic syndrome, insulin resistance syndrome, pluri-metabolic syndrome, central adiposity (visceral)(upper body), diabetic dyslipidemia, decreased insulin sensitization, diabetic retinopathy/neuropathy, diabetic nephropathy/micro and macro angiopathy and micro/macro albuminuria, dyslipidemia, diabetic cardiomyopathy, diabetic gastroparesis, obesity, increased hemoglobin glycoslation, impaired renal and hepatic function.<br>
A preferred method according to methods A or B is wherein cognitive dysfunction is selected from the group consisting of dementia secondary to atherosclerosis, transient cerebral ischemic attacks, neurodegeneration, neuronal deficient, and delayed onset or procession of Alzheimer's disease.<br>
A preferred method according to methods A or B is wherein the CETP inhibitor is a compound of formula I<br>
(Formula Removed)<br>
or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of<br>
said prodrug;<br>
wherein R1 is Y, W-X or W-Y;<br>
wherein W is carbonyl;<br>
X is -O-Y;<br>
wherein Y for each occurrence is independently Z or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo and said nitrogen is optionally mono-, or di-substituted with oxo;<br>
R2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo; or said R2 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
R3 is a fully saturated, one or two membered carbon chain wherein said carbon is optionally mono-substituted with oxo, and said carbon chain is mono-substituted with V;<br>
wherein V is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said V substituent is optionally mono-, di-, or tri-substituted independently with halo, (C1-C2)alkyl, wherein said (C1-C2)alkyl substituents are also optionally substituted with from one to five fluorines; R4 is acetyl formyl or (C1-C6)alkoxycarbonyl; R5 and R8 are hydrogen;<br>
R6 and R^are independently hydrogen, halo, (C1-C2)alkoxy or a saturated (C1-C2)alkyf chain wherein said (C1-C2)alkyl chain is optionally mono-, di- or tri-substituted independently with fluorines.<br>
A preferred method according to methods A or B is wherein the CETP inhibitor is [2R.4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-<br>
J<br>
amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester or a pharmaceutically acceptable salt of said compounds.<br>
Yet another aspect of this invention is a pharmaceutical composition (designated C) comprising:<br>
(a)	a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof;<br>
(b)	an antihypertensive agent or a pharmaceutically acceptable salt thereof; and<br>
(c)	a pharmaceutically acceptable carrier or diluent.<br>
Yet another aspect of this invention is a pharmaceutical composition (designated D) comprising:<br>
(a)	a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof;<br>
(b)	an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof;<br>
(c)	an antihypertensive agent or a pharmaceutically acceptable salt thereof; and<br>
(d)	a pharmaceutically acceptable carrier or diluent.<br>
A preferred pharmaceutical composition (designated E) according to compositions C or D is wherein the HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, glenvastatin, dalvastatin, carvastatin, crilvastatin, bervastatin, cerivastatin, rosuvastatin, pitavastatin, mevastatin, or rivastatin and wherein said antihypertensive agent is a calcium channel blocker, an ACE inhibitor, an A-ll antagonist, a diuretic, a beta-adrenergic receptor blocker or an alpha-adrenergic receptor blocker.<br>
A preferred pharmaceutical composition (designated F) according to compositions D or E is comprises rosuvastatin or hemicalcium salt of atorvastatin.<br>
A preferred pharmaceutical composition according to compositions C, D or F is wherein said calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.<br>
The present invention also relates to a method of treating a disorder or condition selected from cerebrovascular disease, coronary artery disease, ' hypertension, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular disease, peripheral vascular disease, reno-vascular disease, renal disease, splanchnic vascular disease, vascular hemostatic disease, diabetes, inflammatory disease, autoimmune disorders and other systemic disease indications, immune function modulation, pulmonary disease, anti-oxidant disease, sexual dysfunction, cognitive dysfunction, schistosomiasis and cancer in a mammal, comprising administering to said mammal a therapeutically effective amount of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, in amounts that render the active agents effective in the treatment of said disorder or condition.<br>
The present invention further relates to a method of treating a disorder or condition selected from cerebrovascular disease, coronary artery disease, hypertension, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular disease, peripheral vascular disease, reno-vascular disease, renal disease, splanchnic vascular disease, vascular hemostatic disease, diabetes, inflammatory disease, autoimmune disorders and other systemic disease indications, immune function modulation, pulmonary disease, anti-oxidant disease, sexual dysfunction, cognitive dysfunction, schistosomiasis and cancer in a mammal (including a human being either male or female) comprising administering to said mammal a therapeutically effective amount of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, in amounts that render the active agents effective in the treatment of said disorder or condition.<br>
The present invention further relates to a method of treating a disorder or condition selected from cerebrovascular disease, coronary artery disease, hypertension, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular<br>
disease, peripheral vascular disease, reno-vascular disease, renal disease, splanchnic vascular disease, vascular hemostatic disease, diabetes, inflammatory disease, autoimmune disorders and other systemic disease indications, immune function modulation, pulmonary disease, anti-oxidant disease, sexual dysfunction, cognitive dysfunction, schistosomiasis and cancer in a mammal, including a human, comprising administering to a mammal in need of such treatment an amount of a compound of Formula I,<br>
(Formula Removed)<br>
Formula I<br>
a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said<br>
prodrug;<br>
wherein R1 is Y, W-X or W-Y;<br>
wherein W is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;<br>
X is -O-Y, -S-Y, -N(H)-Y or -N-(Y)2;<br>
wherein Y for each occurrence is independently Z or a fully saturated,<br>
partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-,.di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z;<br>
wherein Z is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered<br>
rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxyIl.(C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyioxycarbonyl, mon'o-N- or di-N,N-(C1-C6)alky)amino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
R2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R2 is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said R2 ring is optionally attached through (C1-C4)alky|;<br>
wherein said R2 ring is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N.N-C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, oxo or (C1-C6)alkyloxycarbonyl; R3 is hydrogen or Q;<br>
wherein Q is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally<br>
mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V;<br>
wherein V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said V substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N-ordi-N,N-(C1-C6) alkylcarboxamoyl, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C5)alkylamino wherein said (C1-C6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyI or (C2-C6)alkenyl substituents are also optionally substituted with from one to nine fluorines; R4 is cyano, formyl, W1Q1, WV, (C1-C4)alkyleneV1 or V2; wherein W1 is carbonyl, thiocarbonyl, SO or S02,<br>
wherein Q1 is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons may oplionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V1;<br>
wherein V1 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said V1 substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C1-C6)aIkoxy, hydroxy, oxo, amino, nitro, cyano, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)aIkyl substituent is optionally mono-substituted with oxo, sard (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
wherein V2 is a partially saturated, fully saturated or fully unsaturated five to seven membered ring containing one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said V2 substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C2)alkyl, (C1-C2)alkoxy, hydroxy, or oxo wherein said (C1-C2)alkyl optionally has from one to five fluorines; and<br>
wherein either R3 must contain V or R4 must contain V1; R5, R6, R7 and R8 are independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T or a partially saturated, fully saturated or fully unsaturated (C1-C12) straight or branched carbon chain wherein carbon may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with T;<br>
wherein T is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)aIkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N-or di-N,N-(Cr<br>
C6)alkylamino, said (C1-C6)alkyl substituent also optionally has from one to nine fluorines;<br>
wherein R5 and R6, or R6 and R7, and/or R7and R8 may also be taken together and can form at least one ring thai is a partially saturated or fully unsaturated four to eight membered ring optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;<br>
wherein said rings formed by R5 and R6, or R6 and R7, and/or R7and R8 are optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C1-C4)alkylsulfonyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkyIamino, said (Cr C6)alkyl substituent also optionally has from one to nine fluorines;<br>
optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, in amounts that render the active agents effective in the treatment of said disorder or condition.<br>
The present invention further relates to a method of treating a disorder or condition selected from cerebrovascular disease, coronary artery disease, hypertension, ventricular dysfunction, cardiac arrhythmia, pulmonary vascular disease, peripheral vascular disease, reno-vascular disease, renal disease, splanchnic vascular disease, vascular hemostatic disease, diabetes, inflammatory disease, autoimmune disorders and other systemic disease indications, immune function modulation, pulmonary disease, anti-oxidant disease, sexual dysfunction, cognitive dysfunction, schistosomiasis and cancer in a mammal (including a human being either male or female comprising administering to a mammal in need of such treatment an amount of a compound of Formula I,<br>
(Formula Removed)<br>
Formula I<br>
a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said<br>
prodrug;<br>
wherein R1 is Y, W-X or W-Y;<br>
wherein W is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;<br>
X is -O-Y, -S-Y, -N(H)-Y or -N-(Y)2;<br>
wherein Y for each occurrence is independently Z or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with 2;<br>
wherein Z is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)aIkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)aIkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio,<br>
amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
R2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the<br>
connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R2 is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said R2 ring is optionally attached through (C1-C4)alkyl;<br>
wherein said R2 ring is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alky/, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, oxo or (C1-C6)alkyloxycarbonyl; R3 is hydrogen or Q;<br>
wherein Q is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one-heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V;<br>
wherein V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered<br>
rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said V substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxyâ€ž (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N-or di-N,N-(C1-C6) alkylcarboxamoyl, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkyIamino wherein said (C1-C6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyl or (C2-C6)alkenyl substituents are also optionally substituted with from one to nine fluorines; R4 is cyano, formyl, W1Q1, W1V' (C1-C4)alkyleneV1 or V2;<br>
wherein W1 is carbonyl, thiocarbonyl, SO or S02,<br>
wherein Q1 is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons may optionally be replaced with one heteroatom selected from oxygen, sulfur and<br>
i<br>
nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V1;<br>
wherein V1 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected Independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated br fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said V1 substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, oxo, amino, nitro, cyano, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-substituted with oxo, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
wherein V2 is a partially saturated, fully saturated or fully unsaturated five to seven membere'd ring containing one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said V2 substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C2)alkyl, (C1-C2)alkoxy, hydroxy, or oxo wherein said (C1-C2)alkyl optionally has from one to five fluorines; and<br>
wherein either R3 must contain V or R4 must contain V1; R5, R6, R7and R8 are independently hydrogen, a bond, nitro ox halo wherein said bond is substituted with T or a partially saturated, fully saturated or fully unsaturated (C1-C12) straight or branched carbon chain wherein carbon may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with T;<br>
wherein T is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered. rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr Cs)alkylamino, said (C1-C6)alkyl substituent also optionally has from one to nine fluorines;<br>
wherein R5 and R6, or R6 and R7, and/or R7 and R8 may also be taken together and can form at least one ring that is a partially saturated or fully unsaturated four to eight membered ring optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;<br>
wherein said rings formed by R5 and R6, or R6 and R7, and/or R7and R8 are optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C1-C4)aIkylsulfonyl, (C2-C6)alkenyl, hydroxy, (C1-C6)a!koxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkyJamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (CrC4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (Cr CB)alkyl substituent also optionally has from one to nine fluorines;<br>
and an antihypertensive agent or a pharmaceutically acceptable salt thereof; optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, in amounts that render the active agents effective in the treatment of said disorder or condition.<br>
The term "cerebrovascular disease", as used herein, is selected, but not limited to, the group consisting of ischemic attacks (e.g., transient), ischemic stroke (transient), acute stroke, cerebral apoplexy, hemorrhagic stroke, neurologic deficits post-stroke, first stroke, recurrent stroke, shortened recovery time after stroke and provision of thrombolytic therapy for stroke. Preferable patient populations include patients with or without pre-existing stroke or coronary heart disease.<br>
The term "coronary artery disease", as used herein, is selected, but not limited to, the group consisting of atherosclerotic plaque (e.g., prevention, regression, stabilization), vulnerable plaque (e.g., prevention, regression, stabilization), vulnerable plaque area (reduction), arterial calcification (e.g., calcific aortic stenosis), increased coronary artery calcium score, dysfunctional vascular reactivity, vasodilation disorders, coronary artery spasm, first myocardial infarction, myocardia re-infarction, ischemic cardiomyopathy, stent restenosis, PTCA restenosis, arterial restenosis, coronary bypass graft restenosis, vascular bypass restenosis, decreased exercise treadmill time, angina pectoris/chest pain, unstable angina pectoris, exertional dyspnea, decreased exercise capacity, ischemia (reduce time to), silent ischemia (reduce time to), increased severity and frequency of ischemic symptoms, reperfusion after thrombolytic therapy for acute myocardial infarction,<br>
The term "hypertension", as used herein, is selected, but not limited to, the group consisting of lipid disorders with hypertension, systolic hypertension and diastolic hypertension.<br>
The term'"ventricular dysfunction", as used herein, is selected, but not limited to, the group consisting of systolic dysfunction, diastolic dysfunction, heart failure, congestive heart faffure, dilated cardiomyopathy, idiopathic dilated cardiomyopathy, and non-dilated cardiomopathy.<br>
The term "cardiac arrhythmia", as used herein, is selected, but not limited to, the group consisting of atrial arrhythmias, supraventricular arrhythmias, ventricular arrhythmias and sudden death syndrome.<br>
The term "pulmonary vascular disease", as used herein, is selected, but not limited to, the group consisting of pulmonary hypertension, peripheral artery block, and pulmonary embolism.<br>
The term "peripheral vascular disease", as used herein, is selected, but not limited to, the group consisting of peripheral vascular disease and claudication.<br>
The term "reno-vascular/renal disease", as used herein, is selected, but not limited to, the group consisting of renal vascular diseases, renal hypertension and renal arterial stenosis.<br>
The term "splanchnic vascular disease", as used herein, is selected, but not limited to, the group consisting of ischemic bowel disease.<br>
The term "vascular hemostatic disease", as used herein, is selected, but not limited to, the group consisting of deep venous thrombosis, vaso-occlusive complications of sickle cell anemia, varicose veins, pulmonary embolism, transient ischemic attacks, embolic events, including stroke, in patients with mechanical heart valves, embolic events, including stroke, in patients with right or left ventricular assist devices, embolic events, including stroke, in patients with intra-aortic balloon pump support,-embolic events, including stroke, in patients with artificial hearts, embolic events, including stroke, in patients with cardiomyopathy, embolic events, including stroke, in patients with atrial fibrillation or atrial flutter.<br>
The term "diabetes", as used herein, refers to any of a number of diabetogenic states including type I diabetes, type II diabetes, Syndrome X, Metabolic syndrome, lipid disorders associated with insulin resistance, impaired glucose tolerance, non-insulin dependent diabetes, microvascular diabetic complications, reduced nerve conduction velocity, reduced or loss of vision, diabetic retinopathy, increased risk of amputation, decreased kidney function, kidney failure, insulin resistance syndrome, pluri-metabolic syndrome, central adiposity (visceral)(upper body), diabetic dyslipidemia, decreased insulin sensitization, diabetic<br>
retinopathy/neuropathy, diabetic nephropathy/micro and macro angiopathy and micro/macro albuminuria, diabetic cardiomyopathy, diabetic gastroparesis, obesity, increased hemoglobin glycoslation (including HbA1 C), improved glucose control, impaired renal function (dialysis, endstage) and hepatic function (mild, moderate, severe).<br>
The terms "inflammatory disease, autoimmune disorders and other systemic diseases", as used herein, are selected, but not limited to, the group consisting of multiple sclerosis, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, irritable bowel disease, Crohn's disease, colitis, vasculitis, lupus erythematosis, sarcoidosis, amyloidosis, apoptosis, and disorders of the complement systems. The term "immune function disease", as used herein, is selected, but not limited to, the group consisting of transplant vasculopathy, solid organ transplant rejection, transplant rejection, impaired toxin sequestration/removal, elevated levels of CXC chemokines, interleukins including interleukin-1, 6 and 8, neutrophil-activating pirotein-2 (NAP-2), melanoma growth stimulatory activity protein (MGSA), elevated levels of CC chemokines, RANTES, MIP-1 alpha and beta, MCP-1, -2, -3, -4, -5 Eotaxin-1, -2, -3, C-reactive protein including highly sensitive C-reactive protein'and TNFalpha.<br>
The term "pulmonary disease", as used herein, is selected, but not limited to, the group consisting of pulmonary fibrosis, emphysema, obstructive lung disease, chronic hypoxic lung disease, antioxidant deficiencies, hyper-oxidant disorders and asthma.<br>
The term "anti-oxidant disease", as used herein, is selected, but not limited to, -the group consisting of aging, mortality, apoptosis and increased oxidative stress.<br>
The term "sexual dysfunction", as used herein, is selected, but not limited to, the group consisting of male sexual dysfunction, erectile dysfunction and female sexual dysfunction, female sexual arousal dysfunction.<br>
The term "cognitive dysfunction", as used herein, is selected, but not limited to, the group consisting of dementia secondary to atherosclerosis, neurodegeneration, neuronal deficient, and delayed onset or procession of Alzheimer's disease.<br>
Additionally, CETP compounds and the combinations included herewith are also useful for neurodegenerative diseases such as Parkinson's, Huntington's disease, amyloid deposition and amylotrophic lateral sclerosis.<br>
The term'"cancer", as used herein, is defined, but not limited to, resistance to chemotherapy, unregulated cell growth, hyperplasia (e.g., benign prostatic hyperplasia) and any of a number of abnormal multiplication or increase in the number of normal cells in normal arrangement in a tissue. The compounds and combinations included herein are also useful for cancer prevention.<br>
The CETP inhibitors and combinations thereof included herein are useful for reducing global cardiovascular risk and global risk scores.<br>
The CETP inhibitors are also useful for modulation of plasma and or serum or tissue lipids or lipoproteins, such as HDL subtypes (e.g., increase, including pre-beta HDL, HDL-1,-2 and 3 particles) as measured by precipitation or by apo-protein content, size, density, NMR profile, FPLC and charge and particle number and its constituents; and LDL subtypes (including LDL subtypes e.g., decreasing small dense LDL, oxidized LDL, VLDL, apo(a) and Lp(a)) as measured by precipitation, or by apo-protein content, size density, NMR profile, FPLC and charge; IDL and remnants (decrease); phospholipids (e.g., increase HDL phospholipids); apo-lipoproteins (increase A-l, A-ll, A-IV, decrease total and LDL B-100, decrease B-48, modulate C-ll, C-lll, E, J); paraoxonase (increase, anti-oxidant effects, antiinflammatory effects); decrease post-prandial (hyper)lipemia; decrease triglycerides, decrease non-HDL; elevate HDL in subjects with low HDL due to increased CETP mass or activity and optimize and increase ratios of HDL to LDL (e.g., greater than 0.25).<br>
The CETP inhibitors are also useful for increased sterol efflux/bile acid production such as reverse cholesterol transport; increased efflux from lesions; increased transport of cholesterol to liver; increased bile acid production; increased excretion of bile acids/sterols; increase bile acid flow - reduce gout cholystasis, gall stones, pancreatitis.<br>
The CETP inhibitors are also useful for cardiovascular indications such as arterial sclerotic foci; reduction in mortality due to cardiovascular events, reduction in morbidity due to cardiovascular events including, hospitalization, emergency room visits, rehospitalization; improvement in quality of life in patients with cardiovascular disease.<br>
The CETP compounds improve exercise capacity in patients with heart failure, improve oxygen consumption in patients with heart failure, improve walk distance (e.g. 6 minute) in patients with heart failure, increase treadmill exercise time.<br>
The CETP compounds also reduce human serum C-reactive protein levels, inducible cell adhesion molecule (ICAM) levels, vascular cell adhesion molecules (VCAM) levels, E-selection levels, C-reactive protein, fibrogen, chemokine and modulate of prostaglandia metabolism (including prostacyclins PGI).<br>
The CETP compounds also have anticoagulant action and antithrombotic activity and the CETP compounds also reduce platelet aggregation, reduce fibrogen levels and reduce levels of PAI-1.<br>
Specific preferred compounds of the present invention include the following: [2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-isopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl~amino]-6-chloro-2-cyclopropyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2S,4S]2-cyclopropyl-4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid isopropyl ester;<br>
[2S,4S]4-t(3,5-bis-trifluororpethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H~quinoline-1 -carboxylic acid tert-butyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
- - [2S.4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-f(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyI)-methoxycarbonyl-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-ben2yl)-methoxycarbonyl-amino]-2-ethyl-6-trifluororriethyI-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester;<br>
[2S,4S]4-[(3,5-bis-tn'fluoromethyl-ben2yl)-methoxycarbonyI-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R.4S] 4-[(3,5-bis-trifiuoromethyl-ben2y()-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; [2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester,<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2SI4S]4-[(3,5-bis-trifIuoromethyl-beri2yl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester; [2R,4S]4-[acetyl-(315-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoh'ne-1-carboxylic acid isopropyl ester; or [2R,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoIine-1-carboxylic acid ethyl ester;<br>
[2S,4S]4-[1-(3,5-bis-trifluoromethyl-benzyl)-ureido]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; [2R)4S]4-tacetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifIuoromethyl-benzyl)-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid isopropyl ester;<br>
[2S,4S] 4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyf)-amino]~2-cyclopropy|-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-bis-trif[uoromethyl-benzyl)-formyl-amino]-2-ethyI-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2S14S]4-[acetyl-(3,5-bis-trifluoromethyl-ben2yl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxyIic acid isopropyl ester; [2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2SAS]4-l(3,5-bis-trifluoromethyl-benzy))-formyl-amino]-2-cyclopropy}-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trif!uoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester, or a pharmaceuticaily acceptable salt of said compounds.<br>
The term "HMG CoA reductase inhibitor" is selected, but not limited to, the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, glenvastatin, dalvastatin, carvastatin, crilvastatin, bervastatin, cerivastatin, rosuvastatin, pravastatin, mevastatin, or rivastatin.<br>
The term "antihypertensive agent" which may be used in accordance with this invention is any antihypertensive agent thatis effective including for example, a calcium channel blocker, an ACE inhibitor, an A-ll antagonist, a diuretic, a beta-adrenergic receptor blocker, vasodilators or an alpha-adrenergic receptor blocker. -   The present invention further relates to the hemicalcium salt of atorvastatin. The term "antihypertensive agent" is further selected, but not limited to, a calcium channel blocker, said calcium channel blocker being verapamil, diltiazem, miibefradil, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, avanidpine, amlodipine, manidipine, cilinidipine, lercanidipine or felodipine or a pharmaceuticaily acceptable salt of said calcium channel blocker. The present invention further relates to the calcium channel blocker being selected from felodipine, nifedipine or amlodipine or a pharmaceuticaily acceptable salt thereof.<br>
The present invention further relates to the antihypertensive agent being selected from ari A-ll antagonist, said A-ll antagonist being losartan, irbesartan, telmisartan or valsartan or a pharmaceuticaily acceptable salt of said A-ll antagonist.<br>
The present invention further relates to the antihypertensive agent being selected from a diuretic, said diuretic being amiloride, bendroflumethiazide or a<br>
i<br>
pharmaceuticaily acceptable salt thereof.<br>
The present invention further relates to the antihypertensive agent being selected from a beta-adrenergic receptor blocker, said beta-adrenergic receptor blocker being carvedilol'or a pharmaceuticaily acceptable salt thereof.<br>
The present invention further relates to the antihypertensive agent being selected from an ACE inhibitor, said ACE inhibitor being benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, trandolapri, ramipril, zestril, zofenopril, cilaapril, temocaprir, spirapril, moexipril, delapril, imidapril, ramipril, terazosin, urapidin, indoramin, amolsulalol, alfuzosin or a pharmaceuticaily acceptable salt thereof.<br>
The present invention further relates to the antihypertensive agent being selected from an alpha-adrenergic receptor blocker, said alpha-adrenergic receptor blocker being doxazosin, prazosin, trimazosin or a pharmaceuticaily acceptable salt thereof.<br>
The present invention relates to a pharmaceutical composition comprising:<br>
(a)	a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceuticaily acceptable salt thereof;<br>
(b)	an antihypertensive agent or a pharmaceuticaily acceptable salt thereof; and<br>
(c)	a pharmaceuticaily acceptable carrier or diluent.<br>
         The present invention relates to a pharmaceutical composition comprising: (a) a cholesteryl ester transfer protein (CETP) hhibitor or a<br>
pharmaceuticaily acceptable salt thereof;	<br>
(b),an HMG CoA reductase inhibitor or a pharmaceuticaily<br>
acceptable salt thereof;<br>
(c)	an antihypertensive agent or a pharmaceuticaily acceptable salt thereof; and	<br>
(d)	a pharmaceuticaily acceptable carrier or diluent.<br>
As used herein the term mammals is meant to refer to all mammals which contain CETP in their plasma, for example, rabbits and primates such as monkeys and humans. Certain other mammals e.g., dogs, cats, cattle, goats, sheep and horses do not contain CETP in their plasma and so are not included herein.<br>
The term "treating", "treat" or "treatment" as used herein includes preventative (e.g., prophylactic) and palliative treatment.<br>
By "pharmaceutically acceptable" is meant the carrier, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation and not deleterious to the recipient hereof.<br>
The expression "prodrug" refers to compounds that are drug precursors which following administration, release the drug in vivo via some chemical or physiological process (e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the desired drug form).<br>
The expression "pharmaceutically-acceptable salt" refers to nontoxic anionic salts containing anions such as (but not limited to) chloride, bromide, iodide, sulfate, bisulfate, phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, methanesulfonate and 4-toluenesulfonate. The expression also refers to nontoxic cationic salts such as (but,not limited to) sodium, potassium, calcium, magnesium, ammonium orprotonated benzathine (N,N'-dibenzylethylenediamine), choline, ethanolamine, diethanolamine, ethylenediamine, meglamine (N-methyl-glucamine), benethamine (N-benzylphenethylamine), piperazine or tromethamine (2-amino-2-hydroxyrnethyl-1,3-propenediol).<br>
As used herein, the expressions "reaction-inert solvent" and "inert solvent" refers to a solvent or a mixture thereof which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.<br>
The term "cis" refers to the orientation of two substitutents with reference to each other and the plane of the ring (either both "up" or both "down"). Analogously, the term "trans" refers to the orientation of two substitutents with reference to each other and the plane of the rign (the substitutents being on opposite sides of the ring).<br>
Alpha and Beta refer to the orientation of a substituent with reference to the plan of the ring (i.e., page). Beta is above the plane of the ring (i.e., page) and Alpha is below the plane of the ring (i.e., page).<br>
The chemist of ordinary skill will recognize that certain compounds of this invention will contain one or more atoms which may be in a particular stereochemical or geometric configuration, giving rise to stereoisomers and configurational isomers. All such isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are also included.<br>
Detailed Description of the Invention The invention is not limited by any particular structure or group of CETP inhibitors. Rather, the invention has general applicability to CETP inhibitors as a class. Compounds which may be the subject of the invention may be found in a number of patents and published applications, including DE 19741400 A1; DE 19741399 A1; WO 9914215 A1; WO 9914174; DE 19709125 A1; DE 19704244 A1; DE 19704243 A1; EP 818448 A1; WO 9804528 A2; DE 19627431 A1; DE 19627430 A1; DE 19627419 A1; EP 796846 A1; DE 19832159; DE 818197; DE 19741051; WO 994-1237 A1; WO 9914204 A1; WO 9835937 A1; JP 11049743; WO 200018721; WO 200018723; WO 200018724; WO 200017164; WO 200017165; WO 200017166; EP 992496; and EP 987251, all of which are hereby incorporated by reference in their entireties for all purposes.<br>
One class of CETP inhibitors that finds utility with the present invention consists of oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines having the Formula I   (Formula Removed)<br>
Formula I and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds; wherein R1-1 is hydrogen, Y,, W,X1, W1Y1;;<br>
wherein W, is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl; X, is -O-Y,, -S-Yh -N(H)-Y, or-N-(Y,)2;<br>
wherein Y1 for each occurrence is independently Z1 or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z1,<br>
wherein Z\ is a partially saturated, fully saturated or fully unsaturated three to , eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyciic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Z\ substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (C-,-C4)alkylthio, amino, nitro, cyano, oxo, carboxyl, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-oir tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxyl, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines; R1.3 is hydrogen or Q,;<br>
wherein Qi is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V];<br>
wherein V is a partially saturated, fully saturated or fully unsaturated three to eight membered'ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or'a bicyclic ring consisting of two fused partially saturated, fufly saturated or fully unsaturated threeto six membered rings, taken independently, optionally having one to four heteroatoms selected<br>
independently from nitrogen, sulfur and oxygen;<br>
wherein said V1 substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carbamoyl, mono-N-or di-N,N-(C1-C6) alkylcarbamoyl, carboxyl, (C1-C6)alkyloxycarbonyl, mono-N-or di-N,N-(Ci-C6)alkylamino wherein said (C1-C6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxyl, (C1-C6)alkyloxycarbonyl, mono-N- or di-N.N-f(C1-C6)alkylamino, said (C1-C6)alkyl or (C2-C6)alkenyl substituents are also optionally substituted with from one to nine fluorines; R,-4 is Q1-1 or V1-1<br>
wherein Q1-1 is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with<br>
vM;<br>
wherein V1-1 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said V1-1 substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C1-C6)alkoxy, amino, nitro, cyano, (Cr C6)alkyloxycarbonyl, mono-N~ or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)a!kyl substituent is optionally mono-substituted with oxo, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
wherein either R1-3 must contain V1 or R1-4 must contain V1-1; and R1-5, R1-6 , R1-7 and R1-8 are each independently hydrogen, hydroxy or oxy wherein said oxy is substituted with T1 or a partially saturated, fully saturated or fully unsaturated one to twelve membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-or di-substituted with oxo, and said carbon chain is optionally mono-substituted with T,;<br>
wherein T1 is a partially saturated, fully saturated or fully unsaturated three to , eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said T1 substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyIoxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines.<br>
Compounds of Formula I and their methods of manufacture are disclosed in commonly assigned United States Patent No. 6,140,342, United States Patent No. 6,362,198, and European Patent publication 987251, all of which are incorporated herein by reference in their entireties for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula I:<br>
[2R,4S]4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-dinitro-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-rnethyI-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(2,6-dichloro-pyridin-4-ylmethyl):methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxyiic acid ethyl ester;<br>
[2R,4S]4-[(3;5-bis-trifluoromethyl-beri2yl)-methoxycarbonyl-aminoJ-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methoxy-2-methyl-3,4-dihydro-2H-quirioline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-methoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-ethoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
" [2R.4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2,2,2-trifluoro-ethylester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;<br>
[2R,4S]4-[(3I5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethoxy-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester,<br>
[2R,4S](3,5-bis-trifluoromethyl-benzyl)-(1-butyryl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;<br>
[2R.4S] (3,5-bis-trifluoromethyl-benzyl)-(1-butyl-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester; and<br>
[2R,4S](3,5-bis-trifluoromethyl-benzyl)-[1-(2-ethyl-butyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester, hydrochloride. Another class of CETP inhibitors that finds utility with the present invention consists of 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinoIines, having the Formula II  <br><br>
(Formula Removed)<br>
Formula II and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds;<br>
wherein RII is hydrogen, YII, WrXII, WII-YII; wherein WII is a carbonyl, thiocarbonyl, suifinyl or sulfonyl; Xâ€ž is -0-Yâ€ž, -S-Yâ€ž, -M(H)-Yâ€ž or -N-(Yâ€ž)2;<br>
wherein YII for each occurrence is independently ZII or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z0;<br>
ZII is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Zn substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, (Cr )alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-<br>
or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C-,-C4)aIkylthio,<br>
amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-<br>
C^alkyJamino, said (C1-C6)a\ky\ is also optionally substituted with from one to nine<br>
fluorines;<br>
Rn-3 is hydrogen or Qn;<br>
wherein Qn is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with VIII;<br>
wherein VH is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Vn substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (CVQOalkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- ordi-N,N-(C1-C6) alkylcarboxamoyl, carboxy, (CVCeJalkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino wherein said (C1-C6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (Ci-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino or said (C1-C6)alkyl or (C2-C6)alkenyl substituents are optionally substituted with from one to nine fluorines; RJM is QIM or V,i-i<br>
wherein Q|M a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said<br>
carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with VIM;<br>
wherein V^ is a partially saturated, iully saturated or fully unsaturated, .three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said VIM substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (CrCe)alkoxy, amino, nitro, cyano, (d-C6)alkyloxycarbonyl, mono-N- or di~N,N-(GrC6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-substituted with oxo, said (Ci-C6)alkyl substituent is optionally substituted with from one to nine fluorines;<br>
wherein either Ru-3 must contain V)( or R|M must contain VJM; and Rn-5, Ru-6. Riband RH-B are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with TH or a partially saturated, fully saturated or fully unsaturated (Ci-C12) straight or branched carbon chain wherein carbon may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di-'or tri-substituted independently with h.alo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon is optionally mono-substituted with TH;<br>
wherein TH is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Tn substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (C^-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(CrCe)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (CrC^IkylfhidTaTfiinor nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr<br>
C6)alkylaminoJ said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
provided that at least one of substituents Rn-5, R||.6,' R11-7 and R|W is not hydrogen and is not linked to the quinoline moiety through oxy.<br>
Compounds of Formula II and their methods of manufacture are disclosed in commonly assigned United States Patent No. 6,147,090, United States Patent Application No. 09/671,400 filed September 27, 2000, and PCT Publication No. WO00/17166, ail of which are incorporated herein by reference in their entireties for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula \\:<br>
[2R,4S]4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-7-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-Bis-trifluoromethyl-ben2yl)-methoxycarbonyl-amino]-7-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4SJ4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2,6,7-trimethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6,7-diethyl-2-methyl-3,4-dihydro-2H-qu/noline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-ethyl-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
-    - [2R,4S] 4-[(3,5-Bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylicacid ethyl ester; and<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines, having the Formula III<br><br>
(Formula Removed)<br>
Formula III and pharmaceutical^ acceptable salts, enantiomers, or stereoisomers of said compounds;<br>
wherein RUM is hydrogen, Ym, WHrXi,i, Wm-Yi,,; wherein Wm is a carbonyl, thiocarbonyl, sulfinyl.or sulfonyl; X,â€ž is -0-Y1(I, -S-Y,,,, -N(H)-Y(I( or -N-(Y,â€ž)2;<br>
Ym for each occurrence is independently Zm or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said parbon chain is optionally mono-substituted with Zm;<br>
wherein 2m is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Zm substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (Cr C4)a!kylthio, amino, nitro, cyano, oxo, carboxy, (Ci-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-<br>
or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (Ci-C4)alkylthio, amino, nitro, cya'no, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino, said ((C1-C6))alkyl optionally substituted with from one to nine fluorines; RIII.3 is hydrogen or Q,n;<br>
wherein QIII is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with hafo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with VIII;<br>
wherein VIII is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, 67~a~6icycÂ¥cririg"cd7)s^"sfjng of two" fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Vm substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (Gr C4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N-(C1-C6) alkylcarboxamoyl, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(d-C6)alkylamino wherein said (C1-C6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C-i-C6)alkoxy, (Cr C^alkylthio, amino, nitro, cyano, oxo, carboxy, (Ci-C6)alkyloxycarbonyl, mono-N-or di-KN-fCVCsJalkylamino or said (C1-C6)alkyl or (C2-C6)alkenyl are optionally substituted with from one to nine fluorines; R111.4 is Q111-1 orVm.-,;<br>
wherein QHM a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-<br>
substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and<br>
said carbon chain is optionally mono-substituted with<br>
VIII;<br>
wherein VIII-1 is a partially saturated, fully saturated or fully unsaturated,, three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said VIII-1 substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)aikyl, (C1-C6)alkoxy, amino, nitro, cyano, (C1 C6)alkyioxycarbonyl, mono-N- or di-N,N-(C1-C6)aikylamino wherein said {C1-C6)aJkyf substituent is optionally mono-substituted with oxo, said (C1-C6)alkyl substituent optionally having from one to nine fluorines;<br>
wherein either RIII-3 must contain VIII or RIII-4 must contain VIII-1; and RIII-5 and RIII-6, or RIII-6 and RIII-7, and/or RIII-7and RIII-8 are taken together and form at least one four to eight membered ring that is partially saturated or fully unsaturated optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;<br>
wherein said ring or rings formed by RIII-5and RIII-6, or RIII-6 and RIII-7, and/br Riband Rm.B are optionally mono-,,di- or tri-substituted independently with halo, (Cr C6)alkyl, (C1-C4)alkylsulfonyl, (C2-C6)alkenyl, hydroxy, (C1-C6)aJkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkylqxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (CrC6)alkyl substituent optionally having from one to nine fluorines;<br>
provided that the RIII-5 , RIII-6 , RIII-7 and/or RIII-8, as the case may be, that do not form at least one ring are each independently hydrogen, halo, (C1-C6)afkoxy or C1-C6)alkyl, said (C1-C6)alkyl optionally having from one to nine fluorines.<br>
Compounds of Formula III and their methods of manufacture are disclosed in commonly assigned United States Patent No. 6,147,089, United States Patent No. 6,310,075, and European Patent Application No. 99307240.4 filed September 14, 1999, alt of which are incorporated herein by reference in their entireties for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula ill:<br>
[2R, 4S]4-[(3,5-bis-trif[uoromethyl-benzyI)-methoxycarbonyl-amino]-2-methyl-2,3,4,6,7,8-hexa'hydro-cyclopenta[g]quinoline-1-carboxyIic acid ethyl ester;<br>
[6R, 8S]8-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-methyl-3,6,7,8-tetrahydro-1 H-2-thia-5-aza-cyciopenta[b]naphthalene-5-carboxylic acid ethyl ester;<br>
[6R, 8S]8-[(3,5-bis-trifluoromethyl-benzy])-methoxycarbonyl-amino]-6-methyl-3,(3,7,8-tetrahydro-2H-furo[2,3-g]quinoline-5-carboxyIic acid ethyl ester;<br>
[2R,4S]4-[(3I5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-3,4,6,8-tetrahydro-2H-furo[3,4-g]quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3I5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methyl-3,4,6,7,8,9-hexahydro-2H-benzo[g]quinoline-1-carboxylic acid propyl ester;<br>
[7R.9S] 9-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-7-methyl-1 2,3,7,8,9,hexahydro-6-aza-cyclopentafalnaphthalene-6-carboxylic acid ethyl ester; and<br>
[6S.8R] 6-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-8-methyl-1,2,3,6,7,8-hexahydro-9-aza-cyclopenta[a]naphthalene-9-carboxylic acid ethyl ester.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of 4-carboxyamino-2-substituted-1,2,3,4,-tetrahydroquinolines, having the Formula IV<br>
(Formula Removed)<br>
Formula IV<br>
and pharmaceutical^ acceptable salts, enantiomers, or stereoisomers of said<br>
compounds;<br>
wherein RV-1 is hydrogen, YIV, W|vX)v or W,V-Y|V;<br>
wherein Wiv is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;<br>
XIV is -0-Y)V, -S-YIV) -H(H)-YN or -N-(Y,v)2;    â€¢<br>
wherein Y!V for each occurrence is independently ZN or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with ZIv<br>
wherein ZIv is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said ZIv substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-or tri-substituted independently with halo, hydroxy, (C1-C6)aIkoxy, (C1-C4)alkyIthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
Riv-2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said RN.2 is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to<br>
two heteroatoms'selected independently from oxygen, sulfur and nitrogen, wherein said RIv-2 ring is optionally attached through (C1-C4)aIkyI;<br>
wherein said RIv-2 ring is optionally mono-, di- or tri-substitufed independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C4)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)a!kylthio, oxo or (C1-C6)alkyloxycarbonyl;<br>
with the proviso that RIv-2 is not methyl; Riv-3 is hydrogen or QIv;<br>
wherein QIv is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with VIv;<br>
wherein VIv is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said VIv substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (CrC6)a)kyl, (C2-C6)alkenyl, hydroxy, (CrC6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N-(CrC6) alkylcarboxamoyl, carboxy, (CrC6)alkyloxycarbonyl, mono-N- or di~N,N-(Cr C6)alkylamino wherein said (CrC6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyI, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyI or (C2-C6)alkenyl substituents are also optionally substituted with from one to nine fluorines; Riv-4's QIv-1 or VIv-1;<br>
wherein QlV-1 a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with<br>
wherein VlV-1  is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said VlV-1  substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C1-C6)alkoxy, amino, nitro, cyano, (C1 C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-substituted with oxo, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br><br>
wherein either Riv-3 must contain Vtv or RIV-4must contain VIV-1; RIV-5 &gt; RIV-6. RIV-7 and RIV-8 are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with TIV or a partially saturated, fully saturated or fully unsaturated (C1-C12) straight or branched carbon chain wherein carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon is optionally-mono-substituted with TIV;<br>
wherein TIV is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Tiv substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)aIkoxy, (C1 C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N.N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-or tri-substituted independently with hydroxy, (C-rC6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1 C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines; and<br>
wherein RIV-5 and PIV-6, or RIv-6 and RIv-7, and/or RIV-7 and RIV-8 may also be taken together and can form at least one four to eight membered ring that is partially saturated or fully unsaturated optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;<br>
wherein said ring or rings formed by R|V-5 and R|V-6, or R|V-6 and R|V-7, and/or RIV-7 and RIV-8 are optionally mono-, di- or tri-substituted independently with halo, (C1 C6)alkyl, (C1-C6)alkylsulfonyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1 C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N.N-(C1-C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
with the proviso that when R|V-2 is carboxyl or (C1-C4)alkylcarboxyl, then RV-1 is not hydrogen.   â€¢<br>
Compounds of Formula IV and their methods of manufacture are disclosed in commonly assigned United States Patent No. 6,197,786, United States Application Serial No. 09/685,3000 filed 10/10/00, and PCT Publication No. WO 00/17164, all of which are incorporated herein by reference in their entireties for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from one of the following compounds of Formula IV:<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-isopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; [2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-cyclopropyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2S,4S]2-cyclopropyl-4-[(3,5-dichloro-ben2yl)-methoxycarbonyl-amino]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyI-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;<br>
[2R,4R]4-[(3,5-bis-trifluoromethyl-benzyI)-<br>
methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinaline-1-carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid isopropyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid isopropyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-tnfluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester; and<br>
[2R,4S]4-[(3,5-bis-trifIuoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-triJ"luoromethyI-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester.<br>
â€¢ In a preferred embodiment, the CETP inhibitor is [2R,4S]-4-[(3,5-bis-trifluoromethyl-benzyI)-methoxycarbonyI-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester also known as torcetrapib.   Torcetrapib is shown by the following Formula<br>
(Formula Removed)<br>
CETP inhibitors, in particular torcetrapib, and methods for preparing such compounds are disclosed in detail in U.S. Patent Nos. 6,197,786 and 6,313,142, in PCT Application Nos. WO 01/40190A1, WO 02/088085A2, and WO 02/088069A2, the disclosures of which are herein incorporated by reference. Torcetrapib has an unusually low solubility in aqueous environments such as the lumenal fluid of the human Gl tract. The aqueous solubility of torceptrapib is less than about 0.04 Âµg/ml. Torcetrapib must be presented to the Gl tract in a solubility-enhanced form in order to achieve a sufficient drug concentration in the Gl tract in order \o achieve sufficient absorption into the blood to elicit the desired therapeutic effect.<br>
Formula V<br>
Another class of CETP inhibitors that finds utility with the present invention consists of 4-amino substituted-2-substituted-1,2,3,4,-tetrahydroquinolines, having the Formula V<br>
(Formula Removed)<br>
and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said<br>
compounds;<br>
wherein Rv-1 is Yv&gt; Wv-Xv or Wv-Yv;<br>
wherein Wv is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;<br>
Xv is -O-Yv, -S-Yv, -N(H)-YV or -N-(YV)2;<br>
wherein Yv for each occurrence is independently Zv or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently wiih halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Zv;<br>
wherein Zv is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Zv substituent is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (C1 C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alky!oxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di-or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(Cr C6)alkylamino, said (C1-C6)alkyl substituent is also optionally substituted with from one to nine fluorines;<br>
RV-2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with<br>
hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-or di-substituted with oxo; or said Rv-2 is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said Rv-2 ring is optionally attached through (C1-C4)alkyl;<br>
wherein said RV-2 ring is optionally mono-, di- or tri-substituted independently with halo, (C2-C6)alkenyl, (C1-C6) alkyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(d-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, oxo or (C1-C6)alkyloxycarbonyl; RV-3 is hydrogen or Qv;<br>
wherein Qv is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- ortri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Vv;<br>
wherein Vv is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Vv substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N-(C1-C6) alkylcarboxamoyl, carboxy, (C1-C6)a)kyloxycarbonyl, mono-N-or di-N,N-(C1 C6)alkyiamino wherein said (C1-C6)alkyl or (C2-C6)alkenyl substituent is optionally mono-, di- or tri-substftuted independently with hydroxy, (C1-C6)afkoxy, (Cr C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)aIkyloxycarbonyl, mono-N- or<br>
di-N,N-(C1-C6)alkylarnino, said (C1-C6)a]kyl or (C2-C6)alkenyl substituents are also optionally substituted with from one to nine fluorines; RV-4 is cyano, formyl, WV-iQv-i, WV-iVV-i, (C1-C4)alkyleneVv-i or Vv.2; wherein WV-t is carbonyl, thiocarbonyl, SO or SO2,<br>
wherein QV-i a fully saturated, partially unsaturated or fully unsaturated one to six membered straight ox branched carbon chain wherein the carbons may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Vv-1<br>
wherein Vv-1 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;   (<br>
wherein said \AM substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, oxo, amino, nitro, cyano, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-substituted with oxo, said (C1-C6)aikyl substituent is also optionally substituted with from one to nine fluorines;<br>
wherein VV-2 is a partially saturated, fully saturated or fully unsaturated five to seven membered ring containing one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said Vv.2 substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C2)a!kyl, (C1-C2)alkoxy, hydroxy, or oxo wherein said (C1-C2)alkyl optionally has from one to five fluorines; and<br>
wherein Rv-4 does not include oxycarbonyl linked directly to the C4 nitrogen; wherein either Rv-3 must contain Vv or RV-4 must contain VV-1 Rv-5 , Rv-6  Rv-7 and Rv.8are independently hydrogen, a bond, nitro or halo wherein said bond is substituted with Tv or a partially saturated, fully saturated or fully unsaturated (C1-C2) straight or branched carbon chain wherein carbon may<br>
optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Tv;<br>
wherein TV is a partially saturated, fully saturated or fully unsaturated three to twelve membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;<br>
wherein said Tv substituent is optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C2-C6)alkenyl, hydroxy, (C1-C6)a!koxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl subst/tuent is optionally mono-, di-or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyl substituent also optionally has from one to nine fluorines;<br>
wherein Rv-5 and FV-6, or RV-6 and Rv-7 and/or Rv-7 and RV-8 may also be taken together and can form at least one ring that is a partially saturated or fully unsaturated four to eight membered ring optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;<br>
wherein said rings formed by RV-5 and Rv-6, or Rv-6 and Rv-7, and/or Rv-7and Rv-f are optionally mono-, di- or tri-substituted independently with halo, (C1-C6)alkyl, (C1-C4)alkylsulfonyl, (C2-C6)alkenyl, hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino wherein said (C1-C6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C1-C6)alkoxy, (C1-C4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C1-C6)alkyloxycarbonyl, mono-N- or di-N,N-(C1-C6)alkylamino, said (C1-C6)alkyl substituent also optionally has from one to nine fluorines.<br>
Compounds of Formula V and their methods of manufacture are disclosed in commonly assigned United States Patent No. 6,140,343, United States Patent<br>
Application Serial No. 09/671,221 filed September 27, 2000, and PCT Publication No. WO 00/17165, all of which are incorporated herein by reference in their entireties for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from one ofâ€žthe following compounds of Formula V:<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-ben2yI)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoiine-1-carboxylic acid isopropyl ester;<br>
[2S,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoIine-1-carboxylic acid tert-butyl ester; [2R,4S]4-[acetyi-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxy)ic acid ethyl ester;<br>
[2S,4S]4-[1-(3,5-bis-trifluoromethyl-benzyl)-ureido]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; [2R,4S]4-[acetyI-(3,5-bis-trrfIuoromethyI-benzyI)-amino]-2-ethyl-6-trifluoromethyl-3,4~dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzy))-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester;<br>
-[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifIuoromethyI-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
t2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-ethyI-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyI-6-trif!uoromethyl-3,4-dihydro-2H-quinoline-1-carboxyIic acid ethyl ester;<br>
[2S,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; [2R,4S]4-[(3,5-bis-trifluoromethyl-benzy])-formyl-amino]-2-ethyI-6-trifluoromethy-3,4 dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2S,4S]4-[(3,5-bis-trifIuoromethyI-benzyl)-formyl-amino]-2-cyclopropyl-6-trifluoromethyl-3',4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;<br>
[2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-formyl-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; and<br>
[2R,4S]4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-<br><br>
trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of cycloalkano-pyridines having the Formula VI<br>
(Formula Removed)<br>
Formula VI and pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds; in which<br>
AVI denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with up to five identical or different substituents in the form of a halogen, nitro, hydroxyl, trifiuoromethyl, trifluoromethoxy or a straight-chain or branched alkyl, acyl, hydroxyalkyi or alkoxy containing up to 7 carbon atoms each, or in the form of a group according to the formula -BNRVI-3RVI-4, wherein<br>
RVI-3 and RVI-4are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alkyl containing up to 6 carbon atoms,<br>
DVI denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with a phenyl, nitro, halogen, trifiuoromethyl or trifluoromethoxy, or a radical according to the formula RVI-5-Lvr,<br>
or RVI-9TVIVVIxVI wherein<br>
RVI-5, RVI-6 and RVI-9 denote, independently from one another, a cycloalkyl containing 3 to 6 carbon atoms, or an any! containing 6 to 10 carbon atom or a 5- to 7-membered, optionally benzo-condensed, saturated or unsaturated, mono-, bi- or tricyclic heterocycle containing up to 4 heteroatoms from the series of S, N and/or O, wherein the rings are optionally substituted, in the case of the nitrogen-containing rings also via the N function, with up to five identical or different substituents in the form of a halogen, trifluoromethyl, nitro, hydroxyl, cyano, carboxyl, trifiuoromethoxy, a straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl containing up to 6 carbon atoms each, an aryl or trifluoromethyl-substituted aryl containing 6 to 10 carbon atoms each, or an optionally benzo-condensed, aromatic 5-to 7-membered heterocycle containing up to 3 heteoatoms from the series of S, N and/or O, and/or in the form of a group according to the formula BORVMO. -SRvm, -S02RVI-12 or BNRVI-13RVI-14. wherein<br>
RVMO. RVI-11 and RVI-12 denote, independently from one another, an aryl<br>
containing 6 to 10 carbon atoms, which is in turn substituted with up to two identical<br>
or different substituents in the form of a phenyl, halogen or a straight-chain or<br>
branched alkyl containing up to 6 carbon atoms,	<br>
RVI-13 and RVI-14 are identical or different and have the meaning of RVI-3 and RVI-4 given above, or<br>
RVI-5 and/or RVI-6 denote a radical according to the formula<br>
(Formula Removed)<br>
RVI-7 denotes a hydrogen or halogen, and<br>
RVI-8 denotes a hydrogen, halogen, azido, trifluoromethyl, hydroxyl, trifiuoromethoxy, a straight-chain or branched alkoxy or alkyl containing up to 6 carbon atoms each, or a radical according to the formula<br>
(Formula Removed)<br>
wherein<br>
RVI-15 and RVI-16 are identical or different and have the meaning of RVI-3and RVI-4 given above, or<br>
RVI-7 and RVI-8 together form a radical according to the formula =0 or =NRVI-7, wherein<br>
RVI-17denotes a hydrogen or a straight-chain or branched alkyl, alkoxy or acyl containing up to'6 carbon atoms each,<br>
t<br>
LVI denotes a straight-chain or branched alkylene or alkenylene chain containing up to 8 carbon atoms each, which are optionally substituted with up to two hydroxyl groups,<br>
TVIand XVI are identical or different and denote a straight-chain or branched afkylene chain containing up to 8 carbon atoms, or<br>
TVIor XVI denotes a bond,<br>
VVi denotes an oxygen or sulfur atom or an BNRVI-18 group, wherein'<br>
RVI-18 denotes a hydrogen or a straight-chain or branched alkyl containing up to 6 carbon atoms or a phenyl,<br>
EVI denotes a cycloalkyl containing 3 to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a cycloalkyl containing 3 to 8 carbon atoms or a hydroxyl, or a phenyl, which is optionally substituted with a halogen or trifluoromethyl,<br>
RVI-1 and RVI-2 together form a straight-chain or branched alkylene chain containing up to 7 carbon atoms, which must be substituted with a carbonyl group and/or a radical according to the formula<br>
(Formula Removed)<br>
wherein<br>
a and b are identical or different and denote a number equaling 1, 2 or 3, RVI-19 denotes a hydrogen atom, a cycloalkyl containing 3 to 7 carbon atoms, a straight-chain or branched silylalkyl containing up to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a hydroxyl, a straight-chain or a branched alkoxy containing up to 6 carbon atoms or a phenyl, which may in turn be substituted with a halogen, nitro, trifluoromethyl, trifluoromethoxy or phenyl or tetrazole-substituted phenyl, and an alkyl that is optionally substituted with a group according to the formula BORVI-22, wherein<br>
RVI-22 denotes a straight-chain or branched acyl containing up to 4 carbon atoms or benzyl, or<br>
RVI-5. RVI-6 and RVI-9 denote, independently from one another, a cycloalkyl containing 3 to 6 carbon atoms, or an aryl containing 6 to 10 carbon atom or a 5-to 7-membered, optionally benzo-condensed, saturated or unsaturated, mono-, bi- or tricyclic heterocycle containing up to 4 heteroatoms from the series of S, N and/or O, wherein the rings are optionally substituted, in the case of the nitrogen-conta'ining rings also via the N function, with up to five identical or different substituents in the form of a halogen, trifluoromethyl, nitro, hydroxyl, cyano, carboxyl, trifluoromethoxy, a straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl containing up to 6 carbon atoms each, an aryl or trifluoromethyl-substituted aryl containing 6 to 10 carbon atoms each, or an optionally benzo-condensed, aromatic 5-to 7-membered heterocycle containing up to 3 heteoatoms from the series of S, N and/or O, and/or in the form of a group according to the formula BORVI-10. -SRVI-11, -S02RVI-12 or BNRVI-13RVI-14, wherein<br>
RVI-10 RVI-11 and RVI-12 denote, independently from one another, an aryl containing 6 to 10 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a phenyl, halogen or a straight-chain or branched a!kyl containing up to 6 carbon atoms,<br>
RVI-132 and RVI-14 are identical or different and have the meaning of RVI-13 and RVI-4 given above, or<br>
RVI-5 and/or RVI-6 denote a radical according to the formula<br>
(Formula Removed)<br>
RVI-7 denotes a hydrogen or halogen, and<br>
RVI-6 denotes a hydrogen, halogen, azido, trifluoromethyl, hydroxyl, trifluoromethoxy, a straight-chain or branched alkoxy or alkyl containing up to 6 carbon atoms each, or a radical according to the formula<br>
wherein <br>
RVI-15 and RVI-16are identical or different and have the meaning of RVI-13 and RVI-4 given above, or<br>
RVI-7 and RVI-8 together form a radical according to the formula =0 or =NRVI-17, wherein<br>
RVI-7 denotes a hydrogen or a straight-chain or branched alkyl, alkoxy or acyl containing up to'6 carbon atoms each,<br>
LVIdenotes a straight-chain or branched alkyiene or alkenylene chain conlaining up to 8 carbon atoms each, which are optionally substituted with up to two hydroxyl groups,<br>
TVI and XVI are identical or different and denote a straight-chain or branched alkyiene chain containing up to 8 carbon atoms, or TVI or XVI denotes a bond,<br>
VVI denotes an oxygen or sulfur atom or an BNRVI-18 group, wherein" RVI-18 denotes a hydrogen or a straight-chain or branched alkyl containing up to 6 carbon atoms or a phenyl,<br>
EVI denotes a cycloalkyl containing 3 to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a cycloalkyl containing 3 to 8 carbon atoms or a hydroxyl, or a phenyl, which is optionally substituted with a halogen or trifluoromethyl,<br>
RVI-1 and RVI-2 together form a straight-chain or branched alkyiene chain containing up to 7 carbon atoms, which must be substituted with a carbonyl group and/or a radical according to the formula<br>
(Formula Removed)<br>
wherein<br>
a and b are identical or different and denote a number equaling 1, 2 or 3, RVI-9 denotes a hydrogen atom, a cycloalkyl containing 3 to 7 carbon atoms, a straight-chain or branched silylalkyl containing up to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a hydroxyl, a straight-chain or a branched alkoxy containing up to 6 carbon atoms or a phenyl, which may in turn be substituted with a halogen, nitro, trifluoromethyl, trifluoromethoxy or phenyl or tetrazole-substituted phenyl, and an alkyl that is optionally substituted with a group according to the formula BORVI-22. wherein<br>
Rvi-22 denotes a straight-chain or branched acyl containing up to 4 carbon atoms or benzyl, or<br>
RVI-19 denotes a straight-chain or branched acyl containing up to 20 carbon atoms or benzoyl, which is optionally substituted with a halogen, trifluoromethyl, nitro or trifiuoromethoxy, or a straight-chain or branched fluoroacyl containing up to 8 carbon atoms,<br>
RVI-20 and RVI-21 are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alky! containing up to 6 carbon atoms, or<br>
RVI-20 and RVI-21 together form a 3- to 6-membered carbocyclic ring, and a the carbocyclic rings formed are optionally substituted, optionally also geminally, with up to six identical or different substituents in the form of trifluoromethyl, hydroxy!, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy containing 3 to 7 carbon atoms each, a straight-chain or branched alkoxycarbonyl, alkoxy or alkylthio containing up to 6 carbon atoms each, or a straight-chain or branched alkyl containing up to 6 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a hydroxyl, benzyloxy, trifluoromethyl, benzoyl, a straight-chain or branched alkoxy, oxyacyl or carboxyl containing up to 4 carbon atoms each and/or a phenyl, which may in turn be substituted with a halogen, trifluoromethyl or trifiuoromethoxy, and/or the carbocyclic rings formed are optionally substituted, also geminally, with up, to five identical or different substituents in the form of a phenyl, benzoyl, thiophenyl or sulfonylbenzyl, which in turn are optionally substituted with a halogen, trifluoromethyl, trifiuoromethoxy or nitro, and/or optionally in the form of a radical according to the formula<br>
wherein <br>
c is a number equaling 1, 2, 3 or 4,<br>
d is a number equaling 0 or 1,<br>
Rvi-23 and RVI-24 are identical or different and denote a hydrogen, cycloalkyl containing 3 to 6 carbon atoms, a straight-chain or branched alkyl containing up to 6 carbon atoms, benzyl or phenyl, which is optionally substituted with up to two identical or different substituents in the form of halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the carbocyclic rings formed are optionally substituted with a spiro-linked radical according to the formula<br>
(Formula Removed)<br>
wherein<br>
WVI denotes either an oxygen atom or a sulfur atom,<br>
YVI and Y=VI together form a 2- to 6-membered straight-chain or branched alkylene chain,'<br>
e is a number equaling 1, 2, 3, 4, 5, 6 or 7,<br>
f is a number equaling 1 or 2,<br>
RVI-25, RVI-26, RVI-27, RVI-28, RVI-29, RVI-3o and RVI31 are identical or different and denote a hydrogen, trifluoromethyl, phenyl, halogen or a straight-chain or branched alkyl or alkoxy containing up to 6 carbon atoms each, or<br>
RVI-25 and RVI-26 or RVI-27 and RVI-28 each together denote a straight-chain or<br><br>
branched alkyl chain containing up to 6 carbon atoms or<br>
RVI-25 and RVI-26 or RVI-27 and RVI-28 each together form a radical according to the Formula<br>
(Formula Removed)<br>
wherein	<br>
WVI has the meaning given above,<br>
g is a number equaling 1, 2, 3, 4, 5, 6 or 7,<br>
RVI-32 and Rvi-33 together form a 3- to 7-membered heterocycle, which contains an oxygen or sulfur atom or a group according to the formula SO, S02 or BNRvi-34, wherein<br>
Rvi-34 denotes a hydrogen atom, a phenyl, benzyl, or a straight-chain or branched alkyl containing up to 4 carbon atoms, and salts and N oxides thereof, with the exception of 5(6H)-quinolones, 3-benzoyl-7,8-dihydro-2,7,7-trimethyl-4-phenyl. Compounds of Formula VI and their methods of manufacture are disclosed in European Patent Application No. EP 818448 A1, United States Patent No. 6,207,671 and United States Patent No. 6,069,148, all of which are incorporated herein by reference in their entireties for all purposes.<br>
in a preferred embodiment, the CETP inhibitor is selected from one of the ollowing compounds of Formula VI:<br>
2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-3-(4-trifluoromethylbenzoyl)-<br>
l,6,7,8-tetrahydro-1 H-quinolin-5-one;	<br>
2-cyclopentyl-4-(4-fiuorophenyl)-7,7-dimethyl-3-(4-trifluoromethylbenzoyl)-7,8-dihydro-6H-quinolin-5-one;<br>
[2-cyclopentyl-4-(4-fluorophenyl)-5-hydroxy-7,7-dimethyl-5,6,7,8-tetrahydroquinoIin-3-ylJ-(4-trifluoromethylphenyl)-methanone;<br>
[5-(t-butyldimethylsilanyloxy)-2-cyclopentyl-4-(4-fiuorophenyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanone;<br>
[5-(t-butyldimethylsilanyIoxy)-2-cyclopentyl-4-(4-fluorophenyl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl]-(4-trifluoromethylphenyl)-methanol;<br>
5-(t-butyldimethylsilanyioxy)-2-cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-(4-trifluoromethylphenyl)-methyl]-7,7-dimethyl-5,6,7,8-tetrahydroquinoline; and<br>
2-cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-(4-trifluoromethylphenyl)-methyl]-7,7-dimethyI-5,6,7,8-tetrahydroquinoIin-5-ol.<br>
Another class of CETP inhibitors that finds utility with the present inventidn consists of substituted-pyridines haying the Formula vII<br>
(Formula Removed)<br>
Formula vII or a pharmaceutical^ acceptable salt or tautomer thereof, wherein<br>
RVII2 and RVII6 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, fiuorinated alkyl, fiuorinated aralkyi, chlorofluorinated alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkoxyalkyl, and alkoxycarbonyl; provided that at least one of RVII-2 and RvÂ»-6 is fiuorinated alkyl, chlorofluorinated alkyl or alkoxyalkyl;<br>
RVII3 is selected from the group consisting of hydroxy, amido, arylcarbonyl,<br>
heteroarylcarbohyl, hydroxymethyl     <br>
-CHO,-CO2RVII-7, wherein RVII-7 is selected from the group consisting of hydrogen, alkyl and<br>
cyanoalkyl; and<br>
(Formula Removed)<br>
wherein RVII-15a is selected from the group consisting of hydroxy, hydrogen, halogen, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy and heterocyclyloxy, and<br>
RVII-16a is selected from the group consisting of alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, and heterocyclyl, arylalkoxy, trialkylsilyloxy;<br>
RVII-4 is selected from the group consisting of hydrogen, hydroxy, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyi, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl, heteroarylalkyl heterocyclylalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl, hetereoarylalkenyl, heterocyclylalkenyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, heteroaroyloxy, heterocyclyloyloxy, alkoxycarbonyl, alkenoxycarbonyl, alkynoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocyclyloxycarbonyl, thio, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, cycloalkylthio, cycloalkenylthio, alkylthioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, heteroarylthioalkyl, heterocyclylthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, arylthioalkenyl, heteroarylthioalkenyl, heterocyclythioalkenyl, alkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, heterocyclylamino, aryldialkylamino, diarylamino, diheteroarylamino, alkylarylamino, alkylheteroarylamino, arylheteroarylamino, trialkylsilyl, trialkenylsilyl, triarylsilyl, -CO(0)N(RVII-8aRVII-8=), wherein RVII-8a and RVII-8B are independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, -S02RVII9, wherein RVII-9 is selected from the group consisting of hydroxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, -OP(O)(ORVII-10A) (ORVII-10B), wherein RVII-10and RVII 10b are independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and -OP(S) (ORVII-11A) (ORVII-11B),<br>
herein RVII-11a and RVII-11b are independently selected from the group consisting of aikyl, alkenyl, alkynyl, aryi, heteroaryl and heterocyclyl;<br>
RVII-5 is selected from the group consisting of hydrogen, hydroxy, halogen,<br>
alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl,<br>
aryi, heteroaryl, heterocyclyl, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy,<br>
helerocyclyloxy, alkylcarbonyloxyalkyl, alkenylcarbonyloxyalkyl,<br>
alkynylcarbonyloxyalkyl, arylcarbonyloxyalkyl, heteroarylcarbonyloxyalkyl,<br>
heterocyclylcarbonyloxyalkyl, cycloalkylalkyl, cycloalkenylalkyl, aralkyl,<br>
heteroarylalkyl, heterocyclylalkyl, cycloalkylalkenyl, cycloalkenylalkenyl, aralkenyl,<br>
heteroarylalkenyl, heterocyclylalkenyl, alkylthioalkyl, cycloalkylthioalkyl,<br>
alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, heteroarylthioalkyl,<br>
heterocyclylthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl,<br>
arylthioalkenyl, heteroarylthioalkenyl, heterocyclylthioalkenyl, alkoxyalkyl,<br>
alkepoxyalkyl, alkynoxylalkyl, aryloxyalkyl, heteroaryloxyalkyl, heterocyclyloxyalkyl,<br>
alkoxyalkenyl, alkenoxyalkenyl, alkynoxyalkenyl, aryloxyalkenyl,<br>
heteroaryloxyalkenyl, heterocyclyloxyalkenyl, cyano, hydroxymethyl, -C02RVII-14,<br>
wherein RVII-14 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryi,<br>
heteroaryl and heterocyclyl;	<br>
(Formula Removed)<br>
wherein RVII-15B is selected from the group consisting of hydroxy, hydrogen, halogen, alkylthio, aJkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, aroyloxy, and alkylsulfonyloxy, and<br>
RVII-16b is selected form the group consisting of alkyl, alkenyl, alkynyl, aryL, heteroaryl, heterocyclyl, arylalkoxy, and trialkylsilyloxy;<br>
(Formula Removed)<br>
wherein RVII-17 and RVII-18 are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl;<br>
(Formula Removed)<br>
wherein RVII-19 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, -SRVII-20. -ORVII-21, and BRVII-22CO2RVII-23 wherein<br>
RVII-20is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aminoaryl, aminoheteroaryl, aminoheterocyclyl, alkylheteroarylamino, arylheteroarylamino,<br>
RVII-21 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl,<br>
RVII-22is selected from the group consisting of alkylene or arylene, and<br>
RVII-23 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;<br>
wherein RVII25 is heterocyclylidenyl;<br>
(Formula Removed)<br>
wherein RVII-24 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, aralkyl, aralkenyl, and aralkynyl;<br>
(Formula Removed)<br>
wherein RVII-26 and RVII-27 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;<br>
(Formula Removed)<br>
wherein RVII-28 and RVII-29 are independently selected from the group consisting of hydrogen, alkyi, cycloalkyl, alkenyl, alkynyl, aryl,-heteroaryl, and heterocyclyl; <br>
wherein RVII-30 and RVII-31 are independently alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, and heterocyclyloxy; and<br>
(Formula Removed)<br>
wherein RVII-32 and RVII-33 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl;<br>
(Formula Removed)<br>
wherein RVII-36 is selected from the group consisting of alkyl, alkenyl, aryl, heteroaryl and heterocyclyl;<br>
(Formula Removed)<br>
wherein RVII-37 and RVII-38 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyciyl;<br>
(Formula Removed)<br>
wherein RVII-39 is selected from the group consisting of hydrogen, alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio and heterocyclylthio, and<br>
RVII-40 is selected from the group consisting of haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, haloheterocyclyl, cycloalkyl, cycloalkenyl, heterocyclylalkoxy, heterocyclylalkenoxy, heterocyclylalkynoxy, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio and heterocyclylthio;<br>
-N=RVii.4i,<br>
wherein RVII-41 is heterocyclylidenyl;<br>
(Formula Removed)<br>
wherein RVII-42 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyciyl, and<br>
RVII-43 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyciyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl, and haloheterocyclyl;<br>
(Formula Removed)<br>
wherein RVII-44 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyciyl;<br>
(Formula Removed)<br>
wherein RVII-45 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, haloalkyl, haloalkeny!, haloalkynyl, haloaryl, haloheteroaryl, haloheterocyclyl, heterocyclyl, cycloalkyialkyl, cycioalkenylalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl, cycloalkylalkenyi, cycloalkenylalkenyl, aralkenyl, heteroarylalkenyl, heterocyclylalkenyl, alkyithioalkyl, alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl.heteroarylthioalkyl, heterocyclylthioalkyl, alkylthioalkenyl, alkenylthioalkenyl, alkynylthioalkenyl, aryithioalkenyl, heteroarylthioalkenyl, heterocyclylthioalkenyl, aminocarbonylalkyl, aminocarbonylalkenyl, aminocarbonylalkynyl, aminocarbonylaryl, aminocarbonylheteroaryl, and aminocarbonylheterocyclyl,<br>
-SRVII46 and -CH2RVII-47<br>
wherein RVIM6 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and<br>
RVIM7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl; and<br>
(Formula Removed)<br>
wherein RVII-48 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl, and<br>
RVII-49 is selected from the group consisting of alkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, heterocyclyloxy, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroaryl and haloheterocyclyl;<br>
(Formula Removed)<br>
wherein RVII-50 is selected from the group consisting of hydrogen, alkyl, cyoloalkyl, alkenyl, alkynyl,aryl,heteroaryl heterocyclyl, alkoxyl alkenoxy, -alkynoxy, aryloxy, heteroaryloxy and heterocyclyloxy;<br>
(Formula Removed)<br>
wherein RVIII-51 is selected from the group consisting of alkyl, alkenyl, aikynyl, aryl, heteroaryl, heterocyclyl, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, haloheteroarvl and haloheterocyclyl: and<br>
(Formula Removed)<br>
wherein RVIII-53 is selected from the group consisting of alkyl, alkenyl, aikynyl, aryl, heteroaryl and heterocyclyl;<br>
provided that when RVIII-5 is selected from the group consisting of heterocyclylalkyl and heterocyclylalkenyl, the heterocyclyl radical of the corresponding heterocyclylalkyl or heterocyclylalkenyl is other than Î´-lactone; and<br>
provided that when RVIII-4 is aryl, heteroaryl or heterocyclyl, and one of RVII-2 and RVII-6 is trifluoromethyl, then the other of RVII-2 and RVII-6 is difluoromethyl.<br>
Compounds of Formula Vll and their methods of manufacture are disclosed in PCT Publication No. WO 9941237-A1, which is incorporated herein by reference in its entirety for all purposes.<br>
In a preferred embodiment, the CETP inhibitor of Formula Vll is dimethyl 5,5-dithiobis[2-difluoromethyl-4-(2-methylpropyl)-6-(trifluoromethyl)-3-pyridine-carboxylate].<br>
Another class of CETP inhibitors that finds utility with the present invention consists of substituted biphenyls having the Formula VIII<br>
(Formula Removed)<br>
Formula vIII or a pharmaceutically acceptable salt, enantiomers, or stereoisomers thereof, in which<br>
AVIII stands for aryl with 6 to 10 carbon atoms, which is optionally substituted<br>
up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl,<br>
trifiuoromethoxy, or by straight-chain or branched alky!, acyl, or alkoxy with up to 7<br>
carbon atoms each, or by a group of the formula	<br>
-NRVIII-1RVIII-2, wherein	<br>
RVIII-1 and RVIII-2 are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms,<br>
DVIII stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,<br>
EVIII and LVIII are either identical or different and stand for straight-chain or branched alkyl with up to 8 carbon atoms, which is optionally substituted by cycloalkyl with 3 to 8 carbon atoms, or stands for cycloalkyl with 3 to 8 carbon atoms, or EVIII has the above-mentioned meaning and<br>
LVIII in this case stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifiuoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula<br>
-NRVIII-3RVIII-4- wherein RVIII-3 and RVIII-4 are identical or different and have the meaning given above for RVIII-1 and RVIII-2, or<br>
EVIII stands for straight-chain or branched alkyl with up to 8 carbon atoms, or stands for aryl with 6 to 10 carbon atoms, which is optionally substituted up to 3 times in an identical manner or differently by halogen, hydroxy, trifluoromethyl, trifiuoromethoxy, or by straight-chain or branched alkyl, acyl, or alkoxy with up to 7 carbon atoms each, or by a group of the formula<br>
-NRVIII-5RVIII-6, wherein RVIII-5 and RVIII-6 are identical or different and have the meaning given above for RVIII-1-1 and RVIII-2. and<br>
LVIII in this case stands for straight-chain or branched alkoxy with up to 8 carbon atoms or for cycloalkyloxy with 3 to 8 carbon atoms, TVIII stands for a radical of the formula<br>
(Formula Removed)<br>
RvII-7 and RvII-8 are identical or different and denote cycloalkyl with 3 to 8 carbon atoms, or aryl with 6 to 10 carbon atoms, or denote a 5- to 7-member aromatic, optionally benzo-condensed, heterocyclic compound with up to 3 heteroatoms from the series S, N and/or O, which are optionally substituted up to 3 times in an identical manner or differently by trifluoromethyl, trifiuoromethoxy, halogen, hydroxy, carboxyl, by straight-chain or branched alkyl, acyl, alkoxy, or alkoxycarbonyl with up to 6 carbon atoms each, or by phenyl, phenoxy, or thiophenyl, which can in turn be substituted by halogen, trifluoromethyl, or trifiuoromethoxy, and/or the rings are substituted by a group of the formula<br>
-NRvII-11RvIII-12, wherein RVIII-11 and Rvtn-12 are identical or different and have the meaning given above for RVIII-11 and RVIII-2,<br>
XVIII denotes a straight or branched alkyl chain or alkenyl chain with 2 to 10<br>
carbon atoms each, which are optionally substituted up to 2 times by hydroxy,<br>
"" RVIII denotes hydrogen',"and' "<br>
RVIII-10 denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, mercapto,<br>
trifiuoromethoxy, straight-chain or branched alkoxy with up to 5 carbon atoms, or a<br>
radical of the formula	,<br>
-NRVIII-13RVIII-14, wherein RVIII-13 and RVIII-14 are identical or different and have the meaning given above for RVIII-1 and RVIII-2. or<br>
RVIII-9 and RVIII-10 form a carbonyl group together with the carbon atom. Compounds of Formula VIII are disclosed in PCT Publication No. WO 9804528, which is incorporated herein by reference in its entirety for all purposes.<br>
Formula IX<br>
(Formula Removed)<br>
or a pharmaceutically acceptable salt or tautomer thereof;<br>
Another class of CETP inhibitors that finds utility with the present invention-consists of substituted 1,2,4-triazoles having the Formula IX<br>
wherein Rix-1 is selected from higher alkyl, higher alkenyl, higher alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyi, alkylthioalkyl, arylthioalkyl, and cycloalkylalkyl;<br>
wherein RiX-2 is selected from aryl, heteroaryl, cycloalkyl, and cycloalkenyl, wherein<br>
RIX-2 is optionally substituted at a substitutable position with one or more radicals independently selected from alkyl, haloalkyl, alkylthio, aikylsulfinyl, alkylsulfonyl, alkoxy, halo, aryloxy, aralkyloxy, aryl, aralkyl, aminos ulfonyl, amino, monoalkylamino and dialkylamino; and<br>
wherein RIX-3 is selected from hydrido, -SH and halo; provided Rix-2 cannot be phenyl or 4-methylphenyl when RIX-1 is higher alkyl and when RIX-3 is BSH.<br>
Compounds of Formula IX and their methods of manufacture are disclosed in PCT Publication No. WO 9914204, which is incorporated herein by reference in its entirety for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula IX:<br>
2,4-dihydro-4-(3-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(2-fiuorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(2-methylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(3-chlorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2, 4-dihydro-4-(2-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(3-methylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
4-cyclohexyl-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(3-pyridyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(2-ethoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(2,6-dimethylphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(4-phenoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
4-(1,3-benzodioxol-5-yl)-2,4-dihydro-5-tridecyl-3H-1,2,4- triazole-3-thione;<br>
4-(2-chlorophenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(4-methoxyphenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-5-tridecyl-4-(3-trifluoromethylphenyl)-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-5-tridecyl-4-(3-fiuorophenyl)-3H-1,2,4-triazoie-3-thione;<br>
4-(3-chloro-4-methylpheny!)-2.4-dihydro-5-tridecyI-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(2-methylthiopheny])-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
4-(4-benzy!oxyphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-tria2ole-3-thione;<br>
2,4-dihydro-4-(2-naphthyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-5-tridecyl-4-(4-trifluoromethylphenyl)-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-( 1 -naphthyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(3-methyIthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(4-methylthiophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
2,4-dihydro-4-(3,4-dimethoxyphenyl)-5-trfdecyl-3H-1,2,4-triazole-3-thione; 2,4-dihydro-4-(2,5-dimethoxyphenyl)-5-tridecyl-3H-1,2,4-triazo!e-3-thione; 2,4-dihydro-4-(2-methoxy-5-chlorophenyl)-5-tridecyl-3H-1,2,4-triazole-3-thione;<br>
4-(4-aminosulfonylphenyl)-2,4-dihydro-5-tridecyl-3H-1,2,4-triazole-3-thione; 2,4-dihydro-5-dodecyl-4-(3-methoxyphenyl)-3H-1,2,4-triazole-3-thione; 2,4-dihydro,-4-(3-methoxyphenyl)-5-tetradecyl-3H-1,2,4-triazole-3-thione; 2,4-dihydro-4-(3-methoxyphenyl)-5-undecyl-3H-1,2,4-triazole-3-thione,-and 2,4-dihydro-(4-methoxyphenyl)-5-pentadecyl-3H-1,2,4-triazole-3-thione. Another class of CETP inhibitors that finds utility with the present invention consists of hetero-tetrahydroquinolfnes having the Formula X<br>
(Formula Removed)<br>
Formula X and pharmaceutically acceptable salts, enantiomers, or stereoisomers or N-oxides of said compounds; in whiich<br>
Ax represents cycloalkyl with 3 to 8 carbon atoms or a 5 to 7-membered, saturated, partially saturated or unsaturated, optionally benzo-condensed heterocyclic ring containing up to 3 heteroatoms from the series comprising S, N and/or O, that in case of a saturated heterocyclic ring is bonded to a nitrogen function, optionally bridged over it, and in which the aromatic systems mentioned above are optionally substituted up 5-times in an identical or different substituents in the form of halogen, nitro, hydroxy, trifluoromethyl, trifluoromethoxy or by a<br>
straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy each having up to 7 carbon atoms or by a group of the formula BNRX-3Rx-4. in which<br>
RX-3 and Rx-4 are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms, or<br>
Ax represents a radical of the formula<br>
(Formula Removed)<br><br>
Dx represents an aryl having 6 to 10 carbon atoms, that is optionally substituted by phenyl, nitro, halogen, trifluorm ethyl or trifluormethoxy, or it represents a radical of the formula<br><br>
(Formula Removed)<br>
in which<br>
Rx-5. Rx-6 and Rx-9 independently of one another denote cycloalkyl having 3 to 6 carbon atoms, or an aryl having 6 to 10 carbon atoms or a 5- to 7-membered aromatic, optionally benzo-condensed saturated or unsaturated, mono-, bi-, or tricyclic heterocyclic ring from the series consisting of S, N and/or O, in which the rings are substituted, optionally, in case of the nitrogen containing aromatic rings via the N function, with up to 5 identical or different substituents in the form of halogen, trifluoromethyl, nitro, hydroxy, cyano, carbonyl, trifluoromethoxy, straight straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy, or alkoxycarbonyl each having up to 6 carbon atoms, by aryl or trifluoromethyl-substituted aryl each having 6 to 10 carbon atoms or by an, optionally benzo-condensed, aromatic 5- to 7-<br>
membered heterocyclic ring having up to 3 heteroatoms from the series consisting of<br>
S, N, and/or O, and/or substituted by a group of the formula BORX-10, -SRX-11, S02Rx-<br>
12 or BNRx-13Rx-14,<br>
in which	<br>
Rx-10, Rx-11 and Rx-12 independently from each other denote aryl having 6 to 10 carbon atoms, which is in turn substituted with up to 2 identical or different substituents in the form of phenyl, halogen or a straight-chain or branched alkyl having up to 6 carbon atoms,<br>
RX-13 and RX-14 are identical or different and have the meaning of Rx-3 and RX-4 indicated above, or<br>
RX-5 and/or RX-6 denote a radical of the formula<br>
(Formula Removed)<br>
or -<br>
RX-7 denotes hydrogen or halogen, and<br>
Rx-8 denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, trifiuoromethoxy, straight-chain or branched alkoxy or alkyl having up to 6 carbon atoms or a radical of the formula<br>
BNRX-15Rx-16, in which<br>
RX-15 and Rx-16 are identical or different and have the meaning of Rx-3 and RX-4 indicated above, or<br>
Rx-7 and Rx-8 together form a radical of the formula =0 or =NRX-17, in which<br>
Rx-17 denotes hydrogen or straight chain or branched alkyl, alkoxy or acyl having up to 6 carbon atoms,<br>
l_x denotes a straight chain or branched alkylene or alkenylene chain having up to 8 carbon atoms, that are optionally substituted with up to 2 hydroxy groups,<br>
Tx and Xx are identical or different and denote a straight chain or branched alkylene chain with up to 8 carben atoms or<br>
Tx or Xx denotes a bond,<br>
Vx represents an oxygen or sulfur atom or an BNRX-18group, in which<br>
Rx-18 denotes hydrogen or straight chain or branched alkyl with up to 6 carbon atoms or phenyl,<br>
Ex represents cycloalkyl with 3 to 8 carbon atoms, or straight chain or branched alkyl with up to 8 carbon atoms, that is optionally substituted by cycloalkyl with 3 to 8 carbon atoms or hydroxy, or represents a phenyl, that is optionally substituted by halogen or trifluoromethyl,<br>
RX-1 and RX-2 together form a straight-chain or branched alkylene chain with up to 7 carbon atoms, that must be substituted by carbonyl group and/or by a radical with the formula<br>
(Formula Removed)<br>
in which a and b are identical or different and denote a number equaling 1,2, or 3,<br>
Rx-19 denotes hydrogen, cycloalkyl with 3 up to 7 carbon atoms, straight chain or branched silylalkyl with up to 8 carbon atoms or straight chain or branched alkyl with up to 8 carbon atoms, that are optionally substituted by hydroxyl, straight chain or branched alkoxy with up to 6 carbon atoms or by phenyl, which in turn might be substituted by halogen, nitro, trifluormethyl, trifluoromethoxy or by phenyl or by tetrazole-substituted phenyl, and alkyl, optionally be substituted by a group with the formula BORx-22, in which<br>
Rx-22 denotes a straight chain or branched acyl with up to 4 carbon atoms or<br>
1<br>
benzyl, or<br>
Rx-19 denotes straight chain or branched acyl with up to 20 carbon atoms or ben2:oyl, that is optionally substituted by halogen , trifluoromethyl, nitro or trifluoromethoxy, or it denotes straight chain or branched fluoroacyl with up to 8 carbon atoms and 9 fluorine atoms,<br>
Rx-20 and Rx-21 are identical or different and denote hydrogen, phenyl or straight chain or branched alkyl with up to 6 carbon atoms, or<br>
Rx-20 and RX-21 together form a 3- to 6- membered carbocyclic ring, and the carbocyclic rings formed are optionally substituted, optionally also geminally, with up to six identical or different substituents in the form of triflouromethyl, hydroxy, nitrite, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy with 3 to 7 carbon atoms each, by straight chain or branched alkoxycarbonyl, alkoxy or alkylthio with up to 6 carbon atoms each or by straight chain or branched alkyl with up to 6 carbon atoms, which in turn is substituted with up to 2 identically or differently by hydroxyl, benzyloxy, trifluoromethyl, benzoyl, straight chain or branched alkoxy, oxyacyl or carbonyl with up to 4 carbon atoms each and/or phenyl, which may in turn be substituted with a halogen, trifuoromethyl or trifluoromethoxy, and/or the formed carbocyclic rings are optionally substituted, also geminaliy, with up to 5 identical or different substituents in the form of phenyl, benzoyl, thiophenyl or sulfonylbenzyl, which in turn are optionally substituted by halogen, trifluoromethyl, trifluoromethoxy or nitro, and/or optionally are substituted by a radical with the formula<br>
in which                 c denotes a number equaling 1, 2, 3, or 4,<br>
d denotes a number equaling 0 or 1,<br>
in which<br>
Wx denotes either an oxygen or a sulfur atom<br>
(Formula Removed)<br>
RX-23 and RX-24 are identical or different and denote hydrogen, cycloalkyl with 3 to 6 carbon atoms, straight chain or branched alkyl with up to 6 carbon atoms, benzyl or phenyl, that is optionally substituted with up to 2 identically or differently by halogen, trifluoromethyl, cyano, phenyl or nitro, and/or the formed carbocyclic rings are substituted optionally by a spiro-linked radical with the formula<br>
(Formula Removed)<br>
Yx and Yx together form a 2 to 6 membered straight chain or branched ene chain, '<br>
notes a number equaling 1,2, 3,4, 5, 6, or 7, ' ic-tes a number equaling 1 or 2,<br>
Rx-25. Rx-26, Rx-27. Rx-28. Rx-29, Rx-30 and Rx-31 are identical or different and ote hydrogen, trifluoromethyl, phenyl, halogen or straight chain or branched alkyl Ikoxy with up to 6 carbon atoms each,<br>
Rx-25 and RX-26 or RX-27 and RX-28 respectively form together a straight chain or nched alkyl chain with up to 6 carbon atoms,<br>
Rx-25 and RX-26 or RX-27 and RX-28 each together form a radical with the formula<br>
(Formula Removed)<br>
which<br>
Wx has the meaning given above, denotes a number equaling 1, 2, 3, 4, 5, 6, or 7,<br>
Rx-32 and Rx-33 form together a 3- to 7- membered heterocycle, which contains n oxygen or sulfur atom or a group with the formula SO, S02 or<br>
NR;
1 which<br>
Rx-34 denotes hydrogen, phenyl, benzyl or straight or branched alkyl with up to  carbon atoms.<br>
Compounds of Formula X and their methods of manufacture are disclosed in Â°C1 Publication No. WO 9914215, which is incorporated herein by reference in its sntirety for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula X:<br>
2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-(3-thienyl)-3-(4-trifluoromethylbenxoyl)-5,6,7,8-tetrahydroquinoline;<br>
2-oyclopentyl-3-[fluoro-(4-trifluoromethylphenyl)methyI]-5-hydroxy-7,7-dimethyl-4-(3.-thienyl)-5,6,7,8-tetrahydroqulhoIineT and<br>
2-cyclopentyl-5-hydroxy-7,7-dimethyl-4-(3-thienyI)-3-(trifluoromethylbenxyl)-5,6,7,8-tetrahydroquinoline.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of substituted tetrahydro naphthalines and analogous compound haying the Formula XI<br>
(Formula Removed)<br>
Formula XI and stereoisomers, stereoisomer mixtures, and salts thereof, in which<br>
AXI stands for cycloalkyl with 3 to 8 carbon atoms, or stands for aryl with 6 to 10 carbon atoms, or stands for a 5- to 7-membered, saturated, partially unsaturated or unsaturated, possibly benzocondensated, heterocycle with up to 4 heteroatoms<br>
t<br>
from the series S, N and/or O, where aryl and the heterocyclic ring systems mentioned above are substituted up to 5-fold, identical or different, by cyano, halogen, nitro, carboxyl, hydroxy, trifluoromethyl, trifluoro- methoxy, or by straight-chain or branched alkyl, acyl, hydroxyalkyl, alkylthio, alkoxycarbonyl, oxyalkoxycarbonyl or alkoxy each with up to 7 carbon atoms, or by a group of the formula<br>
-NRXI-3RXI-4, in which<br>
RXI-3 and RXI-4 are identical or different and denote hydrogen, phenyl, or straight-chain or branched alkyl with up to 6 carbon atoms<br>
DXIstands for a radical of the formula<br>
(Formula Removed)<br>
in which<br>
RXI-5 RXI-6 and RXI-9, independent of each other, denote cycloalkyl with 3 to 6 carbon atoms, or denote aryl with 6 to 10 carbon atoms, or denote a 5- to 7-<br>
membered, possibly benzocondensated, saturated or unsaturated, mono-, bi- or tricyclic heterocycle with up to 4 heteroatoms of the series S, N and/or O, where the cycles are possibly substitutedCin the case of the nitrogen-containing rings also via the N-functionCup to 5-fo!d, identical or different, by halogen, trifluoromethyl. nitro, hydroxy, cyano, carboxyl, trifluoromethoxy, straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl with up to 6 carbon atoms each, by aryl or trifluoromethyl substituted aryl with 6 to 10 carbon atoms each, or by a possibly benzocondensated aromatic 5- to 7-membered heterocycle with up to 3 heteroatoms of the series S, N and/or O, and/or are substituted by a group of the formula<br>
-ORXI-10. -SRXI-10 . -SO2RXI-12 or -NRXI-13RXI-14, in which<br>
RXI-10 RXI-11 and RXI-12, independent of each other, denote aryl with 6 to 10 carbon atoms, which itself is substituted up to 2-fold, identical or different, by phenyl, halogen, or by straight-chain or branched alkyl with up to 6 carbon atoms,<br>
RXI-13 and RXI-14 are identical or different and have the meaning given above for RXI-3 and RXI-4, or<br>
RXI-15 and/or RXI-6 denote a radical of the formula<br>
(Formula Removed)<br>
RXI-7 denotes hydrogen, halogen or methyl, and<br>
RXI-8 denotes hydrogen, halogen, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy or alkyl with up to 6 carbon atoms each, or a radical of the formula -NRXI-15RXI-16 in which<br>
RXI-15 and RXI-106 are identical or different and have the meaning given above for RXI-3 and RXI-4, or<br>
RXI-7 and RXI-8 together form a radical of the formula =0 or =NRXI-17, in which RXI-17 denotes hydrogen or straight-chain or branched alkyl, alkoxy or acyl with up to 6 carbon atoms each,<br>
LXIdenotes a straight-chain or branched alkylene- or alkenylene chain with up to 8 carbon atoms each, which is possibly substituted up to 2-fold by hydroxy,<br>
TXI and XXI are identical or different and denote a straight-chain or branched<br>
alkylene chain with up to 8 carbon atoms,	<br>
or<br>
TXI and XXI denotes a bond,<br>
VXI stands for an oxygen- or sulfur atom or for an -NRXI- 18 group, in which<br>
RXI-18 denotes hydrogen or straight-chain or branched alkyl with up to 6 carbon atoms, or phenyl,<br>
EXI stands for cycloalkyl with 3 to 8 carbon atoms, or stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by cycloalkyl with 3 to 8 carbon atoms or hydroxy, or stands for phenyl, which is possibly substituted by halogen or trifluoromethyl,<br>
RXI-1 and RXI-2 together form a straight-chain or branched alkylene chain with up to 7 carbon atoms, which must be substituted by a carbonyl group and/or by a radical of the formula<br>
(Formula Removed)<br>
in which<br>
a and b are identical or different and denote a number 1, 2 or 3 RXI-19 denotes hydrogen, cycloalkyl with 3 to 7 carbon atoms, straight-chain or branched silylalkyl with up to 8 carbon atoms, or straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by hydroxy, straight-chain or branched alkoxy with up to 6 carbon atoms, or by phenyl, which itself can be substituted by halogen, nitro, trifluoromethyl, trifluoromethoxy or by phenyl substituted by phenyl ortetrazol, and alky] is possibly substituted by a group of the formula -ORx,_<br>
22.	'<br>
in which<br>
RXI-22 denotes straight-chain or branched acyl with up to 4 carbon atoms, or benzyl, or<br>
RXI-19 denotes straight-chain or branched acyl with up to 20 carbon atoms or benzoyl, which is possibiy substituted by halogen, trifluoromethyl, nitro or trifluoromethoxy, or denotes straight-chain or branched fluoroacyl with up to 8 carbon atoms and 9 fluorine atoms,<br>
RXI-20 and RXI-21 are identical or different, denoting hydrogen, phenyl or straight-chain or branched alkyl with up to 6 carbon atoms, or<br>
RXI-20 and RXI-21 together form a 3- to 6-membered carbocycle, and, possibiy also geminally, the alkylene chain formed by RXI-1and RXI-2 is possibly substituted up to 6-fold, identical or different, by trifluoromethyi, hydroxy, nitrile, halogen, carboxyl, nitro, azido, cyano, cycloalkyl or cycloalkyloxy with 3 to 7 carbon atoms each, by straight-chain or branched alkoxycarbonyl, alkoxy or alkoxythio with up to 6 carbon atoms each, or by straight- chain or branched alkyl with up to 6 carbon atoms, which itself is substituted up to 2-fold,<br>
identical or different, by hydroxyl, benzyloxy, trifluoromethyi, benzoyl, straight-chain or branched alkoxy, oxyacyl or carboxyl with up to 4 carbon atoms each, and/or phenyl-which itself can be substituted by halogen, trifluoromethyi or trifluoromethoxy, and/or the alkylene chain formed by RXI-1 and RXI-2 is substituted, also geminally, possibly up to 5-fold, identical or different, by phenyl, benzoyl, thiophenyl or sulfobenzyl -which themselves are possibly substituted by halogen, trifluoromethyi, trifluoromethoxy or nitro, and/or the aikylene chain formed by RXI-1 and RXI-2 is possibly substituted by a radical of the formula<br>
in which <br>
c denotes a number 1, 2, 3 or 4,<br>
d denotes a number 0 or 1,<br>
RXI-23 and RXI-24 are identical or different and denote hydrogen, cycloalkyl with 3 to 6 carbon atoms, straight-chain or branched alkyl with up to 6 carbon atoms, benzyl or phenyl, which is possibly substituted up to 2-fold, identical or different, by halogen, trifluoromethyi, cyano, phenyl er-nitro, and/or the alkylene chain formed by RXI-1 and RXI-2 is possibly substituted by a spiro-jointed radical of the formula<br>
(Formula Removed)<br>
in which<br>
WXII denotes either an oxygen or a sulfur atom,<br>
YXII and YXII together form a 2- to 6-membered straight-chain or branched alkylene chain,<br>
e is a number 1, 2, 3, 4, 5, 6 or 7,<br>
f denotes a number I or 2,<br>
RXI-25. RXI-26, RXI-27, RXI-28. RXI-29. RXI-30 and RXI-31 are identical or different and denote hydrogen, trifluoromethyl, phenyl, halogen, or straight-chain or branched alkyl or alkoxy with up to 6 carbon atoms each, or<br>
RXI-25 and RXI-26 or RXI-27 and RXI-28 together form a straight-chain or branched alkyl chain with up to 6 carbon atoms, or<br>
Rxi-25 and RXI-26 or RXI-27 and RXI-28 together form a radical of the formula<br>
(Formula Removed)<br>
in which<br>
WXI has the meaning given above,<br>
g is a number 1, 2, 3, 4, 5, 6 or 7,<br>
RXI-32 and RXI-33 together form a 3- to 7-membered heterocycle that contains an oxygen- or sulfur atom or a group of the formula SO, S02 or -NRXI-34 in which<br>
Rxi-34 denotes hydrogen, phenyl, benzyl, or straight-chain or branched alkyl with up to 4 carbon atoms.<br>
Compounds of Formula XI and their methods of manufacture are disclosed in PCT Publication No. WO 9914174, which is incorporated herein by reference in its entirety for all purposes.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of 2-aryl-substituted pyridines having the Formula (XIl)<br><br>
(Formula Removed)<br>
Formula XII or pharmaceutically acceptable salts, enantiomers, or stereoisomers of said compounds, in which<br>
AXII and EXII are identical or different and stand for aryl with 6 to 10 carbon atoms which is possibly substituted, up to 5-fold identical of different; by halogen, hydroxy, trifluoromethyl, trifluoromethoxy, nitro or by straight-chain or branched alkyl, acyl, hydroxy alkyl or alkoxy with up to 7 carbon atoms each, or by a group of the formula -NRXII-1RXII-2 where<br>
RXII-1 and RXII-2 are identical or different and are meant to be hydrogen, phenyl or straight-chain or branched alkyl with up to 6 carbon atoms,<br>
DXII stands for straight-chain or branched alkyl with up to 8 carbon atoms, which is substituted by hydroxy,<br>
LXII stands for cycloalkyl with 3 to 8 carbon atoms or for straight-chain or branched alkyl with up to 8 carbon atoms, which is possibly substituted by cycloalkyl with 3 to 8 carbon atoms, or by hydroxy,<br>
TXII stands for a radical of the formula RXII-3 XXII or<br>
(Formula Removed)<br>
where<br>
RXII-3 and RXII-4 are identical or different and are meant to be cycloalkyl with 3 to 8 carbon atoms, or any! with 6 to 10 carbon atoms, or a 5- to 7-membered aromatic, possibly benzocondensated heterocycle with up to 3 heteroatoms from the series S, N and/or O, which are possibly substituted, up to 3-fold identical or different,<br>
by trifluoromethyl, trifluoromethoxy, halogen, hydroxy, carboxyl, nitro, by straight-chain or branched alkyl, acyl, alkoxy or alkoxycarbonyl with up to 6 carbon atoms each, or by phenyl, phenoxy or phenylthio which in turn can be substituted by halogen, trifluoromethyl or trifluoromethoxy, and/or where the cycles are possibly substituted by a group of the formula -NRXII-7RXII-8, where<br>
RxII-7 and RXii-8 are identical or different and have the meaning of RXII-1 and RxII-2 given above,<br>
XXII is a straight-chain or branched alkyl or alkenyl with 2 to 10 carbon atoms each, possibly substituted up to 2-fold by hydroxy or halogen,<br>
RxII-5 stands for hydrogen, and<br>
RxII-6 means to be hydrogen, halogen, mercapto, azido, trifluoromethyl, hydroxy, trifluoromethoxy, straight-chain or branched alkoxy with up to 5 carbon atoms, of a radical of the formula BNRXII9 RXII-10. where<br>
RxII-9 and RxII-10 are identical or different and have the meaning of RxII-1 and Rxn-2 given above, or<br>
RxII-5 and RxII-6, together with the carbon atom, form a carbonyl group. Compounds of Formula XII and their methods of manufacture are disclosed in EP 796846-A1, United States Patent No. 6,127,383 and United States Patent No. 5,925,645, all of which are incorporated herein by reference in their entireties for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XII:<br>
4,6-bis-(p-fluorophenyl)-2-isopropyl-3-[(p-trifluoromethylphenyl)-(fluoro)-methyl]-5-(1-hydroxyethyl)pyridine;<br>
2,4-bis-(4-fluorophenyl)-6-isopropyl-5-[4-(trifluoromethylphenyl)-fluoromethyl]-3-hydiroxymethyl)pyridine,- and<br>
2,4-bis-(4-fluorophenyl)-6-isopropyl-5-[2-(3-trifluoromethylphenyl)vinyl]-3-hydroxymethyl)pyridine.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of compounds having the Formula (XIII)<br>
(Formula Removed)<br>
Formula Xlll<br>
or pharmaceutically acceptable salts, enantiomers, stereoisomers, hydrates, or solvates of said compounds, in which<br>
RXIV is a straight chain or branched C1-10 alkyl; straight chain or branched C2-10 alkenyl; halogenated C1-4 lower alkyl; C3-10 cycloaikyl that maybe substituted; C5-8 cycloalkeny) that may be substituted; C3-10 cycloalkyl C1-10 alkyl that may be substituted; aryl that may be substituted; aralkyl that may be substituted; or a 5- or 6-membered heterocyclic group having 1 to 3 nitrogen atoms, oxygen atoms or sulfur atoms that may be substituted,<br>
XxII-1, Xxii-2 Xxii-3, Xxii-4 may be the same or different and are a hydrogen atom; halogen atom; C1-4 lower alkyl; halogenated C1-4 lower alkyl; C1-4 lower aikoxy; cyano group; nitro group; acyl; or aryl, respectively;<br>
Yxii is -CO-; or BSOz-; and<br>
Zxii is a hydrogen atom; or mercapto protective group.<br>
Compounds of Formula XHl and their methods of manufacture are disclosed in PCT Publication No. WO 98/35937, which is incorporated herein by reference in its entirety for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XIII:<br>
N,N'-(dithiodi-2,1-phenylene)bis[2,2-dimethyl-propanamide];<br>
N,N'-(dtthiodi-2,1 -pheny!ene)bis[1 -methyl-cyclohexanecarboxamide];<br>
N,N'-(dithiodi-2,1-phenylene)bis[1-(3-methylbutyl)-cycIopentanecarboxamide];<br>
N,N'-(dithiodi-2,1,phenylene)bis[1-(3-methylbutyI)-cyclohexanecarboxamide];<br>
N,N'-(dithiodi-2,1 -pheny!ene)bis[1 -(2-ethylbutyI)-cyclohexanecarboxamide};<br>
N,N,-(dithiodi-2,1-phenylene)bis-tricyclo[3.3.1.13,7]decane-1-carboxamide;<br>
propanethioic acid, 2-methyl-,S-[2[[[1-(2-ethylbutyi)cyclohexyl]carbonyl]amino]phenyl] ester;<br>
propanethioic acid, 2,2-dimethyl-, S-[2-[[[1-(2-ethylbutyl)cyciohexyi]carbonyl]amino]phenyl] ester; and<br>
ethanethioic acid, S-[2-[[[1-(2-ethyIbutyl)cyclohexyl]carbonyl]amino]phenyl] ester.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of polycyclic aryl and heteroaryl tertiary-heteroalkyiamines having the Formula XIV<br>
(Formula Removed)<br>
Formula XIV<br>
and pharmaceutically acceptable forms thereof, wherein:<br>
nXIV is an integer selected from 0 through 5;<br>
RxIv-i is selected from the group consisting of haloalkyl, haloalkenyl, haloalkoxyalkyl, and haloalkenyloxyalkyl;<br>
XXIV is selected from the group consisting of O,H, F,  S(O) ,NH,N(OH), N(alkyl), and N(alkoxy);<br>
RXIV-15 is selected from the group consisting of hydrido, alky!, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl, cycloalkylalkyl,<br>
cycloalkylalkehyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyi, haioalkoxyalkyl, haloalkenyioxyalkyl, halocycloalkoxyalkyi, halocycloalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, monocarboalkoxyalkyl, monocarboalkoxy, dicarboalkoxyalkyl, monocarboxamido, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, dialkoxyphosphonoalkyl, trialkylsilyl, and a spacer selected from the group consisting of a covalent single bond and a linear spacer moiety having from 1 through 4 contiguous atoms linked to the point of bonding of an aromatic substituent selected from the group consisting of RXIV-4,-RXIV-8,-RXIV-9, and-RXIV-13 to form a heterocyclyl ring having from 5 through 10 contiguous members with the provisos that said spacer moiety is other than a covalent single bond when RxIv-2 is alkyl and there is no RXIV-16 wherein X is H or F;<br>
DXIV-1 DXIV-2. JXIV-1 JXIV-2 and KxIv-1 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one of DxIv-i, DxIv-2, JxIv-1. JxIv-2 and KxIv-i is a covalent bond, no more than one of DxIv-1, DXIV-2, JXIV-1, JXIV-2 and KXIV-1 is O, no more than one of DxIv-1, DXIV-2, JXIV-1, JXIV-2 and KXIV-1 is S, one of DxIv-i, DXIV-2, JxIv-i, JxIv-2 and KXIV-1 must be a covalent bond when two of DXIV-1, DXIV-2, JXIV-1, JXIV-2 and KXIV-1 are O and S, and no more than four of DXIV-1, DXIV-2. JXIV-1. JXIV-2 and KXIV-1 are N;<br>
DXIV-3, DXIV-4. JXIV-3. JXIV-4 and KXIV-2 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one of DxIv-3, DXIV-4, JxIv-3,' "JXIV-4 and KXIV-2 is a covalent bond, no more than one of DXIV-3 DXIV-4, JXIV-3 JXIV-4 and KXIV-2 is O, no more than one of DXIV-3, DXIV-4, JxIv-3. JxIv-4 and KXIV-2 is S, one of DXIV-3 DxIv-4, JXIV-3, JXIV-4 and KXIV-2 must be a covalent bond when two of DXIV-3, DxIv-4, JxIv-3, JxIv-4 and KxIv-2 are O and S, and no more than four of DXIV-3, DxIv-4. JxIv-3, JxIv-4 and KxIv-2 and KXIV-2 are N;<br>
RxIv-2 is independently selected from the group consisting of hydrido, hydroxy, hydroxyalkyl, amino, aminoalkyl, alkylamino, dialkylamino alkyl alkenyl, alkynyl, aryl, araikyl, aralkoxyalkyl, aryloxyalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl,<br>
alkylthioalkyl, aralkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl,<br>
cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl,<br>
halocycloalkyl, halocycloalkenyl, haloalkoxy, aloalkoxyalkyl, haloalkenyloxyalkyl,<br>
halocycloalkoxy,	<br>
halocycloalkoxyalkyl, halocycioalkenyloxyalkyl, perhalo'aryl, perhaloaralkyl,  perhaloaryioxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyi, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl, aralkylsuifonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsufonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkyisulfonylalkyl, carboxy, carboxyalkyl, carboalkoxy,<br>
carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyphosphono,<br>
diaralkoxyphosphono, dialkoxyphosphonoalkyl, and diaralkoxyphosphonoalkyl;<br>
RxIv-2 and RxIv-3 are taken together to form a linear spacer moiety selected from the group consisting of a covalent single bond and a moiety having from 1 ' through 6 contiguous atoms to form a ring selected from the group consisting of a cycloalkyi having from 3 through 8 contiguous members, a cycioalkenyl having from 5 through 8 contiguous members, and a heterocyclyl having from 4 through 8 contiguous members;<br>
RxIv-3 is selected from the group consisting of hydrido, hydroxy, halo, cyano, aryloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, acyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, heteroarylthio, aralkylthio, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, aroyl, heteroaroyl, aralkylthioaikyl, heteroaralkylthioalkyi, heteroaryloxyalkyi, alkenyloxyalkyl, alkyithioalkyi, arylthioalkyl, cycloalkyi, cycloalkylalkyl, cycloalkylaikenyl, cycioalkenyl, cycloalkenylalkyi, haloalkyl," haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy,<br>
halocycloalkoxyalkyl, halocycioalkenyloxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryioxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, monocarboa1koxyalkyI,^Tcarboa1koxya1kyI, monocyanoalkyl, dicyanoaikyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl,<br>
aryisulfinyl, arylsulfinylalkyi, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl,<br>
aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl,<br>
cycloalkyisufonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl,<br>
heteroarylsulfinylalkyl, aralkylsulfinylalkyi, aralkyisulfonylalkyl, carboxy, carboxyalkyl,<br>
carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyphosphono,<br>
diaralkoxyphosphono, dialkoxyphosphonoalkyl, and diaralkoxyphosphonoalkyl;<br>
YXIV is selected from a group consisting of a covalent single bond;(C(RxIv-<br>
14)WqXIVwherein qXiv is an integer selected from 1 and 2 and (CH(RXIV-14))gXIV-WxIv-<br>
(CH(RxIv-14))PXIV wherein gXiv and pXIV are integers independently selected from 0<br>
and 1;<br>
RxIv-14 is independently selected from the group consisting of hydrido,<br>
hydroxy, halo, cyano, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, acyl,<br>
aroyl, heteroaroyl, heteroaryloxyalkyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio,<br>
alkyl, alkenyl alkynyl aryl, aralkyl arylqxyajkyl, aralkoxyalkylalkoxy, alkylsulfinylalkyl,<br>
alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkoxythioalkyl, alkoxyalkyl,<br>
heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl,<br>
cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl,<br>
haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl,<br>
haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyi,<br>
perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl,<br>
heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyi, dicarboalkoxyalkyl,<br>
monocyanoalkyl, dicyanoalkyi, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl,<br>
haloalkylsulfinyl, haloalkylsulfonyl, aryisulfinyl, arylsulfinylalkyl, arylsulfonyl,<br>
arylsulfonylalkyl, aralkylsulfinyr, araikylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl,<br>
cycloalkylsulfinylalkyl, cycloalkyisufonylalkyl, heteroarylsulfonylalkyl,<br>
heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyi,<br>
aralkyisulfonylalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide,<br>
carboxamidoalkyl, carboaralkoxy, dialkoxyphosphono, diaralkoxyphosphono,<br>
dialkoxyphosphonoalkyi, diaralkoxyphosphonoalkyl, a spacer selected from a moiety<br>
having a chain length of 3 to 6 atoms connected to the point of bonding selected from<br>
the group consisting of RxIv-9 and RxIv-13 to form a ring selected from the group<br>
consisting of a cycloalkenyl ring having from 5 through 8 contiguous members and a<br>
heterocyciyi ring having from 5 through 8 contiguous members-and a spacer selected<br>
from a moiety having a chain length of 2 to 5 atoms connected to the point of bonding<br>
selected from the group consisting of Rxw-4 and RXIV-8 to form a heterocyclyl having from 5 through 8 contiguous members with the proviso that, when YXIV is a covalent bond, an RXIV-14 substituent is not attached to YXIV-<br>
RXIV-14 and RXIV-14, when bonded to the different atoms, are taken together to form a group selected from the group consisting of a covalent bond, alkylene', haloalkyiene, and a spacer selected from a group consisting of a moiety having a chain length of 2 to 5 atoms connected to form a ring selected from the group of a saturated cycloalkyl having from 5 through 8 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;<br>
RxIv-14 and RxIv-14, when bonded to the same atom are taken together to form a group selected from the group consisting of oxo, thiono, alkylene, haloalkyiene, and a spacer selected from the group consisting of a moiety having a chain length of 3 to 7 atoms connected to form a ring selected from the group consisting of a cycloalkyl having from 4 through 8 contiguous members, a cycloalkenyl having from 4 through 8 contiguous members, and a heterocyclyl having from 4 through 8 contiguous members;<br>
WXiv is selected from the grpup consisting of O, C(O), C(S), C(0)N(RxIv-14), C(S)N(RXIV-14), (RXIV-14)NC(O), (RXIV-14)NC(S), S, S(O), S(o)2, S(O)2N(RXIV-14), (RXIV-14)NS(O)2, and N(RXIV-14) with the proviso that RxIv-14 is selected from other than halo and cyano;<br>
ZXiv is independently selected from a group consisting of a covalent single bond, (C(RxIv-15)2)qxIv-2 wherein qxIv-2 is an integer selected from 1 and 2, (CH(RxIv-i5))XIV-W-(CH(RXIV15))kxiv wherein JXIV and kXIV-5 are integers independently selected from 0 and 1 with the proviso that, when ZXIV is a covalent single bond, an RXIV-15 substituent is not attached to ZXiv;<br>
RxIv-15 is independently selected, when ZXIV is (C(RXIV-15)2)qxiv wherein qXiv is an integer selected from 1 and 2, from the group consisting of hydrido, hydroxy, halo, cyano, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioaikyl.arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyf,<br>
lalkenyl, halocycloalkyl, halocycioalkenyi, haloalkoxy, haloalkoxyalkyl, alkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, haloaryl, perhafoaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, eroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, diocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, hoalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, Isulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cloalkylsulfinylalkyl, cycloalkylsufonylalkyl, heteroarylsulfonylalkyl, eroarylsulfinyl,<br>
teroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulfonylalkyl, rboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, alkoxyphosphono, diaralkoxyphosphono, dialkoxyphosphonoalkyl, aralkoxyphosphonoalkyl, a spacer selected from a moiety having a chain length of 3 6 atoms connected to. the point of bonding-selected from the group consisting of XIV-4 and RXIV-8 to form a ring selected from the<br>
oup consisting of a cycloalkenyl ring having from 5 through 8 contiguous members id a heterocyclyl ring having from 5 through 8 contiguous members, and a spacer sleeted from a moiety having a chain length of 2 to 5 atoms connected to the point f bonding selected from the group consisting of RXIV-9 and RXIV-13 to form a eterocyclyl having from 5 through 8 contiguous members;<br>
â€¢   RXIV-15 and RXIV-15, when bonded to the different atoms, are taken together to _ 3rm a group selected from the group consisting of a covalent bond, alkylene, aloalkylene, and a spacer selected from a group consisting of a moiety having a hain length of 2 to 5 atoms connected to form a ring selected from the group of a saturated cycloalkyl having from 5 through 8 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;<br>
RxIv-15 and RxIv-15, when bonded to the same atom are taken together to form a group selected from the group consisting of oxo, thiono, alkylene, haloalkylene, and a spacer selected from the group consisting of a moiety having a chain length of 3 to 7 atoms connected to form a ring selected from the group consisting of a cycloalkyl having from 4 through 8 contiguous members, a cycloalkenyl having from 4 through 8 contiguous members ,and a heterocyclyl having from 4 through 8 contiguous members;<br>
RXIV-15 is independently selected, when ZXIV is (CH(RxIv-15))XIVW-(CH(RXIV-15)) kXIV wherein XIV and KXIVare integers independently selected from 0 and 1, from the group consisting of hydrido, halo, cyano, aryloxy, carboxyl, acyl, aroyl, heteroaroyl, hydroxyalkyl, heteroaryloxyalkyl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, alkoxyalkyl, heteroaryloxyalkyl, aralkoxyalkyl, heteroaralkoxyalkyi, alkylsulfonylalkyl, alkylsulfinylalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyi, haloalkyi, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyi, perhaloaryl, perhaloaralkyi, perhaloaryloxyalkyi, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfqnyl,, arylsulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsufonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsuifonylalkyl, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, a spacer selected from a linear moiety having a chain length of 3 to 6 atoms connected to the point of bonding selected from the group consisting of RXIV-4 and RXIV-8 to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members and a heterocyciyl ring having from 5 through 8 contiguous members, and a spacer selected from a linear moiety having a chain length of 2 to 5 atoms connected to the point of bonding selected from the group consisting of RxIv-9 and RxIv-13 to form a heterocyciyl ring having from 5 through 8 contiguous members;<br>
RXIV-4 RXIV-5 RXIV-6. RXIV-7. RXIV-8, RXIV-5 RXIV-10. RXIV-11 RXIV-12, and RXIV-13 are independently selected from the group consisting of perhaloaryloxy, alkanoylalkyl, alkanoylalkoxy, alkanoyloxy, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamido, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, hydrido, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy,<br>
erocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyi, Ikylsulfonyl, a'ralkylsulfonylalkyi, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, ocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl, cloalkylsulfonylalkyI, heteroaryiamino, N-heteroarylamino-N-a!kylamino, teroarylaminoalkyl, haloalkyithio, alkanoyloxy, alkoxy, alkoxyalkyl, haloalkoxylalky!, teroar alkoxy, cycloalkoxy, cycloalkenyloxy, cycloalkoxyalkyl, cycioalkylalkoxy, cloalkenyloxyaikyl, cycloalkylenedioxy, halocycloaikoxy, halocycloalkoxyalkyl, halocycloalkenyloxy, halocycloalkenyloxyalkyl, hydroxy, amino, thio, nitro, lower alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio, arylthioalkyl, jteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, steroarylsulfinylalkyl, heteroarylsulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, aloalkylsulfinylalkyl, haloalkylsulfonylaikyl, alkylsulfonamido, alkylaminosulfonyi, midosuifonyl, monoalkylamidosulfonyi, dialkyl amidosulfonyl, ionoarylamidosulfonyl,-arylsulfonamido,-diarylamidosulfonyl, monoalkyl monoaryl midosuifonyl, arylsulfmyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, leteroarylsulfonyl, heterocyclylsulfonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, leteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalky, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, Tower cycloalkylalkyl, lower cycloalkenylalkyi, halo, laloalkyl; haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyaikyl, hydoxyheteroaralkyi, haloalkoxyalkyl, aryl, heteroaralkynyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido, alkylamidocarbonylamido, arylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl with the proviso that there are one to five non-hydrido ring substituents RxIv-4, RxIv-5, Rxjv-e, RxIv-7, and RxIv-a present, that there are one to five non-hydrido ring substituents RxIv-9, RxIv-10. RxIv-11. RxIv-12, and RxIv-13 present, and RxIv-4, RxIv-s, RxIv-6. RxIv-7, RxIv-s, RxIv-9, RxIv-10. RxIv-11, RxIv-12. and RxIv-13 are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;<br>
^88^<br>
RxIv-4 and RxIv-5, RxIv-s and RxIv-e, Rxtv-e and RxIV-7, RxIv-7 and RxIv-8, RxIv-8 and RxIv-9. RxIv--9 and RxIv-10 RXIV-10 and RxIv--11 RxIv-11 and RxIv-12, and RxIv-12 and RxIv-13 are independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms  connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the provisos that no more than one of the group consisting of spacer pairs RxIv-4 and RxIv-5, RxIv-s and RxIv-6, RxIv-6 and RxIv-7, and RxIv-7 and RxIv-s are used at the same time and that no more than one of the group consisting of spacer pairs RxIv-9 and RxIv-10. RxIv-10 and RxIv-11 RxIv-11 and RxIv-12, and RxIv-12 and RxIv-13 are used at the same   , time;<br>
RxIv-4 and RX|V.9, RxIv-4 and RxIv-13, RxIv-8 and RxIv-9, and RxIv-8and RxIv-13 are independently selected to form a spacer pair wherein said spacer pair is taken together to form a linear moiety wherein said linear moiety forms a ring selected from the group consisting of a partially saturated heterocyclyl ring having from 5 through 8 contiguous members and a heteroaryl ring having from 5 through 6 contiguous members with the proviso that no more than one of the group consisting of spacer pairs RxIv-4 and RxIv-9, RxIv-4 and RxIv-13, RxIv-8 and RxIv-9, and RxIv-8 and RxIv-13 is used at the same time<br>
Compounds of Formula XIV and their methods of manufacture are disclosed in PCT Publication No. WO 00/18721, which is incorporated herein by reference in its entirety for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XIV:<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyI]amino]-1,1,1-trifluoro-2-prqpanoI;<br>
3-[[3-(3-isopropylphenoxy)phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]- 1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-cyclopropylphenoxy)phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)phenyl]-methyljaminoj-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-{2-furyl)phenoxy)phenyl[[[3-(1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]1,1,1-trifluoro-2-propano!;<br>
3-[[3-(2,3-dichIorophenoxy)phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)phenyl]-methylamino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-methlylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-(1,1,2,2- tetrafluoroethoxy)phenoxy]phenyl][[3-( 1,1,2,2-tetrafluoro-ethoxy)phenyl]methyl]amino]-1,1,1-trifIuoro-2-propanol;<br>
3-[l3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(1,1,2,2,-<br>
tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3,5-dimethy]phenoxy)pheny0[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyr|amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-ethy!phenoxy)phenyl][{3-(1,1,2,2-tetrafluoroethoxy) phenylj-melhyl]amin6]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-t-butylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-melhyl]amino]1,1,1 -trifluoro-2-propanol;<br>
3-[[3-('3-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-mei.hyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenylj[[3-
3-[[3-(phenoxy)phenylJ[[3-(1,1,2,2-tetrafluoroethoxy) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methy1][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafiuoroethoxy)phenyl]methyI][3-[[3-(trifluoromethyl)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-dimethylpheny]]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethylthio)-<br>
phenyl]methoxy]phenyl]amino]-1,1 ,-trifluoro-2-propanol;	<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-difluorophenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[cyclohexylmethoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[3-(1,1,2,2- tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-difluoromethoxyphenoxy)pheny!][[3-(1,1,2,2-tetrafluoroethoxy)-phenyf|methyQamino]-1,1,1 -trifluoro-2-propanol^<br>
3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1 ,-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(pentafluoroethymethyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-isopropylphenoxy)phenyl][[3-(pentalluoroethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-cyclopropylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methy0-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-(2-furyl)phenoxy)phenyl]t[3-(pentafluoroethyl)phenyl]methyI]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2,3-d!chlorophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-methylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl-amino]-1,1,1 -tnfiuoro-2-propano!;<br>
3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]pheny][[3--(pentafluoroethyl)-phenyl]methyl]amino]-1,1, 1-trifluoro-2-propanol; 3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyI]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-ethylphenoxy)phenyl][3-(pentafluoroethyI)phenyl]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-t-butylphenoxy)phenyl][[3-(pentafiuoroethyl) phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-methylphenoxy)phenyl][[3-pentafluoroethyl) phenyl]methyl]amino]-1,1,1 -trifluoro-2-prepanoI;<br>
3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol; 3-[[3-(phenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl] amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[3-(pentafluoroethy])phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifluoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1-trifIuoro-2-propano!;<br>
3-[[[3-(pentafiuoroethyl)phenyl]methy]][3-t[3-(trifluoromethyl)phenyl]-me1 hoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(pentafluoroethyl)pheny]]methyI][3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifluoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(pentafluoroethy[)phenyl]methyI][3-[[3,5-difluorophenyf]methoxy]-phenyl]amino]-1,1,1-trifIuoro-2-propanol;<br>
3-[[[3-(pentafluoroethy!)phenyl]methyl][3-[cyclohexylmethoxy]phenyl]-amino]-1,1,1 -trifluoro-2-propano!;<br>
3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[3-(pentafIuoroethyl)phenylJ-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2-trifIuoromethyl-4-pyridyloxy)phenyl][[3-(pentafIuoroethyl)phenyl]-methyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(pentafluoroethyI)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-(pentafluoroethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(3-isopropyIphenoxy)phenyl][[3-(heptafluoropropyI)phenyl]methyl]-am i no]-1,1,1 -trifl uoro-2-propanol;<br>
3-[[3-(3-cyclopropylphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-(2-furyl)phenoxy)phenyl][[3-(heptafIuoropropyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl], amino]-1,1,1 -trifluoro-2-propanol;   <br>
3-[[3-(4-fluorophenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-methyIphenoxy)phenyl][[3-(heptafIuoropropyl) phenyl]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(heptafluoropropyl) phenyl]-methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][[3-(heptafluoropropyl)-phenyl]methyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(hep1afluoropropyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifiuoro-2-propanol;<br>
3-[[3-(3-ethylphenoxy)phenyl][3-(heptafluoropropyl)phelyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br><br>
3-[[3-(3-t-'butyIphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyI]amino]-1,1,1 -trifIuoro-2-propanol;<br>
3-[[3-(3-methylphenoxy)phenyl][[3-(heptafluoropropy!)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(heptafluoropropyl)pheny]]-methyl]amino]-1,1,1-trifluoro-2-propanol; 3-[t3-(phenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl] amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(heptafluoropropyl)phenyl]methyl[3-[[3-(trifiuoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1-tnfluoro-2-propano);<br>
3-[H3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trifluoromethyl)phenyl]-methoxy]pheayl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(heptafluoropropy!)phenyl]methyl3[3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[p-(heptafluoropropyl)phenyl]methyl][3-[[3-(trif luoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(heptaf!uoropropyI)phenyl]methyl][3-[[3,5-difluorophenyQmethoxyJ-phenyQaminoJ-l,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[cyclohexylmethoxy]phenyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2-difiuoromethoxy-4-pyridyloxy)phenyl][f3-(heptafluoropropyl)phenyl]-methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl]]];[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(heptafiuoropropyI)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(3-trifiuoromethyithio)phenoxy]phenyl][[3-(hepfafluoropropyl)phenyl]-methyi]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-chIoro-3-trifluoromethylphenoxy)phenyl][[3-(heptafluoropropyl)-phenyl]-methyl]amino]-1,1,14rifluoro-2-propanol; 3-[[3-(3-triflueromethoxyphenoxy)phenyl][[2-fluoro-5-(trifluoromethuyl)-phenyl]-methylamino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-isopropylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methylamino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-cycIopropyIphenoxy)phenyl][[2-fluoro-5-(trifIuoromethy[)phenyl]-methylamino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]- methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl][[2-fIuoro-5-(trifIuoromethyl) phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2-fluoro-5-bromophenoxy)phenyl][I2-fIuoro-5-(trifluoromethyl)-<br>
phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methylamino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-( 1,1,2,2-tetrafluoroethoxy)phenoxy]pheny!][[2-fluoro-5-(trifluoro-methyl)phenyl]methyl]amino]-1,1,1,trifluoro-2-propanol;<br>
3-f[3-[3-(pentafluoroethyl)phenoxy]phenyl][I2-fiuoro-5-(trifIuoromethy()-phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3,5-dimethylphenoxy)phenyl][f2-fluoro-5-(trifluoromethylphenyl]-methyl]amino]-l.l.l-trifluoro-2-propanol;<br>
3-[[3-(3-ethylphenoxy)phenylJ[[2-fIuoro-5-(trifluoromethy])phenyl]methyI]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-t-butylphenoxy)pheny]][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-(N,N-dimethyIaniino)phenoxy]pheny]][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyI][3-[[3-(trifluoromethoxy)-phenyI]methoxy]phenyI]amino]-1,1,1-trifiuoro-2-propanoI;<br>
3-[[[2-fiuoro-5-(trifIuoromethyl)phenyl]methylI[3-[[[3-(trifluoronnethyI)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
3-[[[2-fluoro-5-(trifluoronriethyl)phenyl]methyl][3-[[3,5-ciimethylphenyri-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanoI;<br>
3-[t[2-fiuoro-5-(trifluoromethyl)phenyl]methyl][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[2-fluoro-5-(trifiuoromethyI)phenyI]methyI][3-[[3,5-difluoropheny]]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl][3-[cycIohexylnnethoxy]-phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1,-trifluoro-propanol;<br>
3-[[3-(2-trifluoromethyI-4-pyridyloxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanoi;<br>
3-[[3-(3-difluoromethoxyphenoxy)phenyl][[2-fluoro-5-(trifluoromethyi)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-H[3-(3-trifluoromethylthio)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)-phenyI]methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifiuoromethoxyphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-isopropylphenoxy)phenyl][[2-fluoro4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(3-cyc!opropylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl][[2-fluro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br><br>
3-[[3-(4-methyIphenoxy)phenyl][[2-fIuoro-4-(trifluoromethyl)phenyl]-methyr| amino]-1,1,1 -trffiuoro-2-propanol;<br>
3-[[3-(2-fJuoro-5-bromophenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-[3-(1,1,2,2-tetrafIuoroethoxy)phenoxy]phenyl3[[2-fluoro-4-(trifluoro-methyI)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propano!;<br>
3-[[3-[3-(pentafIuoroethyl)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3,5-dimethylphenoxy)phenyl][[2-fluoro-4-(trifIuoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-ethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-t-butylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyl-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-methylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyi]-amino]-1,1,1 -trifluoro-2-propanol;  ,<br>
3-[t3-(5,6,7,8-tetrahydro-2-naphthoxy)pheny!][[2-fluoro-4-(trifIuoromethyl)-phenyl]methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(phenoxy)phenyl][[2-fiuoro-4-(trifluoromethyl)phenyl]methylarnino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-[3-(N,N-dimethylamino)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3~[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propano!;<br>
3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3-(trifiuoromethyl)-phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[2-fluoro-4-(trif]uoromethyI)phenylJmethyIJ[3-[[3,5-dimethylphenylj-methoxy]phenyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
3-[p-fluoro-4-(trifluoromethyl)phenyl]methyI][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3,5-difluorophenyl]-methoxy]phenyrjamino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[2-fiuoro-4-{trifluoromethyl)phenyI]methyl][3-[cyc]ohexy!methoxy]-pheny(]amino]-1 ,'1,1-trifIuoro-2-propanol;<br>
3-[[3-(2-difluoromethoxy-4-pyridyIoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyi]methyl]amino]-1,1,1-trifluoro-2-propano[;<br>
3-[[3-(2-trifluoromethyI-4-pyridy!oxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methy!]amino]-1,1,1-trif)uoro-2-propanoI;<br>
3-[[3-(3-difluoromethoxyphenoxy)phenyl][[2-fIuoro-4-(trifIuoromethyl)-phenyljmethy0amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol; and<br>
3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[2-fluoro-4-(trifluoro-methyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of substitued N-Aliphatic-N-Aromatic teritiary-Heteroalkylamines having the Formula XV<br>
(Formula Removed)<br>
Formula XV<br>
and pharmaceutical^ acceptable forms thereof, wherein: nxv is an integer selected from 1 through 2; Aw and Qxv are independently selected from the group consisting of<br>
-CH2(CRxv-37RxV-38)vXV-(CRxV-33RxV-34)uX\rT"xV- (CRxV-35RxV-36)wXV-H,    <br>
(Formula Removed)<br>
with the provisos that one of Axv and Qxv must be AQ-1 and that one of Axv and Qw must be selected from the group consisting of AQ-2 and -CH2(CRxv-37Rxv-38)vxv-(CRxv-<br>
33Rx\/-34)uXV-TxV-(CRxV-35RxV-36)wXV-H;<br>
Txv is selected from the group consisting of a single covalent bond, O, S, S(O), S(O)2l C(Rxv-3)=C(RXV-35), and<br>
vxv is an integer selected from 0 through 1 with the proviso that vxv is 1 when<br>
any one of Rxv-33, Rxv-34, Rxv-35, and Rxv-36 is aryl or heteroaryl;<br>
uxv and wXv are integers independently selected from 0 through 6; Axv-1 is C(Rxv-3o);<br>
Dxv-1. DXv-2, Jxv-1, Jxv-2 and KXV-1 are independently selected from the group consisting of C, N, 0, S and a covalent bond with the provisos that no more than one of DXV-1 , DXV-1  JXV-1  Jxv-2, and KXV-1  is a covalent bond, no more than one of Dxv-1, Dxv-2, Jxv-1. Jxv-2, and Kxv-1 is 0,no more than one of Dxv-1, Dxv-1 Jxv-1, Jxv-2, and Kxv-1 is S, one of Dxv-1, Dxv-2, Jxv-1. Jxv-2, and Kxv-1 must be a covalent bond when two of Dxv-1, DXV-2, Jxv-1. Jxv-2, and Kxv-1 are O and S, and no more than four of Dxv-1, Dxv-2 Jxv-1, Jxv-2, and Kxv-1 are N;<br>
Bxv-1 Bxv-2, Dxv-3. Dxv-4, Jxv-3, Jxv-4, and Kxv-2 are independently selected from the group consisting of C, C(Rxv-3o), N, O, S and a covalent bond with the provisos that no more than 5 of Bxv-1, Bxv-2, Dxv-3, Dxv-4, Jxv-3, Jxv-4, and Kxv-2 are a covalent bond, no more than two of Bxv-1, Bxv-2. Dxv-3, Dxv-4. Jxv-3, Jxv-4, and Kxv-2 are O, no more than two of Bxv-1, Bxv-2. Dxv-3, Dxv-4. Jxv-3, Jxv-4, and Kxv-2 are S, no more than two of Bxv-1. Bxv-2. Dxv-3, Dxv-4, Jxv-3, Jxv-4. and Kxv-2 are simultaneously O and S, and no moreihajitwoof Bxv,i Bxv=2, Dxv-3,.Dxv=4, Jxv-3, Jxv-4, and Kxv-2 are N;<br>
Bxv-1 and Dxv-3, Dxv-3 and Jxv-3, Jxv-3 and Kxv-2, Kxv-2 and Jxv-4, Jxv-4and Dxv-4, and Dxv-4 and Bxv-2 are independently selected to form an in-ring spacer pair wherein said<br>
spacer pair is selected from the group consisting of C(Rxv-33)=C(Rxv-35) and N=N with the provisos that AQ-2 must be a ring of at least five contiguous members, that no more than two of the group of said spacer pairs are simultaneously C(Rxv-33)=C(Rxv-35) and that no more than one of the group of said spacer pairs can be N=N unless the other spacer pairs are other than C(Rxv-33)=C(Rxv-35), O, N, and S;' Rxv-1 is selected from the group consisting of haloalkyl and haloalkoxymethyl; Rxv-2 is selected from the group consisting of hydrido, aryl, alkyl, alkenyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, perhaloaryl, perhaloaralkyl, perhaloaryloxyalkyl and heteroaryl;<br>
Rxv-3 is selected from the group consisting of hydrido, aryl, alkyl, alkenyl, haloalkyl, and haloalkoxyalkyl;<br>
Yxv is selected from the group consisting of a covalent single bond, (CH2)q wherein q is an integer selected from 1 through 2 and (CH2)j-0-(CH2)k wherein j and k are integers independently selected from 0 through 1;<br>
Zxv is selected from the group consisting of covalent single bond, (CH2)q wherein q is an integer selected from 1 through 2, and (CH2),-0-(CH2)k wherein j and k are integers independently selected from 0 through 1;<br>
Rxv-4, Rxv-s. Rxv-9 and Rxv-13 are independently selected from the group consisting of hydrido, halo, haloalkyl, and alkyl;<br>
Rxv-30 is selected from the group consisting of hydrido, alkoxy, alkoxyalkyl, halo, haloalkyl, alkylamino, alkylthio, alkylthioalkyl, aikyl, atkenyl, haloalkoxyâ€ž.and haloalkoxyalkyl with the proviso that Rxv-30 is selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;<br>
Rxv-30. when bonded to Axv-1, is taken together to form an intra-ring linear spacer connecting the Axv-1-carbon at the point of attachment of Rxv-30 to the point of bonding of a group selected from the group consisting of Rxv-10 Rxv-11 Rxv-12. Rxv-31, and Rxv-32 wherein said intra-ring linear spacer is selected from the group consisting of a covalent single bond and a spacer moiety having from 1 through 6 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl having from 3 through 10 contiguous members, a cycloalkenyl having from 5 through 10 contiguous members, and a heterocyclyl having from 5 through 10 contiguous members;<br>
Rxv-so, when bonded to Axv-1, is taken together to form an intra-ring branched spacer connecting the Axv-i-carbon at the point of attachment of Rxv-30 to the poihts of bonding of each member of any one of substituent pairs selected from the group consisting of subsitituent pairs Rxv-10 and Rxv-11. Rxv-10 and Rxv-31, Rxv-10 and Rxv-32, Rxv-10 and Rxv-12, Rxv-11 and Rxv-31, Rxv-11 and Rxv-32, Rxv-11 and Rxv-12, Rxv-31 and Rxv-32, Rxv-31 and Rxv-12, and Rxv-32 and Rxv-12 and wherein said intra-ring branched spacer is selected to form two rings selected from the group consisting of cycloalkyl having from 3 through 16 contiguous members, cycloalkenyl having from 5 through 10 contiguous members, and heterocyclyl having from 5 through 10 contiguous members;<br>
RxV-4, RxV-5i RxV-6, RxV-7,  RxV-8, RxV-9, RxV-10, RxV-11, RxV-12, RxV-13, RxV-31, RxV-32,<br>
Rxv-30, Rxv-34, Rxv-35, and Rxv-36 are independently selected from the group consisting of hydrido, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, heteroarylamino, N-heteroarylamino-N-alkylamino, heteroarylaminoalkyl, haloalkylthio, alkanoyloxy<br>
alkoxy, alkoxyalkyl, haloalkoxylalkyl, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, cycloalkoxyaikyl,' cycloalkylaikoxy, cycloalkenyloxyalkyl, cycloalkylenedioxy, halocycloalkoxy,<br>
halocycloalkoxyalkyl, halocycloalkenyloxy, halocycloalkenyloxyalkyl, hydroxy, amino, thio, nitro, lower alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio, arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroarylsulfinylaikyl, heteroarylsulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, haloalkylsulfinylalkyl, haloalkylsulfonylalkyl, alkylsuifonamido, alkylaminosulfonyl, amidosulfonyl, monoalkylamidosulfonyl, dialkyl amidosulfonyl, monoarylamidosulfonyl, aryisulfonamido, diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, heterocyclylsulfonyl, heterocyclylthio, alkanoyl, alkenoyi, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haioalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalky, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkyialkanoyl, cycloalkenyl, lower cycloalkylalkyl, lower cycloalkenyialkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, heteroaralkynyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido, alkylamidocarbonylamido, alkylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl with the provisos that RXV-4, RXV-5, Rxv-6, Rxv-7, Rxv-8, Rxv-9, Rxv-10, Rxv-11 Rxv-12, Rxv-13, Rxv-31, Rxv-32, Rxv-33, Rxv-34, Rxv-35, and Rxv-36 are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen, that no more than three of the Rxv-33 and Rxv-34 substituents are simultaneously selected from other than the group consisting of hydrido and halo, and that no more than three of the RXV. 35 and Rxv-36 substituents are simultaneously selected from other than the group consisting of hydrido and halo;<br>
Rxv-9, Rxv-10, Rxv-11. Rxv-12, Rxv-13&gt; Rxv-3i&gt; and Rxv-32 are independently selected to be oxo with the provisos4hat Bxy-1Bxv-2, Dxv-3, Dxv-4, Jxv-3.-Jxv-4, and Kxv-2 are independently selected from the group consisting of C and S, no more than two of<br>
Rxv-9, Rxv-10, Rxv-11, Rxv-12, Rxv-13, Rxv-31, and Rxv-32 are simultaneously oxo, and that<br>
Rxv-9, Rxv-10, Rxv-11, Rxv-12, Rxv-13, Rxv-31, and Rxv-32 are each independently selected<br>
to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent<br>
nature of sulfur, and the divalent nature of oxygen;	<br>
Rxv-4and Rxv-5, Rxv-5 and Rxv-6, Rxv-6 and Rxv-7, Rxv-7 and Rxv-8, Rxv-9 and Rxv-10, Rxv-10 and Rxv-11, Rxv-11 and Rxv-31, Rxv-31 and Rxv-32, Rxv-32 and Rxv-12, and Rxv-12 and Rxv-13 are independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyciyi ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the provisos that no more than one of the group consisting of spacer pairs Rxv-4 and Rxv-5, Rxv-5 and Rxv-6, Rxv-6 and Rxv-7, Rxv-7 and Rxv-8 is used at the same time and that no more than one of the group consisting of spacer pairs Rxv-g and Rxv-10, Rxv-10 and Rxv-11, Rxv-11 and Rxv-31, Rxv-31 and Rxv-32, Rxv-32 and Rxv-12, and Rxv-12 and Rxv-13 are used at the same time;<br>
Rxv-9 and Rxv-11, Rxv-9 and Rxv-12, Rxv-9 and Rxv-13 Rxv-9 and Rxv-31, Rxv-9 and Rxv-32, Rxv-10 and Rxv-12, Rxv-10 and Rxv-13, Rxv-10 and Rxv-31, Rxv-10 and Rxv-32, Rxv-11 and Rxv-12, Rxv-11 and Rxv-13, Rxv-11 and Rxv-32, Rxv-12 and Rxv-31, Rxv-13 and Rxv-31, and Rxv-13 and Rxv-32 are independently selected to form a spacer pair wherein said spacer pair is taken together to form a linear spacer moiety selected from the group consisting of a covalent single bond and a moiety having from 1 through 3 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl having from 3 through 8 contiguous members, a cycloalkenyl having from 5 through 8 contiguous members, a saturated heterocyciyi having from 5 through 8 contiguous members and a partially saturated heterocyciyi having from 5 through 8 contiguous members with the provisos that no more than one of said group of spacer pairs is used at the same time;<br>
Rxv-37 and Rxv-38 are independently selected from the group consisting of hydrido, alkoxy, alkoxyalkyl, hydroxy, amino, thio, halo, haloalkyl, alkylamino, alkylthio, alkylthioalkyl, cyano, alkyl, alkenyl, haloalkoxy, and haloalkoxyaJkyl.<br><br>
Compounds of Formula XV and their methods of manufacture are disclosed in PCT Publication No. WO 00/18723, which is incorporated herein by reference in its entirety for al! purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XV:<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl]<br>
(cyciohexylmethyl)amino]-1,1,1-trifIuoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl]<br>
(cyclopentylmethyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-ch)oro-3-ethylphenoxy)phenyl]<br>
(cyclopropylmethyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-trifiuoromethyl)cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-pentafluoroethyl)<br>
cyclohexyl-methyl]amino]-1,1, l-trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][(3-trifluoromethoxy)<br>
cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-<br>
tetrafluoroethoxy)cyclo-hexylmethyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl]<br>
(cyclohexylmethyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl]<br>
(cyclopentylmethyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[-(3-trifluoromethoxyphenoxy)phenyl]<br>
(cyclopropylmethyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl][(3-trifluoromethyl)cyclohexyl-me1hyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl]](3-pentafluoroethyl)cyclohexyl-methyl]amino]-1,1,1-trifiuoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyl][(3-trifluoromethoxy)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyphenoxy)phenyrj[[3-(1,1,2,2-tetrafluoroethoxy)cycIohexyl-methyl]amino3-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-isopropy]phenoxy)phenyI](cyclohexylmethyl]amino]-1,1,1 -trifiuoro-2-<br>
propanol:<br>
3-[[3-(3-isopropylphenoxy)phenyl](cyclopentyImethyl]amino]-1,1,1 -trifluoro-2-<br>
propanol;	<br>
3-[[3-(3-isopropyIphenoxy)phenyl](cyclopropylmethyl)amino]-1,1,1-trifiuoro-2-<br>
propanol;<br>
3-[[3-(3-isopropylphenoxy)phenyl][(3-trifluoromethyl)cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanoI;<br>
3-[[3-(3-isopropylphenoxy)phenyl3[(3-pentafluoroethyl) cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-{3-isopropyiphenoxy)phenyl][(3-trifluoromethoxy) cyclohexyl-methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[3-(3-isopropylphenoxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2)3-dichIorophenoxy)phenyl](cyclohexylmethyl )amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyi](cyclopentylmethyI) amino]-1,1,1 -trifIuoro-2-propanol;  <br>
3-[[3-(2,3-dichlorophenoxy)phenyl](cyclopropylmethy)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][(3-trifluoromethyl) cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][(3-pentafluoroethyl) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][(3-trifluoromethoxy) cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(2,3-dichlorophenoxy)phenyl][3-(1,1,2,2-tetrafiuoroethoxy)cyclo-hexyl-methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl](cyclohexylmethyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl](cyclopentylmethyI)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phennyl](cycIopropylmethyl)arnino]-1,1,1-triflouro-2-propanol;<br>
 3-[[3-(4-f[uorophenoxy)phenyl][(3-trifluoromethyl)cyclohexy!-methyl]amino]-<br>
1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl][(3-pentafluo'roethyl)cyclohexyl-methyamino]-<br>
1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fluorophenoxy)phenyl][(3-trifluoromethoxy)cyclohexyl-methy[]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(4-fIuorophenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino]-1,1,1-trifiuoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxyben2yloxy]phenyl](cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(34rifluoromethoxybenzyloxy)phenyl] (cyclopentylmethyl)amino]-1,1,1-trifiuoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxybenzyloxy)phenyl] (cyclopropylmethyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][(3-trifluoromethyl)cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][(3-pentafluoroethyl)cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxybenzyloxy]phenyl][(3-trifiuoromethoxy)cyclohexyl-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethoxybenzyloxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)-cyclohexylmethyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethylbenzyloxy)phenyl](cyclohexylmethyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethylbenzyloxy)phenyl](cyclopentylmethyi)amino]-1,1,1-trifluoro-2-propanol;<br>
3-P-(3-trifluoromethylbenzyioxy)phenyl](cyclopropylmethy])amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethylbenzyIoxy)phenyl][(3-trifluoromethyl)cyclohexyI-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethylbenzyloxy)phenyl][(3-pentafluoroethyl)cyclohexyl-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethylbenzyloxy)phenyI][[(3-triflueromethoxy)cycIohexyl-methyl]amino]-l ,1,1 -trifluoro-2-propanol;<br>
3-[[3-(3-trifluoromethylbenzyloxy)phenyl][3-(1,1,2,2-tetrafluoroethoxy)cyclohexyl-methyl]amino3-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethyl)phenyl]methyI](cyclohexyI)amino]-1,1,1-trifiuoro-2-propanol;<br>
3-[[[(3-pentafIuoroethy!)phenyl]methyi](cyclohexyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-trrfluoromethoxy)phenyl]methyl](cyclohexyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl] methyl](cyclohexyl)aminoJ-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethyl)phenyl]methyl](4-methylcyciohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-pentafluoroethyl)phenylJmethyl](4-methylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethoxy)phenyl]methyl](4-methylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](4-methylcyclohexyl)amino]-<br>
1,1,1 -trif luoro-2-propanol;	,<br>
3-[[[(3-trifluoromethyl]phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-pentafluoroethyl)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1 -trif luoro-2-propanol;<br>
3-[[[(3-trifluoromethoxy)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1 -trifiuoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](3-trifluoromethylcyclohexyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethyl)phenyl]methyl][3-(4-chloro-3-ethyIphenoxy)cyclo-hexy l]amino]-1,1,1 -trrfluoro-2-propanol;<br>
3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(4-chloro-3-ethyIphenoxy)cyclo-hexyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethoxy)phenyl]methyl][3-(4-chIoro-3-methylphenoxy)cyclo-hexyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,24etrafluoroethoxy)phenyl]methyl][3-(4-chlo ro-3-ethylphenoxy)-cyclohexyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifl'uoromethyl]phenyl]methyl](3-phenoxycyclohexyI)amino]-1,1,1 -<br>
trifluoro-2-propahol;<br>
3-[[[(3-pentafluoroethyl)phenyl]methyl](3-phenoxycyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifIuoromethoxy)phenyl]methyl(3-phenoxycyclohexyl)amino]-1,1,1-trifluoro2-propanol;<br>
3-[[[3-(1,1 2,2-tetrafluoroethoxy)phenyl]methyl](3-phenoxycyclohexyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-trifioromethyl)phenyl]methyl](3-isopropoxycyclohexyl)amino]-1,1,1,-trifluoro-2-propanol;<br>
3-[[[(3-pentafIuoroethyl)phenyl]methyl](3-isopropoxycyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethoxy)phenyl]methyl](3-isopropoxycyclohexyl)amino]-1,1,1-<br>
trifluoro-2-propanol',-	<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxyl)phenymethyI](3-isopropoxycyclohexyl)-amino]-1,1,1-trifluoro-2-propano[;<br>
3-[[[(3-trifluoromethyl)phenyl]methyl](3-cyclopentyloxycyclohexyI]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-pentafluoroethyl]phenyl]methyl](3-cyclopentyloxycyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
r<br>
3-[[[(3-trifluoromethoxy)phenyl]methyi](3-cyclopentyloxycyclohexyl)amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl](3-cyclopentyloxycyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(2-trifluoromethy])pyrid-6-yl]methyl](3-isopropoxycyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(2-trifiuoromethyl)pyrid-6-yl]methyl)(3-cyclopentyloxycyclohexyl)-amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(2-trifluoromethyl)pyrid-6-yl]methyl) (3-phenoxycyclohexyl)amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(2-trifluoromethyl)pyrid-6-yl]methyI](3-trifluoromethylcyclohexyl)amino3-1,1,1 -trlfluoro-2-propanol;<br>
3-[[[(2-trifiuoromethyI)pyrid-6;:y0methy0[3-(4-chtoro-3-ethylphenoxy)cyclo-hexy]]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(2-trifiuoromethyl)pyrid-6-y]Jmethyl][3-{1,1,2,2-tetrafluoroethoxy)cyclo-â€¢ hexyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-{[[(2-trifIuoromethyI)pyrid-6-yl]methyl](3-pentafluoroethylcyclohexy!)-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(2-trifluoromethy])pyrid-6-y]]methyl](3-trifluoromethoxycyclohexy])-amino]-1,1,1 -trif luoro-2-propanol;<br>
3-[[[(3-trifiuoromethyl)phenyl]methyl[3-(4-chloro-3-ethylphenoxy)propyI]-amiino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)propyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethoxy)phenyl]methyI][3-(4-chloro-3-ethylphenoxy)propyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafIuoroethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-propyl]amino]-1,1,1 -trifluoro-2-propanol; 3-[[[(3-trifluoromethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-2,2-di-fluropropyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[(3-pentaf)uoroethyl)phenyl]methyl][3-(4-chloro-3-ethylphenoxy&gt;-2,2-di-fluropropyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethoxy)pheny!JmethyI][3-(4-chloro-3-ethylphenoxy)-2,2,-di-f luropropyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-(4-chloro-3-ethylphenoxy)-2,2,-difluropropyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-trifluoromethyl)phenyl]methyl][3-(isopropoxy)propyl]amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[(3-pentafluoroethyl)phenyl]methyl][3-(isopropoxy)propyl]amino]-1,1,1-trifiuoro-2-propanol;<br>
3-[[[(3-trffluoromethoxy)phenyl]methyl][3-(isopropoxy)propyl3amino]-1,1,1-trifluoro-2-propanol;<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]]3-(isopropoxy)propyi]amino]-1,1,1-trifiuoro-2-propanol; and<br>
3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenylJmethyl][3-(phenoxy)propyl]amino]-1,1,1 -trifluoro-2-propanol.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of (R)-chiral halogenated 1-substituted amino-(n+l)-aIkano!s having the Formula xvl<br>
(Formula Removed)<br>
Formula XVI and pharmaceuticaliy acceptable forms thereof, wherein:<br>
nWi is an integer selected from 1 through 4;<br>
Xxvi is oxy;<br>
Rxvi-i is selected from the group consisting of haloalkyl, haloalkenyl, haloalkoxymethyl, and haloalkenyloxymethyl with the proviso that RXVM has a higher Cahn-lngold-Prelog stereochemical system ranking than both Rxvi-2 and (CHRxvi-3)n-N(Axvi)Qxvi wherein Axvi is Formula XVI-(II) and Q is Formula XVI-(III);<br>
(Formula Removed)<br>
Rxvl-16 is selected from the group consisting of hydrido, alkyl, acyl, aroyl, heleroaroyi, trialkyisilyl, and a spacer selected from the group consisting of a covalent singJeÂ£ondand-a linear spacer-moiety having -axhain length of _1 io 4 atoms Jinked to the point of bonding of any aromatic substituent selected from the group consisting of Rxvl-4, Rxvl-s. Rxvl-9. and Rxvl-13 to form a heterocyclyl ring having from 5 through 10 contiguous members;<br>
DXVM. Dxvl-2. JXVM, Jxvl-2 and KXVM are independently selected from the group consisting of C, N, O, S and covalent bond with the provisos that no more than one of DXVM. Dxvl-2. JXVM, Jxvl-2 and KXVM is a covalent bond, no more than one DXVM, Dxvl-2, JXVM, Jxvl-2 and KXVM is be O, no more than one of DXVM, Dxvl-2, JXVM, Jxvl-2 and KXVM is S, one of DXVM, Dxvl-2. JXVM, Jxvl-2 and KXVM must be a covalent bond when two of DXVM, Dxvl-2, JXVM, Jxvl-2 and KXVM are O and S, and no more than four of DXVM, Dxvl-2, JXVM, JXVL-2 and KXVM is N;<br>
Dxvl-3, DXVM, Jxvl-3, Jxvu and Kxvl-2 are independently selected from the group consisting of C, N, O, S and covalent bond with the provisos that no more than one is a covalent bond, no more than one of Dxvl-3, Dxvl-4, Jxvl-3, JXVM and Kxvl-2 is O, no more than one of Dxvl-3, Dxvl-4, Jxvl-3, JXVM and Kxvl-2 is S, no more than two of Dxvl-3, Dxvl-4, Jxvl-3, Jxvl-4 and Kxvl-2 is 0 and S, one of Dxvl-3, Dxvl-4, Jxvl-3, JXVM and Kxvl-2 rnust be a covalent bond when two of Dxvl-3, DXVM, Jxvl-3, JXVM and Kxvl^are O and S, and no more than four of Dxvl-3, DXVM, Jxvl-3, JXVM and Kxvl-2 are N;<br>
Rxvl-2 is selected from the group consisting of hydrido, aryl, aralkyl, alkyl, alkenyl, alkenyloxyalkyl, haloalkyl, haloalkenyl, halocycloalkyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl,<br>
perhaloaryl, perhaloaralkyl, perhaioaryioxyalkyl, heteroaryl, dicyanoaikyl, and carboalkoxycyanoalkyl, with the proviso that Rxvl-2 has a lower Cahn-lngold-Prelog system ranking than both Rxvl-1 and (CHRxvl-)n-N(Axvl)Qxvl;<br>
Rxvl-3 is selected from the group consisting of hydrido, hydroxy, cyano, aryl, aralkyl, acyl, alkoxy, alkyl, alkenyl, alkoxyalkyl, heteroaryl, alkenyloxyalkyl, haioalkyi, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, monocyanoalkyl, dicyanoaikyl, carboxamide, and carboxamidoalkyl, with the provisos that (CHRxvl-3)n N(AXVL)QXVL has a lower Cahn-lngold-Prelog stereochemical system ranking than Rxvl-1 and a higher Cahn-lngold-Prelog stereochemical system ranking than Rxvl-2;<br>
Yxvl is selected from a group consisting of a covalent single bond, (C(Rxvl-14)2)q wherein q is an integer selected from 1 and 2 and (CH(RxvM4))g-Wxvr(CH(Rxvl-14))p wherein g and p are integers independently selected from 0 and 1 ;<br>
Rxvl-4 is selected from the group consisting of hydrido, hydroxy, cyano, hydroxyalkyl, acyl,alkoxy,lkyl, alkenyl, alkynyl alkoxyalkyl, haloalkyl haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, monocarboalkoxyalkyl, monocyanoalkyl, dicyanoaikyl, carboalkoxycyanoalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;<br>
ZWi is selected from a group consisting of a covalent single bond, (C(Rxvl-i5)2)q, wherein q is an integer- selected from 1 and 2, and (CH(Rxvl-15)).~VVxvr(CH(Rxvl-is))k wherein j and k are integers independently selected from 0 and 1;<br>
Wxvl is selected from the group consisting of O, C(O), C(S),C(0)N(Rxvl-14). C(S)N(RXvM4),(RxVM4)NC(0)f (Rxvl-u )NC(S), S, S(O), S(0)2, S(0)2H(R^,), (Râ„¢_ 14)NS(0)2, and N(Rxvl-i4) with the proviso that RXVM4 is other than cyano;<br>
Rxvl-i5is selected, from the group consisting of hydrido, cyano, hydroxyalkyl, acyl, alkoxy, alkyl, alkenyl, alkynyl, alkoxyalkyl, haioalkyi, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, monocarboalkoxyalkyl, monocyanoalkyl, dicyanoaikyl, carboalkoxycyanoalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;<br>
RXVI-4 Rxvl-5. Rxvl-6, Rxvl-7. Rxvl-8. Rxvl-9. RxvI-10. Rxvl- Rxvl-12 and Rxvl-13 are independently selected from the group consisting of hydrido, carboxy, heteroaralkylthio, heteroaraikoxy, cycioalkylamino, acylalkyl, acylalkoxy, aroyialkoxy, heterocyciyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl,<br>
cycloalkyisulfonylalkyl, heteroarylamino, N-heteroarylamino-N-alkylamino, heteroaralkyl, heteroarylaminoalky], haloalkylthio, aikanoyloxy, alkoxy, alkoxyalkyl, haloalkoxyialkyl, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, cycloalkoxyalkyi, cycloalkylalkoxy, cycloalkenyloxyalkyl, cycloalkylenedioxy, halocycloalkoxy, , â€ž halocycloalkoxyalkyl, halocycloalkenyloxy, halocycioaikenyloxyalkyl, hydroxy, amino, thio, nitro, lower alkyiamino, alkylthio, alkylthioaikyl, aryiamino, araikylamino, arylthio, arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroarylsulfinylalkyl, heteroarylsulfonyialkyl, alkylsulfonyl, alkylsulfonylalkyl, haloalkylsulfinylaikyl, haloalkylsulfonylalkyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl, amidosulfonyl, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulftnyl, arylsulfonyl, heteroarylthio, heteroarylsulftnyl, heteroarylsulfonyl, heterocyclylsulfonyl, heterocyclylthio, alkanoyi, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalky, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, lower cycloalkylalkyl, lower cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, heteroaralkynyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido, alkylamidocarbonylamido, arylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl with the proviso that Rxvl-4, Rxvl-5, Rxvl-6, Rxvl-7. Rxvl-8, Rxvl-9, RxvI-10. Rxvl-11, Rxvl-12. and Rxvl-13 are each independently selected to maintain the tetravalent nature of carbon, trivaient nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;<br>
Rxvl-4 and Rxvl-5  Rxvl-5 and RxvI-6, Rxvl-6 and RxvI-7 Rxvl-7 and Rxvl-8. Rxvl-9 and Rxvl-10, RxvI-10 and Rxvl-11, RxvI-11 and Rxvl-12, and Rxvl-12 and RxIv-13 are independently selected to form spacer pairs wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5<br>
through 6 contiguous members, and an aryl with the provisos that no more than one of the group consisting of spacer pairs RXVI-4 and RXVI-5. RXVI-5 and RXVI-6, RXVI-6 and Rxvi-7, and Rxvi-7 and Rxvi-8 is used at the same time and that no more than one of the group consisting of spacer pairs Rxiv-9 and RxvI-10, RXVI-10 and RXVI-11, RXVI-11 and RXVI--12, and RXVI-12 and RXVI-13 can be used at the same time;<br>
Rxvi-4 and Rxvi-9, RXVI-4 and RXVI-13. RXVI-8 and RXVI-9, and RXVI-8 and RXVI-13 is independently selected to form a spacer pair wherein said spacer pair is taken together to form a linear moiety wherein said linear moiety forms a ring selected from the group consisting of a partially saturated heterocyclyl ring having from 5 through 8 contiguous members and a heteroaryl ring having from 5 through 6 contiguous members with the proviso that no more than one of the group consisting of spacer pairs RXVI-4 and RXVI-9, RXVI-4 and RXVI-13. RXVI-8 and RXVI-9, and RXVI-8 and RXVI-13 is used at the same time.<br>
Compounds of Formula XVI and their methods of manufacture are disclosed in PCT Publication No. WO 00/18724, which is incorporated herein by reference in its entirety for all purposes.<br>
In a preferred embodiment, the CETP inhibitor is selected from the following compounds of Formula XVI:<br>
(2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-isopropylphenoxy)phenyQ[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-cyclopropylphenoxy)phenylI[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl]II3-(1,1,2,2-tetrafluoroethoxy)pheny!]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2,3-dichlorophenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-f luorophenoxy)phenyl[[3-( 1,1,2,2-tetrafluoroethoxy)phenyl]-methyi]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifIuoro-2-propanol;<br>
(2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl][amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafiuoroethoxy)phenyl]-methyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
(2R)-3-[[3-[3-(1,1,2,2-tetrafiuoroethoxy)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoro-ethoxy)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)-phenyl]methyi]amino]-1,1,1 -trifIuoro-2-propanol;  <br>
(2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)pheny!]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-ethyIphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-t-butylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol:<br>
(2R)-3-[[3-(3-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenylj-me1.hyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(1,1,2,2,-tetrafluoro-<br>
ethoxy)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(phenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(N,N-dimethyIamino)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoro-ethoxy)phenyl]methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(1,1,2,2,-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoromethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
(2R)-3-[P-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3-(trifluoro-methyl)phenyf]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-dimethylphenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[p-(1,1,2,2-tetrafiuoroethoxy)phenyl]methyl][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1 -trffluoro-2-propanol;<br>
(2R)-3-[[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl][3-[[3,5-difiuorophenyl]-methoxy]phenyl]amino3-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[p-(1,1,2,2-tetrafluoroethoxy)phenyl] methyI][3-[cyclohexylmethoxy]-phenyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
(2R)-3-[[3-(2-difluoromethoxy-4-pyridy]oxy)phenyl][[-(1,1,2,2-tetraf luoroethoxy)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-trifluoromethyl-4-pyridy]oxy)phenyl][[3-( 1 ,,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
(2R)-3-[[[3-(3-trifuoromethylthio)phenoxy]phenyl][[3-( 1,1,2,2-tetrafluoroethoxy)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-{ 1,1,2,2-tetraf luoroethoxy)-phenyl]methyl]amino]-1 ,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino-]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-isopropylphenoxy)phenylJ[[3-(pentafIuoroethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-cyclopropylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]-amino]1,1,1,-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-(2-fury!)phenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2,3-dichlorophenoxy)phenyl]p-(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-fluorophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-methylphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1 -trif iuoro-2-propanol;<br>
(2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1-trifiuoro-2-propanol; (2R)-3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-<br>
(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][ [3-(pentafluoroethyl)-phenyl]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-U3-[3-(pentafluoroethyl)phenoxy]phenylJ[[3-(pentafiuoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-f[3-(3,5-dimethylphenoxy)phenyl]H3-(pentafluoroethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-ethylphenoxy)phenyl][[3-(pentafIuoroethyl) phenyl]methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-t-buty!phenoxy)phenyl][[3-(pentafluoroethyl) phenyl]methyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
(2R)-3-[[3-(3-methylphenoxy)phenyl][[3-(pentafluoroethy[) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(phenoxy)phenyl][[3(pentafiuoroethyl) phenyl]methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
(2R)-3-[[3-[3-(N,N-dimethyIamino)phenoxy]phenyl] [[3(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl[3-[[3-(trifluoromethoxy)phenyl]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-{pentafluoroethyl)phenyl]methyl][3-[[;3-(trifluoromethyl)-phenyl]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(pentafluoroethyl)pheny!]methyI][3-[[3,5-dimethylphenyr]methoxy]-phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[[3-(trifiuoromethylthio)phehyl]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(pentaf!uoroethyl)phenyl]methyl][3-[[3,5-difluorophenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(pentafluoroethyl)phenyl]methyl][3-[cycIohexylmethoxy]phenyl]-amino]-1,1,1 -trifIuoro-2-propanol;<br>
(2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(3-trifiuoromethylthio)phenoxy]phenyl][[3-(pentafluoroethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-(pentafluoroethyl)-phenyl]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-trifiuoromethoxyphenoxy)pheny!3[[3-(heptafluoropropyl)phenyl]-methylamino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-isopropylphenoxy)phenyl][[3-(heptafluoropropy))phenyl]methyl]-amino]-1,1,1 -trifl'uoro-2-propanol;<br>
(2R)-3-[[3-(3-cyclopropyiphenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-f[3-(3-(2-furyt)phenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyl]-amino]-1,1,1 -trifiuoro-2-propanol;<br>
(2R)-3-p-(2,3-dichlorophenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methyi]-amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-p-(4-fluorophenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-methylphenoxy)phenyl][[3-(heptafluoropropyl) phenyf]methyl]amino]-1,1,1 ,-trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[3-(heptafiuoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-ch)oro-3-ethy)phenoxy)phenyl][[3-(heptafluoropropyl)phenyl]methy]]-amino]-1,1,1-trifiuoro-2-propanol; (2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl][ [3-(heptafluoropropyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(pentafluoroethyl)phenoxy]phenyl][[3-(heptafluoropropyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3,5-dimethylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-ethy!phenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-t-butylphenoxy)phenyl][[3-(heptafluoropropyI) phenyl]methyl]amino]-1,1, 1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-methylphenoxy)phenyl][[3-(heptafluoropropyl) phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[3-(heptafluoropropyl)phenyl]-methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(phenoxy)phenyl][[3-(heptafiuoropropyl)phenyl]methyl]amino]-1,1,1-trif!uoro-2-propanol;<br>
(2R)-3-[[3-[3-(N,N-dimethylamino)phenoxy]phenylJ[[3-(heptafluoropropyI)pheny!]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(heptafluoropropyl)phenyl]methy]][3-[[3-(trifluoromethoxy)phenyl]-methoxy]pheny[]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(heptafluoropropyl)phenyl]methyl][3-[[3-(trif]uoromethyl)phenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(heptafiuoropropyl)phenyl]methyl][3-[[3,5-dimethylphenyl]methoxy]-phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[t[3-(heptafluoropropyl)phenyl]methyI][3-[[3-(trifluoromethylthio)phenyl]-methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(heptafIuoropropyl)pheny!]methyl][3-[[3,5-difluorophenyl]methoxy]-phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[3-(heptafluoropropyl)phenyl]methyI][3-[cyclohexylmethoxy]phenyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[3-(heptafluoroprppyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(24rifluoromethyl-4-pyridyloxy)phenyl][[3-(heptafluoropropyl)pheny!]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[3-(heptafluoropropyl)pheriyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[3-(heptafluoropropyi)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[3-(heptafluorapropyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-trifIuoromethoxyphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-isopropyIphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-cyclopropylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenylJ-methyI]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fIuoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(2,3-dichIorophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-fluorophenoxy)phenyl][[2-fiuoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1 -trif)uoro-3-propanol;<br>
(2R)-3-[[3-(4-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]-methyl]amino]-1 ,'1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-fiuoro-5-bromophenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-chioro-3-ethylphenoxy)phenyl][[2-fIuoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifiuoro-2-propanol;<br>
(2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl] [[2-fIuoro-5-(trifluoro-methyl)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(pentafIuoroethyl)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methylamino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3,5-dimethyIphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenylj-methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-ethylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-t-butylphenoxy)phenyl]p-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-t[3-(3-methylphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-{5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(phenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-t3-(N,N-dimethylamino,phenoxy3phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl[3[3-[[3-(trifluorornethoxy)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-3-propanol;<br>
(2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyI][3-[[3-(trifluoromethy[)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyI3[3-[[3,5-dimethylphenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyi][3-[[3-(trifluoromethylthio)-phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[t2-f!uoro-5-(trifluoromethyl)phenyl]methyl][3-[[3,5-difluropheny!]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-5-(trifiuoromethyl)phenyI]methyl][3-[cyclohexylmethoxy!-phenyl]amino]-1,1,1 -trifIuoro-2-propanol;<br>
(2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[2-fluoro-5-(trifIuoromethyl)-<br>
phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;	<br>
(2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyI]amino]-1,1,1 -trifiuoro-2-propanol;<br>
(2R)-3-[[3-(3-difluoromethoxyphenoxy)phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanoI;<br>
(2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl][[2-fluoro-5-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[2-fluoro-5-(trifluoro-methyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-trifluoromethoxyphenoxy)phenyl][[2-fiuoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-isopropylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]l-1,1,1-trifIuoro-2-propanol;<br>
(2R)-3-H3-(3-cyclopropylphenoxy)phenyl][[2-flouro-4-(trifluoromethyl)phehyl]-me1hyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-(2-furyl)phenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyi]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(2,3-dichIorophenoxy)pheny[][[2-fluoro-4-(trifluoromethyl)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-fluorophenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]-methylamino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(4-rnethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyI)phenyl]-methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-fluoro-5-bromophenoxy)phenyl][[2-fluoro-4-(trifluoromethyI)-phenyl]methyl]amino]-1,1,1-trifiuoro-2-propanol;<br>
(2R)-3-[[3-(4-ch]oro-3-ethylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(1,1,2,2-tetrafluoroethoxy)phenoxy]phenyl] [[2-fluoro-4-(trifluoromethyl)phenyI]methyI]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(pentafluoroethyl)piienoxy3phenyl]f[2-fluoro-4-(trifluoromethy])-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(3,5-dimethyIphenoxy)phenyl][[2-fluoro-4-(trif]uoromethyl)phenyl]-methyl]aminol-1 ,'1,1-trifIuoro-2-propanol;<br>
(2R)-3-[[3-(3-ethylphenoxy)phenyo[[2-fiuoro-4-(trifiuoromethyl)phenyl]methyl]-amino]-1,1,1 -trifIuoro-2-propanol;<br>
(2R)-3-[[3-(3-t-butylphenoxy)phenyl]r[2-fluoro-4-(trifluoromethyl)phenyflmethyl]-amino]-1,1,1 -trifluoro-2-propanoI;<br>
(2R)-3-[[3-(3-methylphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-amino]-1,1,1 -trifluoro-2-propanoi;<br>
(2R)-3-[[3-(5,6,7,8-tetrahydro-2-naphthoxy)phenyl][[2-fluoro-4-(trifiuoromethyl)-phenyomethyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[t3-(phenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-[3-(N,N-dimethylamino)phenoxy] 4-(trifluoromethyl)-phenyl]methyl]amino]-1,1-1-trifiuoro-2-propanol;<br>
(2R)-3-[I[2-fluoro-4-(trifluoromethy])phenyl]methyo[3-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(3R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyomethyl][3-[[3-(trifluoromethyI)phenyl]methoxy]phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyI][3-[[3,5-dimethylphenyI]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-4-(trifiuoromethyl)phenyl]methyl][3-[[3-(trif luoromethylthio)-phenyfjmethoxy]phenylJamino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl][3-[[3,5-difluorophenyl]-methoxy]phenyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[t2-fluoro-4-(trifluoromethyl)phenyl]methyi][3-[cyclohexylmethoxy]-phenyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-difluoromethoxy-4-pyridyloxy)phenyl][[2-fluoro-4-(trifiuoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[3-(2-trifluoromethyl-4-pyridyloxy)phenyo[[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol;<br>
(2R)-3-[[3-(3-difluoroinethoxyphenoxy)phenyl][[2-fluoro-4-(trifluoromethyl)-phenyl]methyl]amino]-1,1,1 -trifluoro-2-propanol;<br>
(2R)-3-[[[3-(3-trifluoromethylthio)phenoxy]phenyl]t[2-fluoro-4-(trifiuoromethy])-phenyI]methyi]amino]-1,1,1-trifluoro-2-propanoI; and<br><br>
(2R)-3-[[3-(4-chloro-3-trifluoromethylphenoxy)phenyl][[2-fluoro-4-(trif luoromethyl)phenyi]methyl]amino]-1,1,1 -trifluoro-2-propanol.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of quinolines of Formula XvII<br>
(Formula Removed)<br>
Formula XvII and pharmaceutically acceptable forms thereof, wherein:<br>
AxvII denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with up to five identical or different substituents in the form of a halogen, nitro, hydroxyl, trifluoromethyl, trifluoromethoxy or a straight-chain or branched alkyl, acyl, hydroxyalkyl or alkoxy containing up to 7 carbon atoms each, or in the form of a group according to the formula -NRXVIIRXVII-5. wherein<br>
RxvII-4 and RxvII-5 are identical or different and denote a hydrogen, phenyl or a straight-chain or branched alkyl containing up to 6 carbon atoms,<br>
AXVII denotes an aryl containing 6 to 10 carbon atoms, which is optionally substituted with a phenyl, nitro, halogen, trifluoromethyl or trifluoromethoxy, or a radical according to the formula<br>
(Formula Removed)<br>
RxvII-6, RXvII-7. RXVII-IO denote, independently from one another, a cycloalky! containing 3 to 6 carbon atoms, or an aryl containing 6 to 10 carbon atom or a 5- to 7-membered, optionally benzo-condensed, saturated or unsaturated, mono-, bi- or tricyclic heterocycle containing up to 4 heteroatoms from the series of S, N and/or O, wherein the rings are optionally substituted, in the case of the nitrogen-containing rings also via the N function, with up to five identical or different substituents in the form of a halogen, trifluoromethyl, nitro, hydroxyl, cyano, carboxyl, trifluoromethoxy, a straight-chain or branched acyl, alkyl, alkylthio, alkylalkoxy, alkoxy or alkoxycarbonyl containing up to 6 carbon atoms each, an aryl or trifluoromethyl-substituted aryl containing 6 to 10 carbon atoms each, or an optionally benzo-condensed, aromatic 5-to 7-membered heterocycle containing up to 3 heteoatoms from the series of S, N and/or O, and/or in the form of a group according to the formula -ORXVII-11, -SRXVII-12. -SO2RXvII-13. or -NRXvII-14 RXvII-15;<br>
-RXvII-11,-RXvII-12. and RXvII 13denote, independently from one another, an aryl containing 6 to 10 carbon atoms, which is in turn substituted with up to two identical or different substituents in the form of a phenyl, halogen or a straight-chain or branched alkyl containing up to 6 carbon atoms,<br>
RXvII-14 and RXvII-15 are identical or different and have the meaning of RXvII-4 and RXvII-5 given above, or<br>
(Formula Removed)<br>
RXvII-6 and/or RXVII-7 denote a radical according to the formula<br>
RXVII-8 denotes a hydrogen or halogen, and<br>
RXvII-9 denotes a hydrogen, halogen, azido, trifluoromethyl, hydroxyl, trifluoromethoxy, a straight-chain or branched alkoxy or alkyl containing up to 6 carbon atoms each, or a radical according to the formula NRXvII16 RXvII -17<br>
RXvII-16 and RXvII-17 are identical or different and have the meaning of RXvII and RXvII-5 above; or<br>
RXVII-8 and RxvII-9 together form a radical according to the formula =0 or =NRxvII-18<br>
RxvII18 denotes a hydrogen or a straight-chain or branched alkyl, alkoxy or acyl containing up to 6 carbon atoms each;<br>
LXVII denotes a straight-chain or branched alkylene or alkenylene chain containing up to 8 carbon atoms each, which are optionally substituted with up to two hydroxyl groups;<br>
TxvII and XxvII are identical or different and denote a straight-chain or branched alkylene chain containing up to 8 carbon atoms; or TxvII and XxvII denotes a bond; VxvII denotes an oxygen or sulfur atom or -NRxvII-19;<br>
RxvII-19 denotes a hydrogen or a straight-chain or branched alkyl containing up to 6 carbon atoms or a phenyl;<br>
ExvII denotes a cycloalkyl containing 3 to 8 carbon atoms, or a straight-chain or branched alkyl containing up to 8 carbon atoms, which is optionally substituted with a cycloalkyl containing 3 to 8 carbon atoms or a hydroxyl, or a phenyl, which is optionally substituted with a halogen or trifluoromethyl;<br>
RxvII-1 and RxvII2 are identical or different and denote a cycloalkyl containing 3 to 8 carbon atoms, hydrogen, nitro, halogen, trifluoromethyl, trifluoromethoxy, carboxy, hydroxy, cyano, a straight-chain or branched acyl, alkoxycarbonyl or alkoxy with up to 6 carbon atoms, or NRxvn-2oRxvII-21;<br>
RxvII-20 and RxvII-21 are identical or different and denote hydrogen, phenyl, or a straight-chain or branched alkyl with up to 6 carbon atoms; and or<br>
RxvII-1 and/or RxvII-2 are straight-chain or branched alkyl with up to 6 carbon atoms, optionally substituted with halogen, trifluoromethoxy, hydroxy, or a straight-chain or branched alkoxy with up to 4 carbon atoms, aryl containing 6-10 carbon atoms optionally substituted with up to five of the same or different substituents selected from halogen, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, straight-chain or branched alkyl, acyl, hydroxyalkyi, alkoxy with up to 7 carbon atoms and NRxvII-22RxvII-23;<br>
RxvII-22and RxvII-23 are identical or different and denote hydrogen, phenyl or a straight-chain or branched akyl up to 6 carbon atoms; and/or<br>
RxviI and RxvII-2 taken together form a straight-chain or branched alkene or alkane with up to 6 carbon atoms optionally substituted with halogen, trifluorom ethyl, hydroxy or straight-chain or branched alkoxy with up to 5 carbon atoms;<br>
RxvII-3 denotes hydrogen, a straight-chain or branched acyl with up to 20 carbon atoms, a benzoyl optionally substituted with halogen, trifluoromethyl, nitro or<br>
trifluoromethoxy, a straight-chained or branched fluoroacyl with up to 8 carbon atoms and 7 fluoro atoms, a cycloalkyl with 3 to 7 carbon atoms, a straight chained or branched alkyl with up to 8 carbon atoms optionally substituted with hydroxyl, a straight-chained or branched alkoxy with up to 6 carbon atoms optionally substituted with phenyl which may in turn be substituted with halogen, nitro, trifluoromethyl, trifluoromethoxy, or phenyl or a tetrazol substitued phenyl, and/or an alkyl that is optionally substituted with a group according to the formula -ORxvII-24;<br>
Rxvn-24 is a straight-chained or branched acyl with up to 4 carbon atoms or -benzyl.â€”<br>
Compounds of Formula XVII and their methods of manufacture are disclosed in PCT Publication No. WO 98/39299, which is incorporated herein by reference in its entirety for all purposes.<br>
Another class of CETP inhibitors that finds utility with the present invention consists of 4-Phenyltetrahydroquinolines of Formula XVIII<br>
Formula XVIII<br>
(Formula Removed)<br>
, N oxides thereof, and pharmaceutically acceptable forms thereof, wherein:<br>
Axviii denotes a phenyl optionally substituted with up to two identical or different substituents in the form of halogen, trifluoromethyl or a straight-chain or branched alkyl or alkoxy containing up to three carbon atoms;<br>
DxvII denotes the formula<br>
(Formula Removed)<br>
Rxvil-sand Rxvm-6 are taken together to form =0; or RxvIII-5 denotes hydrogen and RxvII-6 denotes halogen or hydrogen; or Rxvin-sand Rxvm-6 denote hydrogen;<br>
Rxvii-7and Rxvm-sare identical or different and denote phenyl, naphthyl, benzothiazolyl, quinolinyl, pyrimidyl or pyridyl with up to four identical or different substituents in the form of halogen, trifluoromethyl, nitro, cyano, trifluoromethoxy, -SO2-CH3 or NRxvIII-gRxvIIRo10<br>
Rxvm-9and Rxvm-10 are identical or different and denote hydrogen or a straight-' chained or branched alkyl of up to three carbon atoms;<br>
ExvII denotes  cycloalkyl of from  three to six carbon atoms or a straight-chained or branched alkyl of up to eight carbon atoms; RXVIII-I denotes hydroxy; Rxvw-2 denotes hydrogen or methyl;<br>
Rxvm-3and Rxvii are identical or different and denote straight-chained or branched alkyl of up to three carbon atoms; or<br>
Rxvm-3and Rxvw-4 taken together form an alkenylene made up of between two and four carbon atoms.<br>
Compounds of Formula XVIII and their methods of manufacture are disclosed in PCT Publication No. WO 99/15504 and United States Patent No. 6,291,477, both of which are incorporated herein by reference in their entireties for all purposes.<br>
The following paragraphs describe exemplary anti-hypertensive agents. Amlodipine and related dihydropyridine compounds are disclosed in U.S. Patent No. 4,572,909, which is incorporated herein by reference, as potent anti-ischemic and antihypertensive agents. U.S. Patent No.4,879,303, which is incorporated herein by reference, discloses amlodipine benzenesulfonate salt (also termed amlodipine besylate). Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers. As such, amlodipine, amlodipine besylate, amlodipine maleate and other pharmaceutically acceptable acid addition salts of<br>
amlodipine have utility as antihypertensive agents and as antiischemic agents. Amlodipine and its pharmaceutically acceptable acid addition salts are also disclosed in U.S. Patent No. 5,155,120 as having utility in the treatment of congestive heart failure.   Amlodipine besylate is currently sold as NorvascÂ®. Amlodipine has the formula    <br>
(Formula Removed)<br>
Calcium channel blockers which are with the scope of this invention- -include, but are not limited to: bepridil, which may be prepared as disclosed in U.S. Patent No. 3,962, 238 or U.S. Reissue No. 30,577; clentiazem, which may be prepared as disclosed in U.S. Patent No. 4,567,175; diltiazem, which may be prepared as disclosed in U.S. Patent No. 3,562, fendiline, which may be prepared as disclosed in U.S. Patent No. 3,262,977; gallopamil, which may be prepared as disclosed in U.S. Patent No. 3,261,859; mibefradil, which may be prepared as disclosed in U.S. Patent No. 4,808,605; prenylamine, which may be prepared as disclosed in U.S. Patent No. 3,152,173; semotiadil, which may be prepared as disclosed in U.S. Patent No. 4,786,635; terodiline, which may be prepared as disclosed in U.S. Patent No. 3,371,014; verapamil, which may be prepared as disclosed in U.S. Patent No. 3,261,859; aranipine, which may be prepared as disclosed in U.S. Patent No. 4,572,909; barnidipine, which may be prepared as disclosed in U.S. Patent No. 4,220,649; benidipine, which may be prepared as disclosed in European Patent Application Publication No. 106,275; cilnidipine, which may be prepared as disclosed in U.S. Patent No. 4,672,068; efonidipine, which may be prepared as disclosed in U.S. Patent No.4,885,284; elgodipine, which may be prepared as disclosed in U.S. Patent No. 4,952,592; felodipine, which may be prepared as disclosed in U.S. Patent No. 4,264,611; isradipine, which may be prepared as disclosed in U.S. Patent No. 4,466,972; lacidipine, which may be prepared as disclosed in U.S. Patent No. 4,801,599; lercanidipine, which<br>
may be prepared as disclosed in U.S. Patent No. 4,705,797; manidipine, which may be prepared as disclosed in U.S. Patent No. 4,892,875; nicardipine, which may be prepared as disclosed in U.S. Patent No. 3,985,758; nifedipine, which may be prepared as disclosed in U.S. Patent No. 3,485,847; nilvadipine, which maybe prepared as disclosed in U.S. Patent No. 4,338,322; nimodipine, which may be prepared as disclosed in U.S. Patent No. 3,799,934; nisoldipine, which may be prepared as disclosed in U.S. Patent No. 4,154,839; nitrendipine, which may be prepared as disclosed in U.S. Patent No. 3,799,934; cinnarizine, which may be prepared as disclosed in U.S. Patent No. 2,882,271; flunarizine, which may be prepared as disclosed in U.S. Patent No. 3,773,939; lidoflazine, which may be prepared as disclosed in U.S. Patent No. 3,267,104; lomerizine, which may be prepared as disclosed in U.S. Patent No. 4,663,325; bencyclane, which may be prepared as disclosed in Hungarian Patent No. 151,865; etafenone, which may be prepared as disclosed in German Patent No. 1,265,758; and perhexiline, which may be prepared as disclosed in British Patent No. 1,025,578. The disclosures of all such U.S. Patents are incorporated herein by reference.<br>
Angiotensin Converting Enzyme Inhibitors (ACE-lnhibitors) which are within the scope of this invention include, ,but are not limited to: alacepril, which may be prepared as disclosed in U.S. Patent No. 4,248,883; benazepril, which may be prepared as disclosed in U.S. Patent No. 4,410,520; captopril, which may be prepared as disclosed in U.S. Patent Nos. 4,046,889 and 4,105,776; ceronapril, which may be prepared as disclosed in U.S. Patent No. 4,452,790; delapril, which may be prepared as disclosed in U.S. Patent No. 4,385,051; enalapril, which may be prepared as disclosed in U.S. Patent No. 4,374,829; fosinopril, which may be prepared as disclosed in U.S. Patent No. 4,337,201; imadapril, which may be prepared as disclosed in U.S. Patent No. 4,508,727; lisinopril, which may be prepared as disclosed in U.S. Patent No. 4,555,502; moveltopril, which may be prepared as disclosed in Belgian Patent No. 893,553; perindopril, which may be prepared as disclosed in U.S. Patent No. 4,508,729; quinapril, which may be prepared as disclosed in U.S. Patent No. 4,344,949; ramipril, which may be prepared as disclosed in U.S. Patent No. 4,587,258; spirapril, which may be prepared as disclosed in U.S. Patent No. 4,470,972; temocapril, which may be prepared as disclosed in U.S. Patent No. 4,699,905; and trandolapril, which may be prepared as<br>
disclosed in U.S. Patent No. 4,933,361. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Angiotensin-ll receptor antagonists (A-II antagonists) which are within the scope of this invention include, but are not limited to: candesartan, which may be prepared as disclosed in U.S. Patent No. 5,196,444; eprosartan, which may be prepared as disclosed in U.S. Patent No. 5,185,351; irbesartan, which may be prepared as disclosed in U.S. Patent No. 5,270,317; Iosartan, which may be prepared as disclosed in U.S. Patent No. 5,138,069; and valsartan, which may be prepared as disclosed in U.S. Patent No. 5,399,578. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Beta-adrenergic receptor blockers (beta- or p-blockers) which are within the<br>
scope of this invention include, but are not limited to: acebutolol, which may be<br>
prepared as disclosed in U.S. Patent No. 3,857,952; alprenolol, which may be<br>
-prepared, as disclosed in Netherlands Patent Application No .6,605,692: 	amosulalol,<br>
which may be prepared as disclosed in U.S. Patent No. 4,217,305; arotinolol, which may be prepared as disclosed in U.S. Patent No. 3,932,400; atenolol, which may be prepared as disclosed in U.S. Patent No. 3,663,607 or 3,836,671; befunolol, which may be prepared as disclosed in U.S. Patent No. 3,853,923; betaxolol, which may be prepared as disclosed in U.S. Patent No. 4,252,984; bevantolol, which may be prepared as disclosed in U.S. Patent No. 3,857,981; bisoprolol, which maybe prepared as disclosed in U.S. Patent No. 4,171,370; bopindolol, which maybe prepared as disclosed in U.S. Patent No. 4,340,541; bucumolol, which maybe prepared as disclosed in U.S. Patent No. 3,663,570; bufetolol, which may be prepared as disclosed in U.S. Patent No. 3,723,476; bufuralol, which may be prepared as disclosed in U.S. Patent No. 3,929,836; bunitrolol, which may be prepared as disclosed in U.S. Patent Nos. 3,940,489 and 3,961,071; buprandolol, which may be prepared as disclosed in U.S. Patent No. 3,309,406; butiridine hydrochloride, which may be prepared as disclosed in French Patent No. 1,390,056; butofilolol, which may be prepared as disclosed in U.S. Patent No. 4,252,825; carazolol, which may be prepared as disclosed in German Patent No. 2,240,599; carteolol, which may be prepared as disclosed in U.S. Patent No. 3,910,924; carvedilol, which may be prepared as disclosed in U.S. Patent No. 4,503,067; celiprolol, which may be prepared as disclosed in U.S. Patent No. 4,034,009; cetamolol, which may be prepared as disclosed in U.S. Patent No. 4,059,622;<br>
cloranolol, which may be prepared as disclosed in German Patent No. 2,213,044; dilevalol, which may be prepared as disclosed in Clifton et al., Journal of Medicinal Chemistry, 1982, 25, 670; epanolol, which may be prepared as disclosed in European Patent Publication Application No. 41,491; indenolol, which may beâ€ž prepared as disclosed in U.S. Patent No. 4,045,482; labetalol, which may be' prepared as disclosed in U.S. Patent No. 4,012,444; levobunolol, which may be prepared as disclosed in U.S. Patent No. 4,463,176; mepindolol, which may be prepared as disclosed in Seeman et al., Helv. Chim. Acta, 1971, 54, 241; metipranolol, which may be prepared as disclosed in Czechoslovakian Patent Application No. 128,471; metoprolol, which may be prepared as disclosed in U.S. Patent No. 3,873,600; moprolol, which may be prepared as disclosed in U.S. Patent No. 3,501,7691; nadolol, which may be prepared ras disclosed in U.S. Patent No. 3,935, 267; nadoxolol, which may be prepared as disclosed in U.S. Patent No. 3,819,702; nebivalol, which may be prepared as disclosed in U.S. Patent No. 4,654,362; nipradilo!, which may be prepared as disclosed in U.S. Patent No. 4,394,382; oxprenolol, which may be prepared as disclosed in British Patent No. 1,077,603; perbutolol, which may be prepared as disclosed in U.S. Patent No. 3,551,493; pindolol, which may be prepared as disclosed in Swiss Patent Nos. 469,002 and 472,404; practolol, which may be prepared as disclosed in U.S. Patent No. 3,408,387; pronethalol, which may be prepared as disclosed in British Patent No. 909,357; propranolol, which may be prepared as disclosed in U.S. Patent Nos. 3,337,628 and 3,520,919; sotalol, which may be prepared as disclosed in Uloth et al., Journal of Medicinal Chemistry, 1966, 9, 88; sufinalol, which may be prepared as disclosed in German Patent No. 2,728,641; talindol, which may be prepared as disclosed in U.S. Patent Nos. 3,935,259 and 4,038,313; tertatolol, which may be prepared as disclosed in U.S. Patent No. 3,960,891; tiiisolol, which may be prepared as disclosed in U.S. Patent No. 4,129,565; timolol, which may be prepared as disclosed in U.S. Patent No. 3,655,663; toliprolol, which may be prepared as disclosed in U.S. Patent No. 3,432,545; and xibenolol, which may be prepared as disclosed in U.S. Patent No. 4,018,824. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Alpha-adrenergic receptor blockers (alpha- or oc-blockers) which are within the scope of this invention include, but are not limited to: amosulalol, which may be<br>
prepared as disclosed in U.S. Patent No. 4,217,307; arotinolol, which may be prepared as disclosed in U.S. Patent No. 3,932,400; dapiprazole, which may be prepared as disclosed in U.S. Patent No. 4,252,721; doxazosin, which may be prepared as disclosed in U.S. Patent No. 4,188,390; fenspiride, which may be prepared as disclosed in U.S. Patent No. 3,399,192; indoramin, which may be prepared as disclosed in U.S. Patent No. 3,527,761; labetolol, which may be prepared as disclosed above; naftopidil, which may be prepared as disclosed in U.S. Patent No. 3,997,666; nicergoline, which may be prepared as disclosed in U.S. Patent No. 3,228,943; prazosin, which may be prepared as disclosed in U.S. Patent No. 3,511,836; tamsulosin, which may be prepared as disclosed in U.S. Patent No. 4,703,063; toiazoline, which may be prepared as disclosed in U.S. Patent No. 2,161,938; trimazosin, which may be prepared as disclosed in U.S. Patent No. 3,669,968; and yohimbine, which may be isolated from natural sources according to         methods well known to those skilled in the art disclosures of all such U.S. patents are incorporated herein by reference.<br>
The term "vasodilator," where used herein, is meant to include cerebral vasodilators, coronary vasodilators and peripheral vasodilators. Cerebral vasodilators within the scope of this invention include, but are not limited to: bencyclane, which may be prepared as disclosed above; cinnarizine, which may be prepared as disclosed above; citicoline, which may be isolated from natural sources as disclosed in Kennedy et a!., Journal of the American Chemical Society, 1955, 77, 250 or synthesized as disclosed in Kennedy, Journal of Biological Chemistry, 1956. 222, 185; cyclandelate, which may be prepared as disclosed in U.S. Patent No. 3,663,597; ciclonicate, which may be prepared as disclosed in German Patent No. 1,910,481; diisopropylamine dichloroacetate, which may be prepared as disclosed in British Patent No. 862,248; eburnamonine, which may be prepared as disclosed in Hermann et al., Journal of the American Chemical Society, 1979, 101, 1540; fasudil, which may be prepared as disclosed in U.S. Patent No. 4,678,783; fenoxedil, which may be prepared as disclosed in U.S. Patent No. 3,818,021; flunarizine, which may be prepared as disclosed in U.S. Patent No. 3,773,939; ibudilast, which may be prepared as disclosed in U.S. Patent No. 3,850,941; ifenprodil, which may be prepared as disclosed in U.S. Patent No. 3,509,164; lomerizine, which may be prepared as disclosed in U.S. Patent No. 4,663,325; nafronyl, which may be prepared as disclosed in U.S. Patent No. 3,334,096; nicametate, which may be prepared as<br>
disclosed in Blicke et al., Journal of the American Chemical Society, 1942, 64,1722; nicergoline, which may be prepared as disclosed above; nimodipine, which may be prepared as disclosed in U.S. Patent No. 3,799,934; papaverine, which may be prepared as reviewed in Goldberg, Chem. Prod. Chem. News, 1954, 17, 371;,, pentifyiline, which may be prepared as disclosed in German Patent No. 860,217; tinofedrine, which may be prepared as disclosed in U.S. Patent No. 3,563,997; vincamine, which may be prepared as disclosed in U.S. Patent No. 3,770,724; vinpocetine, which may be prepared as disclosed in U.S. Patent No. 4,035,750; and viquidil, which may be prepared as disclosed in U.S. Patent No. 2,500,444. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Coronary vasodilators within the scope of this invention include, but are not limited to: amotriphene, which may be prepared as disclosed in U.S. Patent No. 3,010,965; bendazol, which may be prepared as disclosed in J. Chem. Soc. 1958, 2426; benfurodil hemisuccinate, which may be prepared as disclosed in U.S. Patent No. 3,355,463; benziodarone, which may be prepared as disclosed in U.S. Patent No. 3,012,042; chloracizine, which may be prepared as disclosed in British Patent No. 740,932; chromonar, which may be prepared as disclosed in U.S. Patent Nd. 3,282,938; clobenfural, which may be prepared as disclosed in British Patent No. 1,160,925; clonitrate, which may be prepared from propanediol according to methods well known to those skilled in the art, e.g., see Annalen, 1870,155, 165; cloricromen, which may be prepared as disclosed in U.S. Patent No. 4,452,811; dilazep, which may be prepared as disclosed in U.S. Patent No. 3,532,685; dipyridamole, which may be prepared as disclosed in British Patent No. 807,826; droprenilamine, which may be prepared as disclosed in German Patent No. 2,521,113; efloxate, which may be prepared as disclosed in British Patent Nos. 803,372 and 824,547; erythrityl tetranitrate, which may be prepared by nitration of erythritol according to methods well-known to those skilled in the art; etafenone, which may be prepared as disclosed in German Patent No. 1,265,758; fendiline, which may be prepared as disclosed in U.S. Patent No. 3,262,977; floredil, which may be prepared as disclosed in German Patent No. 2,020,464; ganglefene, which may be prepared as disclosed in U.S.S.R. Patent No. 115,905; hexestrol, which may be prepared as disclosed in U.S. Patent No. 2,357,985; hexobendine, which may be prepared as disclosed in U.S. Patent No. 3,267,103; itramin tosylate, which may be prepared as disclosed rn Swedish Patent No. 168,308; khellin, which may be prepared as disclosed in Baxter et al., Journal of<br>
the Chemical Society, 1949, S 30; Iidoflazine, which may be prepared as disclosed in U.S. Patent No. 3,267,104; mannitol hexanitrate, which may be prepared by the nitration of mannitol according to methods well-known to those skilled in the art; medibazine, which may be prepared as disclosed in U.S. Patent No. 3,119,826; nitroglycerin; pentaerythritol tetranitrate, which may be prepared by the nitration of<br>
pentaerythritol according to methods well-known to those skilled in the art; pentrinitrol, which may be prepared as disclosed in German Patent No. 638,422-3; perlnexilline, which may be prepared as disclosed above; pimefylline, which may be prepared as disclosed in U.S. Patent No. 3,350,400; prenylamine, which may be prepared as disclosed in U.S. Patent No. 3,152,173; propatyl nitrate, which may be prepared as disclosed in French Patent No. 1,103,113; trapidil, which may be prepared as disclosed in East German Patent No. 55,956; tricromyl, which may be prepared as disclosed in U.S. Patent No. 2,769,015; trimetazidine, which may be prepared,as   disclosed in U. S. Patent No. 3,262,852; trolnitrate phosphate,which may be prepared by nitration of triethanolamine followed by precipitation with phosphoric acid according to methods well-known to those skilled in the art; visnadine, which may be prepared as disclosed in U.S. Patent Nos. 2,816,118 and 2,980,699. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Peripheral vasodilators within the scope of this invention include, but are not limited to: aluminum nicotinate, which may be prepared as disclosed in U.S. Patent No. 2,970,082; bamethan, which may be prepared as disclosed in Corrigan et al., Journal of the American Chemical Society, 1945, 67, 1894; bencyclane, which may be prepared as disclosed above; betahistine, which may be prepared as disclosed in Walter et al.; Journal of the American Chemical Society, 1941, 63, 2771; bradykinin, which may be prepared as disclosed in Hamburg et al., Arch. Biochem. Biophys., 1958, 76, 252; brovincamine, which may be prepared as disclosed in U.S. Patent No. 4,146,643; bufeniode, which may be prepared as disclosed in U.S. Patent No. 3,542,870; buflomedil, which may be prepared as disclosed in U.S. Patent No. 3,895,030; butalamine, which may be prepared as disclosed in U.S. Patent No. 3,338,899; cetiedil, which may be prepared as disclosed in French Patent Nos. 1,460,571; ciclonicate, which may be prepared as disclosed in German Patent No. 1,910,481; cinepazide, which may be prepared as disclosed in Belgian Patent No. 730,345; cinnarizine, which may be prepared as disclosed above; cyclandelate, which may be prepared as disclosed above; diisopropylamine dichioroacetate, which<br>
may be prepared as disclosed above; eledoisin, which may be prepared as disclosed in British Patent No. 984,810; fenoxedil, which may be prepared as disclosed above; flunarizine, which may be prepared as disclosed above; hepronicate, which may be prepared as disclosed in U.S. Patent No. 3,384,642; ifenprodil, which may be,, prepared as disclosed above; iloprost, which may be prepared as disclosed in U.S. Patent No. 4,692,464; inositol niacinate, which may be prepared as disclosed in Badgett et al., Journal of the American Chemical Society, 1947, 69, 2907; isoxsuprine, which may be prepared as disclosed in U.S. Patent No. 3,056,836; kallidin, which may be prepared as disclosed in Biochem. Biophys. Res. Commun., 1961, 6, 210; kallikrein, which may be prepared as disclosed in German Patent No. 1,102,973; moxisylyte, which may be prepared as disclosed in German Patent No. 905,738; nafronyl, which may be prepared as disclosed above; nicametate, which may be prepared as disclosed above; nicergoline, which may be prepared as disclosed above; nicofuranose, which may be prepared as disclosed in Swiss Patent No. 366,523; nylidrin, which may be prepared as disclosed in U.S. Patent Nos. 2,661,372 and 2,661,373; pentifylline, which may be prepared as disclosed above; pentoxifylline, which may be prepared as disclosed in U.S. Patent No. 3,422,107; piribedil, which may be prepared as disclosed in U.S. Patent No. 3,299,067; prostaglandin Ei, which may be prepared by any of the methods referenced in the Merck Index, Twelfth Edition, Budaveri, Ed., New Jersey, 1996, p. 1353; suloctidil, which may be prepared as disclosed in German Patent No. 2,334,404; tolazoline, which may be prepared as disclosed in U.S. Patent No. 2,161,938; and xanthinol niacinate, which may be prepared as disclosed in German Patent No. 1,102,750 or Korbonits et al., Acta. Pharm. Hung., 1968, 38, 98. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
The term "diuretic," within the scope of this invention, is meant to include diuretic benzothiadiazine derivatives, diuretic organomercurials, diuretic purines, diuretic steroids, diuretic sulfonamide derivatives, diuretic uracils and other diuretics such as amanozine, which may be prepared as disclosed in Austrian Patent No. 168,063; amiloride, which may be prepared as disclosed in Belgian Patent No. 639,386; arbutin, which may be prepared as disclosed in Tschitschibabin, Annalen, 1930, 479, 303; chlorazanil, which may be prepared as disclosed in Austrian Patent No. 168,063; ethacrynic acid, which may be prepared as disclosed in U.S. Patent No. 3,255,241; etozolin, which may be prepared as disclosed in U.S. Patent No.<br>
3,072,653; hydracarbazine, which may be prepared as disclosed in British Patent No. 856,409; isosorbide, which may be prepared as disclosed in U.S. Patent No. 3,160,641; mannitol; metochalcone, which may be prepared as disclosed in Freudenberg et a!., Ber., .1957, 90, 957; muzolimine, which may be prepared as disclosed in U.S. Patent No. 4,018,890; perhexiline, which may be prepared as-disclosed above; ticrynafen, which may be prepared as disclosed in U.S. Patent No. 3,758,506; triamterene which may be prepared as disclosed in U.S. Patent No. 3,081,230; and urea. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Diuretic benzothiadiazine derivatives within the scope of this invention include, but are not limited to: althiazide, which may be prepared as disclosed in British Patent No. 902,658; bendroflumethiazide, which may be prepared as disclosed in U.S. Patent No. 3,265,573; benzthiazide, McManus et al., 136th Am.    Soc  Meeting (Atlantic City.  September 1959), Abstract of papers  pp 13-0; benzylhydrochlorothiazide, which may be prepared as disclosed in U.S. Patent No. 3,108,097; buthiazide, which may be prepared as disclosed in British Patent Nos. 861,367 and 885,078; chlorothiazide, which may be prepared as disclosed in U.S. Patent Nos. 2,809,194 and 2,937,169; chlorthalidone, which may be prepared as disclosed in U.S. Patent No. 3,055,904; cyciopenthiazide, which may be prepared as disclosed in Belgian Patent No. 587,225; cyclothiazide, which may be prepared as disclosed in Whitehead et a!., Journal of Organic Chemistry, 1961, 26, 2814; epithiazide, which may be prepared as disclosed in U.S. Patent No. 3,009,911; ethiazide, which may be prepared as disclosed in British Patent No. 861,367; fenquizone, which may be prepared as disclosed in U.S. Patent No. 3,870,720; indapamide, which may be prepared as disclosed in U.S. Patent No. 3,565,911; hydrochlorothiazide, which may be prepared as disclosed in U.S. Patent No. 3,164,588; hydroflumethiazide, which may be prepared as disclosed in U.S. Patent No. 3,254,076; methyclothiazide, which may be prepared as disclosed in Close et al., Journal of the American Chemical Society, 1960, 82,1132; meticrane, which may be prepared as disclosed in French Patent Nos. M2790 and 1,365,504; metolazone, which may be prepared as disclosed in U.S. Patent No. 3,360,518; paraflutizide, which may be prepared as disclosed in Belgian Patent No. 620,829; polythiazide, which may be prepared as disclosed in U.S. Patent No. 3,009,911; quinethazone, which may be prepared as disclosed in U.S. Patent No. 2,976,289; teclothiazide,<br>
which may be prepared as disclosed in Close et a!., Journal of the American Chemical Society, 1960, 82, 1132; and trichlormethiazide, which may be prepared as dislcosed in deStevens et al., Experientia, 1960, 16, 113. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
Diuretic sulfonamide derivatives within the scope of this invention include, but are not limited to: acetazolamide, which may be prepared as disclosed in U.S. Patent No. 2,980,679; ambuside, which may be prepared as disclosed in U.S. Patent No. 3,188,329; azosemide, which may be prepared as disclosed in U.S. Patent No. 3,665,002; bumetanide, which may be prepared as disclosed in U.S. Patent No. 3,634,583; butazolamide, which may be prepared as disclosed in British Patent No. 769,757; chloraminophenamide, which may be prepared as disclosed in U.S. Patent Nos. 2,809,194, 2,965,655 and 2,965,656; clofenamide, which may be prepared as disclosed in Olivier, Rec. Trav. Chim., 1918, 37, 307; clopamide, which may be prepared as disclosed in U.S. Patent No. 3,459,756; clorexolone, which may be prepared as disclosed in U.S Patent No . 3,183,243; disulfamide, which may be prepared as disclosed in British Patent No. 851,287; ethoxolamide, which may be prepared as disclosed in British Patent No. 795,174; furosemide, which may be ' prepared as disclosed in U.S. Patent No. 3,058,882; mefruside, which may be prepared as disclosed in U.S. Patent No. 3,356,692; methazolamide, which may be prepared as disclosed in U.S. Patent No. 2,783,241; piretanide, which may be prepared as disclosed in U.S. Patent No. 4,010,273; torasemide, which may be prepared as disclosed in U.S. Patent No. 4,018,929; tripamide, which may be prepared as disclosed in Japanese Patent No. 73 05,585; and xipamide, which may be prepared as disclosed in U.S. Patent No. 3,567,777. The disclosures of all such U.S. patents are incorporated herein by reference.<br>
The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by the enzyme HMG-CoA reductase. Statins inhibit HMG-CoA reductase from catalyzing this conversion.   The following paragraphs describe exemplary statins.<br>
Atorvastatin calcium (i.e., atorvastatin hemicalcium), disclosed in U.S. Patent No. 5,273,995, which is incorporated herein by reference, is currently sold as LipitorÂ® and has the formula<br>
(Formula Removed)<br>
Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA. As such, atorvastatin calcium is a potent lipid lowering compound. The free carboxylic acid form of atorvastatin exists predominantly as the lactone of the formula<br>
(Formula Removed)<br>
and is disclosed in U.S. Patent No. 4,681,893, which is incorporated herein by reference.<br>
Statins include such compounds as rosuvastatin disclosed in U.S. RE37.314 E, pitivastatin disclosed in EP 304063 B1 and~US 5,011,930, simvastatin, disclosed in U.S. 4,444,784, which is incorporated herein by reference; pravastatin, disclosed in U.S. 4,346,227 which is incorporated herein by reference; cerivastatin, disclosed in U.S. 5,502,199, which is incorporated herein by reference; mevastatin, disclosed in U.S. 3,983,140, which is incorporated herein by reference; velostatin, disclosed in U.S. 4,448,784 and U.S. 4,450,171, both of which are incorporated herein by reference; fluvastatin, disclosed in U.S. 4,739,073, which is incorporated herein by reference; compactin, disclosed in U.S. 4,804,770, which is incorporated herein by reference; lovastatin, disclosed in U.S. 4,231,938, which is incorporated herein by reference; dalvastatin, disclosed in European Patent Application Publication No.<br>
738510 A2; f luindostatin, disclosed in European Patent Application Publication No. 363934 A1; atorvastatin, disclosed in U.S. Patent No. 4,681,893, which is incorporated herein by reference; atorvastatin calcium (which is the hemicalcium salt of atorvastatin), disclosed in U.S. Patent No. 5,273,995, which is incorporated.herein by reference; and dihydrocompactin, disclosed in U.S. 4,450,171, which is    ' incorporated herein by reference.<br>
Given the positive correlation between lipid modulation and lipid fraction modulation in blood with the development of various disease/conditions such as cardiovascular, cerebral vascular and peripheral vascular diseases, the compounds/combinations of this invention and the salts of such compounds, by virtue of their pharmacologic action, are useful for the prevention, arrestment and/or treatment of disease states/conditions as described above. These include cardiovascular disorders (e.g., angina, cardiac ischemia and myocardial infarction) and complications due to cardiovascular disease.   In particular, given the correlation   between HDL modulation and the disease/conditions described above the CETP compounds described herein and combinations thereof by virtue of their HDL modulating pharmacologic action (e.g., HDL elevation) are useful for the prevention, arrestment and/or treatment of the disease states/conditions as described above. The utility of the compounds/combinations of the invention and the salts of such compounds as medical agents in the treatment of the above described disease/conditions in mammals (e.g. humans, male or female) is demonstrated by the activity of the compounds of this invention in conventional assays (e.g., in vivo assays, in vitro assays) known to those skilled in the art including those described herein. In particular, the PLASMA LIPIDS ASSAY described below may be used to determine the level.of HDL modulation for a given compound/combination and thus its therapeutic impact for the disease/conditions described above. Such assays also provide a means whereby the activities of the compounds/combinations of this invenlion and the salts of such compounds (or the other agents described herein) can be compared to each other and with the activities of other known compounds. The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases.   For example, the characterization of the impact of of the compounds/combinations of this invention and the salts of such compounds {or the other agents described herein) on various lipid fractions can be determined by methods known in the art as are described in<br>
Methods in Enzymology, Vol. 129: Plasma Lipoproteins, Pt. B: Characterization, Cell Biology, and Metabolism.    Albers, John J.; Segrest, Jere P.; Editors.    USA. (1986),    (Academic Press, Orlando, Fla.) and Methods in Enzymology, Vol. 128: Plasma Lipoproteins, Pt. A: Preparation, Structure, and Molecular Biology. Segrest, Jere P.; Albers, John J.; Editors.    USA.    (1986),     992 pp. (Academic Press, Orlando, Fla.). In particular, the PLASMA LIPIDS ASSAY described below may be used to determine the level of HDL modulation for a given compound/combination and thus its therapeutic impact for the disease/conditions described above.<br>
The following are exemplary assays.<br>
CETP IN VITRO ASSSAY The following is a brief description of the assay of cholesteryl ester transfer in human plasma (in vitro) and animal plasma (ex vivo): CETP activity in the presence or absence of drug is assayed by determining the transfer of 3H-labeled cholesteryl oleate (CO) from exogenous tracer HDL to the nonHDL lipoprotein fraction in human plasma, or from 3H-labeled LDL to the HDL fraction in transgenic mouse plasma. Labeled human lipoprotein substrates are prepared similarly to the method described by Morton in which the endogenous CETP activity in plasma is employed to transfer 3H-CO from phospholipid liposomes to all the lipoprotein fractions in plasma. 3H-labeled LDL and HDL are subsequently isolated by sequential ultracentrifugation at the density cuts of 1.019-1.063 and 1.10-1.21 g/ml, respectively. For the activity assay, 3H-labeled lipoprotein is added to plasma at 10-25 nmoles CO/ml and the samples incubated at 37Â° C for 2.5-3 hrs. Non-HDL lipoproteins are then precipitated by the addition of an equal volume of 20% (wt/vol) polyethylene glycol 8000 (Dias). The samples are centrifuged 750 g x 20 minutes and the radioactivity contained in<br>
i<br>
the HDL containing supernatant determined by liquid scintillation. Introducing varying quantities of the compounds of this invention as a solution in dimethylsulfoxide to human plasma, before addition of the radiolabeled cholesteryl oleate, and comparing the relative amounts of radiolabel transferred allows relative cholesteryl ester transfer inhibitory activities to be determined.<br>
CETP IN VIVO ASSSAY Activity of these compounds in vivo can be determined by the amount of agent required to be administered, relative to control, to inhibit cholesteryl ester transfer activity by 50% at various time points ex vivo or to elevate HDL cholesterol<br>
by a given percentage in a CETP-containing animal species. Transgenic mice expressing both human CETP and human apolipoprotein Al (Charles River, Boston, MA) may be used to assess compounds in vivo. The compounds to be examined are administered by oral gavage in an emulsion vehicle containing olive oil and sodium taurocholate. Blood is taken from mice retroorbitally before dosing. At various times after dosing, ranging from 4h to 24h, the animals are sacrificed, blood obtained by heart puncture, and lipid parameters measured, including total cholesterol, HDL and LDL cholesterol, and triglycerides. CETP activity is determined by a method similar to that described above except that 3H-cholesteryI oleate containing LDL is used as the donor source as opposed to HDL. The values obtained for lipids and transfer activity are compared to those obtained prior to dosing and/or to those from mice receiving vehicle alone.<br>
PLASMA LIPIDS ASSAY The activity of these compounds may also be demonstrated by determining the amount of agent required to alter plasma lipid leVels for example HDL cholesterol levels, LDL cholesterol levels, VLDL cholesterol levels or triglycerides, in the plasma of certain mammals, for example marmosets that possess CETP activity and a '<br>
r<br>
plasma lipoprotein profile similar to.that of humans (Crook et al. Arteriosclerosis 10, 625, 1990). Adult marmosets are assigned to treatment groups so that each group has a similar mean Â±SD for total, HDL, and/or LDL plasma cholesterol concentrations. After group assignment, marmosets are dosed daily with compound as a dietary admix or by intragastric intubation for from one to eight days. Control marmosets receive only the dosing vehicle. Plasma total, LDL, VLDL and HDL cholesterol values can be determined at any point during the study by obtaining blood from an antecubital vein and separating plasma lipoproteins into their individual subclasses by density gradient centrifugation, and by measuring cholesterol concentration as previously described (Crook et al. Arteriosclerosis 10, 625, 1990).<br>
Conventional clinical designs and methods of modifying those clinical protocols to facilitate the testing of the compounds/combinations of this invention and the salts of such compounds (or the other agents described herein) for the various disease/conditions described above are known to those skilled in the art.<br>
For example, in such clinical studies levels of atherosclerotic plaque can be measured by various imaging techniques e.g., Intracardiac ultrasound (ICE),<br>
quantitative coronary angiography, intravascular ultrasound (IVUS) including coronary intravascular ultrasound, corotid intimal medial thickness (CIMT) measurement, magnetic resonance imaging (MR!)', magnetic resonance coronary angiography, flow-mediated dilatation, positron emission tomography, multislice computed tomography,, electron beam computed tomography (EBT), mechanical multi-slice spiral CT (MSCT), echo cardiography, coronary angiography, radiography and radionucleotide imaging.<br>
These imaging techniques and the interpretation of them are known and are further described in for example, "Measurement of Subclinical Atherosclerosis:beyond risk factor assessment", Current Opinion in Lipidology 13, 595-603 (2002); "A Comparison of Intravascular, Ultrasound With Coronary Angiography for Evaluation of Transplant Coronary Disease in Pediatric Heart Transplant Recipients", Journal of Heart &amp; Lung Transplantation 22, 44-49 (2003); and "Assessment of Calcium Scoring Performance in Cardiac Computed Tomography", European Radiology 13, 484-97 (2003).<br>
The compounds of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable vehicle, carrier or diluent. Thus, the compounds of this invention can be administered either individually or together in any conventional oral, parenteral or transdermal dosage form.<br>
For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents<br>
and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.<br>
The combinations of this invention may also be adminstered in a controlled<br>
release formulation such as a slow release or a fast release formulation. Such	<br>
controlled release formulations of the combination of this invention may be prepared using methods well known to those skilled in the art. The method of adminstration will be determined by the attendant physician or other person skilled in the art after an evaluation of the subject's condition and requirements. The generally preferred formulation of amlodipine is NorvascÂ®.<br>
Many of the CETP inhibitors of this invention are poorly soluble and a dosage form that increases solubility facilitates the administration of such compounds. One such dosage form is a dosage form comprising (1) a solid amorphous dispersion comprising a cholesteryl ester transfer protein (CETP) inhibitor and an acidic concentration-enhancing polymen and (2) an acid-sensitive HMG-CoA reductase inhibitor. This dosage form is more fully described in U.S. provisional application serial no. 60/435345 filed on December 20, 2002 and entitled "Dosage Forms Comprising a CETP Inhibitor and an HMG-CoA Reductase Inhibitor" the specification of which is hereby incorporated by reference.<br>
The compounds of this invention either alone or in combination with each other or other compounds generally will be administered in a convenient formulation. The following formulation examples only are illustrative and are not intended to limit the scope of the present invention.<br>
Combination tablets of amlodipine besylate, torcetrapib, and atorvastatin hemicalcium were prepared at a scale of ~1kg according to the procedure immediately following the Table. The doses prepared and the composition of the tablets are detailed in the following Table.<br>
(Table Removed)<br>
A separate granulation or blend of each active component was prepared<br>
initially and these three powder mixtures were combined in different proportions to<br>
provide the desired dose combinations.<br>
The atorvastatin hemicalcium granulation was prepared by making a,solution<br>
of the hydroxypropyl cellulose and polysorbate 80 in water. The remaining<br>
components (except magnesium stearate) were then charged to a fluid bed<br>
â€”granulator and wet-granulated with the binder solution by fluidizing them in a warm air stream (30-60C) while spraying the binder solution onto the powders in the granulator. After all the binder solution had been sprayed the granules were dried in the fluidized bed, and milled to remove any large (&gt;1mm) agglomerates. The granules were lubricated by blending them with magnesium stearate.<br>
A dispersion of torcetrapib in the polymer hypromellose (hydroxypropyl methylcellulose) acetate succinate was made by dissolving both components in<br>
acetone and spray drying (see U.S. provisional application serial-no. 60/435,345)  the resulting solution in conventional spray drying equipment. The torcetrapib granulation was made by blending the resulting spray dried dispersion, microcrystalline cellulose, crospovidone, and magnesium stearate together and dry<br>
i<br>
granulating the powder blend by roller compaction. Standard pharmaceutical roller compaction equipment and operating conditions were used. The resulting compacted ribbons were milled to produce granules suitable for further processing. The calcium phosphate and magnesium stearate were added and blended with the granules to create the final lubricated torcetrapib blend.<br>
The amlodipine besylate was simply blended with its excipients to produce a lubricated amlodipine powder blend.<br>
The three active granulations/blends were blended together in the desired proportions using a low-shear twin-shell blender and tableted using a single punch eccentric tablet press.<br>
Administration of the compounds of this invention can be via any method which delivers a compound of this invention systemically and/or locally. These methods include oral routes, parenteral, intraduodenal routes, etc. Generally, the compounds of this invention are administered orally, but parenteral administration (e.g., intraveneous, intramuscular, subcutaneous or intramedullary) may be utilized,<br>
for example, where oral administration is inappropriate for the target or where the patient is unable to ingest the drug.<br>
These methods and combinations are useful depending on the indication/condition to treat mammals including humans.   In addition, they are useful to advantageously and/or selectively treat a variety of patient subgroups including males, females, the elderly (&gt;60), infants (
In general an amount of a compound(s)/combination(s) of this invention is used that is sufficient to achieve the therapeutic effect desired (e.g., HDL elevation). The amount will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgement of the prescribing physician.<br>
In general an effective dosage for the CETP inhibitors of this invention, their prodrugs and the salts of such compounds and progrugs is in the range of about 0.01 to about 100 mg/kg/day, preferably about 0.1 to about 5 mg/kg/day.<br>
An especially preferred dosage of [2R,4S]-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester (torcetrapib) is about 15mg per day to about 240 mg per day, preferably about 30 mg per day to about 120 mg per day. The dosage may be administered in single or multiple dosages (e.g., bid).<br>
A dosage of the combination pharmaceutical agents (e.g., antihypertensive agents, statins) to be used in conjunction with the CETP inhibitors is used that is effective for the indication being treated.<br>
For example, typically an effective dosage for HMG-CoA reductase inhibitors is in the range of about 0.01 to about 100 mg/kg/day.<br>
For example, typically an effective dosage for atorvastatin calcium (known as atorvastatin hemicalcium or LIPITOR) or other salts of atorvastatin is about 10 mg to about 80 mg per day (e.g., 10mg, 20mg, 40mg 80mg).<br>
For example, typically an effective dosage for antihypertensives is in the range of about 0.01 to about 100 mg/kg/day.<br>
For example, typically an effective dosage of amlodipine or a pharmaceutically acceptable salt thereof (e.g., amlodipine besylate, amlodipine mesylate) is in the range of about 5 mg to about 10 mg per day.<br>
An exemplary dosage for the triple combination of amlodipine and a pharmaceutically acceptable salt thereof (e.g., amlodipine besylate)/atorvastatin and i a pharmaceutically acceptable salt thereof (e.g., atorvastatin hemicalcium)/ and [2R,4S]-4-[(3,5-bis-trifluoromethyl-ben2yl)-methoxycarbonyI-amino]-2-ethyl-6-trifluoro methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester (torcetrapib) is in the range of 5-10mg per day/10-80mg per day/30-120mg per day.<br>
For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.<br>
Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences. Mack Publishing Company, Easter, Pa., 15th Edition (1975).<br>
Pharmaceutical compositions according to the invention may contain 0.1%-95% of the compound(s) of this invention, preferably 1 %-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound(s) according to the invention in an amount effective to treat the condition or disease of the subject being treated.<br>
Since the'present invention relates to the treatment of diseases and conditions with a combination of active ingredients which may be administered separately, the invention also relates to combining'separate pharmaceutical compositions in kit form. The kit includes two separate pharmaceutical compositions: amlodipine or a pharmaceutically acceptable acid addition salt thereof and a statin or a pharmaceutically acceptable salt thereof in association. The kit can include an exemplary container means for containing the separate compositions such as a divided bottle or a divided foil packet, however, the separate compositions may also be contained within a single, undivided container. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by_the prescribing physician.<br>
An example of such a kit is so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the fact of the foil whichis opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening' is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.<br>
It may be desirable to provide a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested. Another example of such a memory aid is a calendar printed on the card, e.g., Another example of such a memory aid is a calendar printed on the card, e.g., as follows "First Week, Monday, Tuesday, ...etc.... Second Week, Monday, Tuesday,.<br><br><br><br><br><br>
We Claim:<br>
1.        A pharmaceutical composition for treating a disorder or condition of the kind such as herein described comprising:<br>
(a)       26.26% to 35.37% w/w of a cholesteryl ester transfer protein (CETP) inhibitor which is a compound of formula!:<br>
(Formula Removed)<br>
or   a   prodrug   thereof,   or   a   pharmaceutically   acceptable   salt   of  said compound or of said prodrug; wherein R1 is Y, W-X or W-Y; wherein W is carbonyl; X is -O-Y;<br>
wherein Y for each occurrence is independently Z or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo and said nitrogen is optionally mono-, or di-substituted with oxo;<br>
R2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-,  di- or tri-substituted<br>
independently with halo, said carbon is optionally mono-substituted with oxo said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo; or said R2 is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
R3 is a fully saturated, one or two membered carbon chain wherein said carbon is optionally mono-substituted with oxo, and said carbon chain is mono-substituted with V;<br>
wherein V is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;<br>
wherein said V substituent is optionally mono-, di-, or tri-substituted independently with halo, (C1-C2)alkyl, wherein said (C1-C2)alkyl substituents are also optionally substituted with from one to five fluorines;<br>
R4 is acetyl, formyl or (C1-C6)alkoxycarbonyl;<br>
R5 and R8 are hydrogen;<br>
R6 and R7 are independently hydrogen, halo, (C1-C2)alkoxy or a saturated (C1-C2)alkyl chain wherein said (C1-C2)alkyl chain is optionally mono-, di- or tri-substituted independently with fluorines,<br>
or a pharmaceutically acceptable salt thereof;<br>
(b)	1.6% to 4.75% w/w of an antihypertensive agent or a pharmaceutically acceptable salt;<br>
(c)	0.76% to 1.06% w/w of an HMG CoA reductase inhibitor wherein the HMGr CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, glenvastatin, dalvastatin, carvastatin, crilvastatin, bervastatin, cerivastatin, rosuvastatin, pitavastatin, mevastatin, or rivastatin or a pharmaceutically acceptable salt of said HMG CoA reductase inhibitor , and<br>
the balance being optional conventional pharmaceutically acceptable carrier or diluent of the kind such as herein described.<br>
2.        A pharmaceutical composition as claimed in claim  1  wherein the atorvastatin is a hemicalcium salt of atorvastatin .<br>
3. A pharmaceutical composition as claimed in claims 1 or 2 wherein said antihypertensive agent is amlodipine or a pharmaceutically acceptable salt thereof.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWNvcnJlc3BvbmRlbmNlLXBvLnBkZg==" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-correspondence-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tMTMucGRm" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tMTkucGRm" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-19.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tNC5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzc3NC1kZWxucC0yMDA0LXBjdC0zMDgucGRm" target="_blank" style="word-wrap:break-word;">3774-delnp-2004-pct-308.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="218139-method-of-controlling-a-gas-turbine-electric-power-plant-and-an-apparatus-there-for-carrying-out-the-method.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="218141-a-training-device-for-ball-games.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>218140</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3774/DELNP/2004</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>37/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>12-Sep-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>31-Mar-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>30-Nov-2004</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>PFIZER PRODUCTS INC.,</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>EASTERN POINT ROAD, GROTON, CONNECTICUT 06340, U.S.A.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>TU TRUNG NGUYEN</td>
											<td>PFIZER GLOBAL RESEARCH AND DEVELOPMENT, 50 PEQUOT AVENUE, NEW LONDON, CONNECTICUT 06320, U.S.A.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>CHARLES LESTER SHEAR</td>
											<td>PFIZER GLOBAL RESEARCH AND DEVELOPMENT, 50 PEQUOT AVENUE, NEW LONDON, CONNECTICUT 06320, U.S.A.</td>
										</tr>
										<tr>
											<td>3</td>
											<td>JAMES HAROLD REVKIN</td>
											<td>PFIZER GLOBAL RESEARCH AND DEVELOPMENT, 50 PEQUOT AVENUE, NEW LONDON, CONNECTICUT 06320, U.S.A.</td>
										</tr>
										<tr>
											<td>4</td>
											<td>ROGER BENJAMIN RUGGERI</td>
											<td>PFIZER GLOBAL RESEARCH AND DEVELOPMENT, EASTERN POINT ROAD, GROTON, CONNECTICUT 06340, USA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 45/06</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/IB2003/002792</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-06-18</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/393,395</td>
									<td>2002-07-02</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/218140-a-pharmaceutical-composition-of-a-cetp-inhibitor by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:31:09 GMT -->
</html>
